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Abstract
Pumactant (also called ALEC™) is a synthetic lung surfactant currently licensed in the UK 
for use in the treatment o f neonatal respiratory distress syndrome (RDS). It contains two 
naturally occurring surface-active phospholipids (SAPL): dipalmitoylphosphatidylcholine 
(DPPC) 70% and unsaturated phosphatidylglycerol (PG) 30%. Both of these 
phospholipids are present in the human lung, abdominal cavity and the middle ear. Recent 
theories have suggested that surfactant therapy may be viable in asthma, intraperitoneal 
post-surgical adhesions and otitis media with effusion (glue-ear). Thus, a comprehensive 
characterisation o f SAPL as a powder for use in such medicinal therapies was undertaken 
in the present study. The physicochemical properties o f SAPL were characterised and are 
described. The use o f imaging and particle size measurement techniques enabled the 
characterisation o f SAPL. Fluid-energy milling was used to micronise coarse SAPL and 
in-vitro aerosol performance o f various formulations were assessed using traditional 
pharmaceutical testing apparatus and procedures. Conventional dry powder inhaler 
formulation strategy, using coarse-carrier and aggregated powder systems, as well as novel 
delivery devices and methods were also investigated. The novel delivery devices for 
asthma and intraperitoneal post-surgical adhesions were developed with the view to their 
use in the clinic.
It is hoped that the present study provides new and useful information concerning the 
testing of the novel delivery devices, and the results obtained provide the basis for further 
study and development o f SAPL for the benefit patients.
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The technological development of inhaled drug delivery systems is currently of great interest. 
An attraction of the inhalation route for drug delivery is that unlike other routes of 
administration, adverse systemic side effects can be minimised. Other reasons for inhalation 
being a preferred drug delivery route includes:
a) Locally acting compound is delivered directly to the site of action, leading to a rapid onset 
of action (Timsina et al 1994).
b) The very large pulmonary surface area (70-80m2, Weibel 1962), coupled with a good blood 
supply, provide excellent conditions for efficient drug absorption.
c) Hepatic first-pass metabolism and / or degradation within the gastrointestinal tract are not 
an issue for drugs delivered via inhalation (Lalor and Hickey 1998).
d) Potent drugs can be administered at generally reduced doses, decreasing the likelihood of 
unwanted side effects.
Patients with respiratory diseases such as asthma, adult respiratory distress syndrome (ARDS), 
neonatal respiratory distress syndrome (RDS), and chronic obstructive pulmonary disease 
(COPD) are likely to require continued maintenance using inhaled medication. Thus, 
improvements to inhaled drug delivery systems are very desirable.
The fundamental properties of aerosols have been studied using different techniques, for more 
than a hundred years (Colbeck 1998). Today, new applications for aerosols are being 
developed, involving not only the treatment of pulmonary diseases, but also the delivery of 
drugs for treatment of non-pulmonary conditions, such as A.I.D.S, cystic fibrosis, and diabetes 
(Wood and Knowles 1994). The increasing use of aerosol therapy is due to better 
understanding of the pathophysiology of diseases, allowing physicians to envisage a broader 
range of therapeutic options. In particular, systemic delivery of peptides and proteins (via the 
inhalation route), has generated great interest in recent years and this trend is set to continue 
(Grossman 1994, Edwards et al 1998a). Advances in recombinant DNA technology and 
aerosol generation and delivery can only serve to increase the number and the different types 
of drugs delivered as aerosols.
1.1 Structure and Function of the Respiratory Tract
The primary function of the respiratory tract (RT) is gas exchange: facilitating the movement 
of oxygen into the blood and removing carbon dioxide from the circulation through a very thin 
blood-gas barrier in the exchange areas (Gonda 1990). A secondary function appears to be the 
cleaning and humidifying of the incoming air to prevent damage to this vital organ. Although 
the nose is an integral part of the RT, aerosol delivery of drugs to it or through it for systemic 
activity, is a topic with its own distinct issues. Therefore, only delivery by breathing via the 
mouth is considered in this report.
The RT is broadly divided into three regions: 1) The upper RT, also called oropharyngeal 
region, consists of the mouth, pharynx and larynx. 2) The conducting airways, which include 
the trachea, bronchi and bronchioles. 3) The lower RT, also called the alveolar or pulmonary 
region, which extends from the respiratory bronchioles to the distal alveolar sacs (Kumar and 
Clark 1990, Byron 1994).
The function of the upper RT is to heat and moisten, as well as remove particulate matter from 
the inspired air. The inspired air passes down the trachea and through the bronchioles, 
respiratory bronchioles, and alveolar ducts to the alveoli. Between the trachea and the 
alveolar sacs the airways divide as many as 23 times to form an asymmetric, continuous, 
dichotomously branching structure (Weibel model A) (Weibel 1963). The first 16 divisions 
are in the upper conducting airways that transport air to and from the outside environment. 
The last seven divisions are in the lower pulmonary region where gas exchange occurs by 
diffusion (Ganong 1989). The walls of the conducting airways consist of cartilage, which 
gradually decrease in thickness from the trachea to the bronchi, and are absent from the 
bronchioles and the bronchi. Smooth muscle is also found in the trachea and its function is to 
link the cartilage. The presence of smooth muscle increases from the bronchi to the 
bronchioles. The alveoli are lined by two types of epithelial cells: primary lining cells and 
granular pneumocytes. The physiological function of these cells is to secrete surfactant into 
the lungs. The surfactant is a mixture of lipids, which reduces surface tension in the lungs, 
and prevents lung collapse. The multiple divisions in the airways greatly increase the cross- 
sectional area of the airways, consequently, the air flow velocity in the upper airways (approx.
2
60Lmin'1) decreases to 5Lmin1 in the lower airways. The diameter of the upper airways starts 
at approximately 2cm and decreases to 0.35 mm in the alveoli. In adults, the diameter and 
total depth of the average alveolus is in the region 250-300pm, and the total surface area of the 
alveoli is approximately 70-80m2 (Weibel 1962). The diameter of the alveolar ducts and sacs 
varies between 150-400pm in children and 200-600pm in adults. The average length of the 
alveolar ducts and sacs is approximately 0.7- 1mm (Weibel 1963).
1.1.1 Pulmonary Clearance
The respiratory airways that lead from the exterior to the alveoli do more than serve as gas 
conduits; they play a role in the lung’s defence mechanisms and clearance (Ganong 1989). An 
average adult who has a daily intake of ~10m3 of air (light activity), may inhale as much as 
lOmg of particulate matter which translates to an annual payload of more than 3g. To prevent 
large accumulation of particulate matter in the airways over a lifetime of exposure, the RT has 
a clearance mechanism. The respiratory airways are ciliated and covered by a viscoelastic gel 
or mucus (Gonda 1990). The composition of mucus is complex and varies between 
individuals, regions, modes of breathing, and in disease. Pulmonary surfactant is an important 
constituent of mucus as it lowers the surface tension at the gas-liquid interface and therefore 
reduces the workload on the lung preventing it from collapsing and helping it to re-inflate 
(Bangham 1987). When particles in the range of 2 to 10pm are captured in the upper and 
conducting airways, they are transported upwards from the site of deposition on a mucus 
blanket, by the beating action of the cilia. This moving blanket of mucus is called the 
mucociliary escalator (Brain et al 1985). Final removal of particulate matter transported to the 
throat is commonly by swallowing or expectoration.
If particulate matter (<2pm) deposits on alveolar surfaces, it is usually ingested by pulmonary 
alveolar macrophages (also called dust cells). These cells come from the bone marrow and are 
actively phagocytic, ingesting inhaled bacteria and small particles. They also help process 
inhaled antigens for immunologic attack, and secrete substances that attract leukocytes to the 
lung (Ganong 1989). In addition to phagocytosis, an excess of particles may be removed 
(drained) by the network o f lymphatic channels that line the lung. The drained particles may
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enter the blood stream or become bound to the lung tissue. If the load deposited in the lungs is 
too large, or if  the clearance mechanisms are impaired, a sequestering tissue reaction 
(pneumoconiosis) occurs which may be followed by other pathological events.
For aerosols that deposit in the airways and elicit a physiological response, the relative amount 
of initial trapping along the upper and conducting airways may not be so important. Rather, it 
is the amount of subsequent clearance rather than the initial response that predominates 
whether or not a harmful reaction is felt over long periods of exposure.
1.2 Respiratory Diseases
Diseases of the respiratory system are a major cause of morbidity and mortality throughout the 
world (Kumar and Clark 1990). In the UK, respiratory diseases account for approximately 
20% of all deaths (Byron 1994). In the USA, cases of asthma have risen by 46% between 
1982 and 1993 (Edwards et al 1998a). Respiratory disorders are the single biggest cause of 
days lost from work, and asthma is a major cause of hospitalisation (Frew and Holgate 1993).
1.2.1 Asthma
Asthma is defined as a partial obstruction of air flow in the thoracic airways that varies in 
severity over short periods of time, relief being achieved either spontaneously or as a result of 
treatment (Kumar and Clark 1990). Asthma is also described as a respiratory disease marked 




Although there are many different definitions of asthma, what is certain is that some or all of 
the following symptoms are observed: breathlessness, coughing, wheezing or tightness in the 
chest, exhaustion, speech problems, reduced levels of consciousness, and other such 
symptoms. Asthma attacks tend to be more severe at night and during the early morning 
hours. This is because there is a circadian rhythm in bronchial tone, with maximal 
constriction about 6am and maximal dilation about 6pm (Ganong 1989). Compared with non­
asthmatics, the airways of patients with the disease tend to be hyperresponsive to constrictor 
effects of a large number o f different stimuli, such as exercise, cold air, hyperventilation and 
chemical agents.
1.2.1.2 The Inflammatory Process and Bronchial Epithelium
Asthma is a disorder o f the conducting airways that contract too much and too easily, 
producing variable airflow obstruction. Asthma is also recognised as an inflammatory 
disorder, with oedema and airway leakage of plasma proteins (Kurashima et al 1997). The 
role of inflammatory cells, mediators and the mechanisms by which the inflammatory reaction 
develops is complex. Chung (1986), Kay (1991), Sheth and Lemanske (1995), Adkins and 
Brogden (1998) give comprehensive accounts of the inflammatory process. Briefly, 
inflammation involving mast cells, eosinophils and T-cells is a hallmark of asthma. Mast cells 
are wandering cells found in large numbers in tissues that are rich in connective tissue. Mast 
cells have IgE receptors on their surfaces that discharge the contents of their granules (release 
of histamine from basophils) when IgE-coated antigens bind to the receptors. Mast cells also 
bring about the secretion of leukotrines, which are inflammatory mediators. Leukotriene 
release produces bronchoconstriction (bronchial hyperactivity), constricts arterioles, increases 
vascular permeability, promotes increased mucus production, and attracts neutrophils and 
eosinophils to the inflammatory site. Hence, leukotrines play an important role in the 
pathogenesis of asthma. A study carried out by Woltmann et al (1997) has shown that
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induced sputum measurements can be used to non-invasively assess airway inflammation in 
asthmatic patients. The levels of eosinophils were measured in healthy and asthmatic patients, 
with the results showing marked differences between the two sets studied.
Although the inflammatory process described above causes bronchial hyperactivity, Holgate 
(1998) postulated that bronchial epithelium acts as a key regulator of airway inflammation and 
remodelling in asthma. This theory appears to be supported by Reddington et al (1998), who 
states that restructuring o f the airway wall is a cardinal feature of the disease, which may be 
directly related with chronicity and altered airway mechanics. Although airway remodelling 
has previously been considered to occur late in the pathogenesis of asthma, biopsies from 
children as young as two years of age, who later develop asthma, indicated that thickening of 
the bronchial epithelial membrane is already apparent (Phunek et al 1997). Since bronchial 
epithelium in asthma is exposed to a variety of allergens capable of causing tissue injury, 
damage alteration to the regulation of the bronchial epithelium may lead to chronic mucosal 
inflammation.
1.2.1.3 Classification, Diagnosis and Prevalence
Asthma can be classified into different categories depending on the type of stimuli that gives 
rise to the hyper-responsiveness and hyper-activity o f the lung muscles. The three categories 
are:-
a) Atopic (Extrinsic) Asthma:- Atopy is the tendency to develop specific IgE antibodies to 
commonly encountered allergies by natural sensitisation (Barnes and Rodger 1989). The peak 
period of sensitisation is in the third decade of life. These allergens include pollen, fungal 
spores, animal danders and household dust or mites (Dolovich et al 1983). Other allergens, 
less frequently encountered, include various plant parts (tobacco leaf, coca bean etc.), insect 
dusts, and bacterial enzymes.
b) Non-Atopic (Intrinsic) Asthma: This type of asthma tends to develop in adulthood and is 
caused by such factors as exercise, viral infections and irritants.
c) Occupational Asthma: This type of asthma is due to agents or factors encountered at work. 
Once sensitisation to the specific agent has occurred, nearly all workers with occupational
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asthma develop asthma related to non-specific stimuli such as exercise, infection, cold air and 
fog. In this way, they are similar to patients with non-occupational asthma (Barnes and 
Rodger 1989). The list of sensitisation agents can be long and varied but may include the 
following: Arthropods, crustaceans, fungi, bacteria, wood, metals, chemicals, flour, drugs, 
dyes and enzymes.
The difficulty in diagnosing asthma is influenced by which category the disease falls in. For 
example, with allergic asthma, diagnosis may often be made through review of the medical 
history of the patient and relations. Once the possible trigger factors have been identified, 
then the diagnosis may be fairly accurate.
Asthma affects about 10 million people in the USA (Lalor and Hickey 1998) and about 5% of 
the population worldwide (Crompton 1993). It can range in severity from mild and 
intermittent to severe and chronic, in extreme cases, may be disabling or even life threatening. 
In children, where asthma onset occurs, the majority develops symptoms before the age of 
five. In addition, approximately twice as many boys experience symptoms in childhood, 
although this difference disappears towards adolescence. There is no satisfactory explanation 
for this observed pattern. Between 25-75% of children make full-recoveries and are free of 
their symptoms by adulthood. This may be due to enlargement of their airways during normal 
growth that reduces the significance of the obstruction. In adults, there are no appreciable 
differences between the number of men and women that suffer from the disease. 
Approximately 2000 people a year die from asthma-related illness in the UK (Grossman 
1994).
Geographical variations occur in asthma distribution: It is more common in Western and 
developed countries, than in Far-Eastern or less-developed countries (Kumar and Clark 1990). 
In developing countries, the cases o f asthma may rise as individuals’ life-styles become more 
‘Westernised.’ Studies of occupational asthma suggest that up to 20% of the work force may 
become asthmatic if  exposed to potent sensitisers.
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1.2.1.4 Treatment
Inhalation therapy is the preferred technique (by patients and physicians) for the treatment 
asthma. The majority of devices are pressurised metered-dose inhalers (pMDIs) and a smaller, 
but increasing, number of dry powder inhalers (DPIs). Since asthma is characterised by 
inflammation and obstruction of the airways, the treatment is aimed at eliminating or 
controlling both these factors. Preventative medicine and a reduction in exposure to 
sensitising agents and trigger factors should also be considered when dealing with the disease. 
A pharmacologically active group of compounds used in asthma therapy, adrenoceptor 
stimulants (P2 -stimulants, P2 -agonists) may be sub-divided into selective and non-selective 
categories. The selective category includes: salbutamol, terbutaline, rimeterol, fenoterol, 
salmeterol, formoterol and reproterol, of which terbutaline and salbutamol have been 
considered amongst the safest and most effective beta-stimulants (BNF, No 35, 1998). 
Salbutamol and terbutaline are available in the widest range of formulations. Salmeterol and 
formoterol are longer acting and are not suitable for the relief of an acute attack, but instead 
should be used in long term treatment of nocturnal and exercised-induced asthma (Wallin et al 
1993).
p2-agonists cause activation of adenylate cyclase which in turn catalyses the conversion of 
adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), activating specific 
protein kinases which reduce phosphorylation of myosin, causing a reduction in calcium- 
dependant coupling of actin and myosin and thus leading to smooth muscle relaxation in the 
bronchioles. Stimulation of the p2-adrenoceptors (found in the airways) also inhibits mediator 
release by mast cells, basophils and eosinophils. In addition, levels of mucosal oedema are 
reduced and mucociliary clearance is increased (Bames and Rodger 1989).
Non-selective p2 -agonists include ephedrine and orciprenaline. These are less safe for use 
than other selective agents, because they are more likely to cause arrhythmias and other side 
effects.
Anticholinergic drugs act as competitive antagonists of acetylcholine at muscarinic / 
cholinergic receptors (Partridge and Sanders 1981). The precise term for these types of 
compounds are antimuscarinic drugs, but they are commonly referred to as anticholinergic
8
drugs because of their action against acetylcholine. Examples include ipratropium and 
oxitropium. These drugs are regarded as been more effective in relieving bronchoconstriction 
associated with chronic bronchitis in patients who fail to respond to selective bronchodilators. 
In large doses, they can have a weak local anaesthetic effect and in very large doses, they may 
block nicotinic receptors at the ganglia (Bowman and Rand 1980). Anticholinergic drugs are 
not recommended as first-line agents in the treatment of asthma because they have a relatively 
weaker bronchodilatory effect than p2 -agonists (Gross 1988).
Bronchodilation occurs as a result of stimulation of muscarinic receptors which cause reduced 
vagal tone. This effect occurs in both healthy subjects as well as patients with asthma 
(Partridge and Sanders 1981).
Xanthines, also known as methylxanthines, have been used in the management of asthma 
since the mid-19th century. Although theophylline preparations fall into this class, the narrow 
range and extrapulmonary side effects are a limiting factor in their clinical use. The proposed 
mechanism of action of theophylline and other anti-asthmatics in this class is based on the 
inhibition of phosphodiesterase, leading to increased production of cAMP, thus causing 
bronchodilation.
Drugs such as sodium cromoglycate (SCG) and nedocromil sodium are anti-allergic. These 
drugs are called anti-allergic because they interfere with the pathway that gives rise to mast 
cell activation and cause mediator release, which in turn interacts with primary and secondary 
effector cells in the airways, thus preventing bronchoconstriction. SCG is a synthetic 
derivative of bis-cromone which comes from a herb called Khellin. SCG is a mast-cell 
stabilising agent and inhibits IgE-mediated release of histamine. Nedocromil sodium 
possesses similar properties to SCG but is more potent. These drugs are active 
prophylactically rather than therapeutically and are used primarily in the long-term 
management of asthma because of their ability to reduce airway inflammation (Bernstein and 
Bernstein 1993). Neither SCG nor nedocromil are effective in treating patients with acute 
asthma and should not be used if immediate effects are desired.
Corticosteroids have been used in asthma therapy as early as 1950 (Keeder and MacKey). 
Steroids used in the treatment of asthma include drugs such as beclemethasone and 
budesonide. These drugs are used for prophylactic treatment when patients are using p2- 
stimulants more than once a day. When inhaled, corticosteroids produce many fewer side
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effects than those associated with systemic administration. However, in severe asthma and 
some other respiratory disorders, oral or intravenous corticosteroids are more beneficial than 
inhaled corticosteroids (Smith and Bernstein 1996). The ability to deliver these drugs in 
larger doses, either orally or parenterally, with greater systemic availability is the reason for 
this discrepancy. Corticosteroids reduce bronchial mucosal inflammation and thus reduce 
oedema and secretion of mucus into the airways. Inhaled corticosteroids have been shown to 
suppress airway hyper-responsiveness and are effective at controlling symptoms in a broad 
spectrum of patients (Kaliner 1990).
Other / alternative therapies include the use of antihistamines, mucolytics and a-adrenoceptor 
antagonists. Histamine is known to cause bronchoconstriction by direct stimulation of smooth 
muscle via stimulation of the vagus nerve, therefore, treatment is aimed at preventing this 
event from occurring. Anti-histamines can have a sedative effect and may cause drowsiness. 
Mucolytics are prescribed to aid the ejection and reduction of sputum viscosity in chronic 
asthma patients. Heparin, usually used as an anticoagulant, has anti-inflammatory properties 
which may be effective in asthma, efficacy studies in animals have shown encouraging results.
1.2.2 Adult Respiratory Distress Syndrome (ARDS) and Neonatal RDS
ARDS was first described by Asbaugh and co-workers in 1967, but the aetiology and clinical 
management strategies of the disease is still wide and varied. Statistically, the incidence of 
ARDS varies from 1,000 to 15,000 cases a year in the UK and up to 150,000 cases a year in 
the USA (Lee et al 1994). ARDS results from either direct or indirect injury to the pulmonary 
epithelium and endothelium (Luce 1998) and refers to the acute onset of hypoxaemia and 
decreased lung compliance following certain risk factors such as: aspiration (or other forms of 
pneumonitis); sepsis; acute pancreatitis; multiple blood transfusions; bums; massive trauma; 
inhalation of smoke or other toxic gases and near-drowning (Jones 1990, Zachariades et al 
1993, Raymondos et al 1999). However, since these conditions are non-specific and can 
result from a number of other conditions, there is no precise test for ARDS and the diagnosis 
can only be descriptive (Lachmann and van Daal 1992). Nevertheless, diagnosis criteria for 
ARDS includes: acute onset; chest radiography; monitoring of pulmonary arterial pressure;
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impaired oxygenation. In a consensus conference in 1994, it was agreed that ARDS is the 
most severe end of the spectrum of Acute Lung Injury (ALI) and that the term for the disease 
should be changed to “acute” rather than “adult.” The overall mortality was about 60% (Pepe 
et al 1990) but has improved to <50% due to new approaches in mechanical ventilation, 
patient positioning, and other new therapy strategies (Luce 1998).
1.2.2.1 Pathogenesis of ARDS
As mentioned earlier, ARDS results from direct or indirect injury to pulmonary epithelium 
and endothelium. The decrease in lung compliance is associated with acute lung injury which 
itself is associated with damage to the alveolar membrane by increased capillary permeability 
to water and proteins (Watling and Yanos 1995). The damage to the alveolar membrane 
results in pulmonary oedema, containing serum proteins o f all classes and an increased 
number of inflammatory cells (Lachmann and van Daal 1992). This, in turn, causes damage to 
the pulmonary surfactant in patients with ARDS. As yet, the precise mechanisms, regulatory 
agents and mediators involved in the inflammatory process are unclear.
1.2.2.2 The Clinical Course of ARDS
The course of ARDS can be divided into four phases. The first phase is characterised by 
breathing difficulties and the rate of breathing may also increase, a chest radiograph is taken at 
this stage. The second stage is usually a silent phase, during which the patient appears to be 
doing well. However, measurement of lung compliance or of the alveolar to arterial oxygen 
tension gradient indicate deterioration of pulmonary function and the chest radiograph may 
show minor abnormalities. The third phase is characterised by pulmonary insufficiency and 
represents the fully developed syndrome. The last phase is characterised by dense fibrosis of 
the lung and is terminal (Katzenstein 1982).
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1.2.2.3 Pulmonary Surfactant Function and Dysfunction in ARDS
Surfactant dysfunction has been demonstrated in the initial phases o f ARDS and is linked to 
alveolar instability and collapse (Kennedy et al 1997). Several abnormalities in surfactant 
composition have been described, these include: a decrease in phosphatidylcholine content, an 
increase in minor phospholipid subtypes, an increase in the surfactant total protein to total 
phospholipid and decreases in surfactant apoprotein content (Kennedy et al 1997). It is 
important to understand the normal composition and function of the pulmonary surfactant 
before the disease state is discussed.
1.2.2.3.1 Pulmonary Surfactant Composition and Production
Lipids (see section 1.2.2.3.4, page 23, for general background information) constitute the 
major part of the pulmonary surfactant, approximately ~90%. Analysis of the composition of 
lipids in surface-active material has shown that 80-90% is phospholipids (Sanders 1982). 
Phosphatidylcholine (PC) constitutes about 70-80% of the phospholipids, o f which about 60% 
contains two saturated fatty-acyl moieties. This di-saturated PC (DSPC) is largely dipalmitoyl 
PC (DPPC). The second major phospholipid is phosphatidylgycerol (PG), which makes up 
about 10% of the lung surfactant. Structures of PG and DDPC are shown in Figure 1, page 13.
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DPPC: 1,2-Dipalmitoyl-sn-glycerol-3-Phosphorylcholine 
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Figure 1: Structures of DPPC and PG (Ratio 7:3, % w/w), the two components that make up SAPL.
Where: Ri and R2 are fatty acids (see Appendix 14: Additional Information on SAPL, page 275).
Other phospholipids include phosphatidylinositol (PI), and the presence of PI and the ratio of 
PG to PI give an indication of lung maturity. A low PG/PI ratio is a sign of immaturity. In 
addition to the lipids, the surfactant also contains several specific proteins (also called 
apoproteins or surfactant proteins (SP)-A, SP-B, SP-C and SP-D (Hawgood and Clements 
1990). Detailed biosysnthesis pathways of the various components of lung surfactant can be 
found elsewhere (Batenburg 1995).
The pulmonary surfactant is produced by type II alveolar epithelial cells. The proteins are 
also produced by these cells, but with the exception of SP-C, which are formed in bronchiolar 
epithelial cells (Norton 1990). Once produced, the surfactant is packaged and stored in lipid 
bi-layers in lamellar bodies in the alveolar lumen. The lamellar bodies are secreted into the 
alveolar space where the surfactant is converted to lattice-like structures called tubular myelin 
(See Figure 2, page 14). The tubular myelin serves as the precursor for the phospholipid 
monolayer formed at the air-water interface. Small aggregate material are formed from the
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monolayer, these are called vesicles. These vesicles are taken up by type II cells and / or 
alveolar macrophages for recycling and degradation.
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Figure 2: Schematic representation of the life cycle of the pulmonary surfactant in normal (A) and injured 
(B) lungs.
Key: LB: Lamellar Body, TM: Tubular Myelin, ML: Monolayer, SV: Small Vesicles
1.2.2.3.2 Physiological Mechanisms for the Action of Pulmonary Surfactant
The main function o f the surfactant is to help maintain proper lung function, to act as a surface 
tension lowering agent at the air liquid interface of a continuous liquid layer, or aqueous 
hypophase, assumed to line the alveoli and adjacent terminal airways at all times. This action 
of the surfactant allows collapsed alveoli to open at lower inspiratory pressures and to protect 
the alveoli against collapse during expiration. The continuous layer o f surfactant also helps to 
lubricate the mucosal environment (Hills 1988). A full, detailed, review of pulmonary 
surfactant functions, associated mechanisms of action of the various models, surface tension 
measurement techniques, and other possible roles are given elsewhere (Robertson et al 1984, 
Hills 1988, Hills 1991). Briefly, when surfactants act at air-liquid interfaces, the orientation of
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the molecules are such that polar head groups are in the aqueous phase and the non-polar 
groups point towards the air. This orientation of the monolayer reduces surface energy and, 
thus, the surface tension which can be measured by a number of techniques (e.g. The 
Langmuir trough, Wilhelmy plate method, du Nuoy tensiometer, Pulsating-bubble 
surfactometer and capillary rise method). The surfactant model described above (called the 
‘bubble’ model) for the alveoli was first introduced by von Neegaard in 1929 and refined by 
Clements (1962). However, today, other conflicting models describe the action of the 
surfactant on the alveoli. These models include:
1. The ‘Totally Dry’- model- proposed by Colacicco (1985).
2. The ‘Shell’or ‘Geodesic-Dome’ Model- Proposed by Morley, Bangham and co­
workers (1987).
3. The New (Discontinuous) Model- Proposed by Hills (1997, 1998, 1999).
The totally dry and the shell / geodesic-dome models are outside the scope of this report. But
briefly, the totally dry model proposed by Colacicco (1985) states that, under normal 
physiological conditions, the alveoli are dry with no fluid even in the septal comers (see 
Figure 5d, page 19 and Figure 6a, page 20). It further states that both the liquid and surfactant 
linings seen in SEM images are artefact and that type II cells only release surfactant in 
response to flooding. Thus, surfactant is present in the airways of the neonate. Colacicco 
(1985) also proposes that, by reducing the surface viscosity of fluid that has acquired protein 
in distal airways, surfactant can facilitate the removal of fluid. The validity of the totally dry 
model hinges upon whether so much of the reported morphology is artefact. Hills’ (1997) 
discontinuous model challenges these artefact issues with apparent proof that alveolar 
surfactant is adsorbed on to the alveolar epithelium.
15
At the opposite end of the spectrum of models are those with continuous liquid linings such as 
the traditional bubble model. A variation of this model that allows for a higher melting point 
of a supernatant surfactant layer arises if the concept of a monolayer is dispensed with. The 
geodesic-dome or shell model proposes that the liquid-air interface is masked by a solid phase 
o f DPPC. Galdston and Shah (1967) and Bangham et al (1978) compared this solid surfactant 
layer to “icebergs” or “rafts”, depicting multiple layers as shown in Figure 3.
Dry surfac tant
W at er
W et  sur factant
Figure 3: Molecular configuration of a wet and dry surfactant.
With the wet surfactant, aggregates in water form a smectic mesophase with few molecules free to reach 
the interface. The rafts of dry surfactant have an open-ended structure from which molecules can spread 
freely at the interface to form a monolayer. Refer to Figure 4, page 17 for a graphical representation. 
Reproduced from Bangham et al (1978) with permission.
The solid surfactant opens on expansion / inspiration, to expose a true liquid surface to which 
more surfactant can be recruited from the hypophase. On subsequent compression, this 
recruited surfactant can be condensed to a solid and compacted to form uniform oligolamellar 
rafts. Bangham (1998) proposes that, at end expiration, these floating solids come together to 
form a rigid structure resembling a geodesic dome, thus resisting further collapse and 
establishing alveolar stability. Upon expansion, the solids require an appreciable pressure
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difference before they are prized apart to explain the inspiratory delay in volume increase, 
otherwise attributed to ‘alveolar recruitment / opening’ following closure at end expiration 
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Figure 4: Graph showing the relative performances of wet and dry surfactants with various combinations 
of surfactant proteins.
From the graph it can be seen that dry surfactant spreads fastest at the air-water interface followed by 
wet surfactant with combinations of surfactant proteins A and B.
Hills’ (1997)discontinuous model suggest that in the normal air-filled lung, water repellency is 
imparted by an adsorbed pseudo-cationic surfactant in the form o f surface active phospholipid 
(SAPL), is responsible for alveolar fluid being confined to ‘pools’ observed (e.g. by Weibel 
1982) in the septal comers, and ‘pits’ (see Figure 5(d) and Figure 6(a), page 19) elsewhere 
along what is otherwise an apparently fluid free surface (Hills and Masters 1998, Hills 1999). 
Hills argues that in the ‘bubble’ model, the continuous fluid lining (see Figure 5(c), page 19 
and Figure 6 (b), page 20) can be regarded as a one-sided bubble whose collapsing pressure 
(AP) would be far too large to be physiologically compatible unless surfactant greatly reduced 
the surface tension (y) from the very high value for water, as related by the Laplace equation:
AP  =  2 y  /  r  Equation 1
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where r is the radius of curvature. The other major requirement o f the ‘bubble* model is that 
surface tension of the liquid-air interface is ‘near-zero’ (Guyton et al 1984, Hawgood and 
Clements 1990), otherwise the force (AP) of the concave fluid surface sucking fluid into the 
air space at the septal comers (r decreases in the Laplace equation) would be impossible to 
balance by normal homeostatic mechanisms. Bangham (1987), has claimed that surface 
tension (y) can reach ‘near-zero* transiently during the respiratory cycle, but this have been 





Figure 5: Visual representation of the various events used to describe the role of the pulmonary 
surfactant.
a) The alveoli at birth- Air replaces the fluid in the lungs to form central cores, b) Emptying of the lung 
fluid and establishment of the bubble, c) Formation of the continuous aqueous hypophase and surfactant 
lining, d) Discontinuous model proposed by Hills (1988, 1997), see Figure 6, page 20 for more detail.
(a ) (b )
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Figure 6: The discontinuous model of the alveolus
a) With fluid confined to ‘pools’ and ‘pits’ from which it can tension the dry patches of the wall by pulling 
in excess epithelial membrane as ‘pleats’. The gas-transfer surface is kept essentially dry by water 
repellency induced by a layer of surfactant directly adsorbed onto the epithelial surface. The ‘pools’ can 
assume a convex profile to act as ‘corner pumps’ (Hills 1982) for returning fluid to the interstitium. If 
flooding continues, the ‘pools’ will link up to form the ‘bubble’ model (b), but as the pathological and not 
the normal physiological state.
Morphological evidence for the adsorption of surfactant to the alveolar epithelium tissue has 
been given via electron microscopy, by Ueda et al (1985) for the adult lung, and separately by 
Hills and Masters (1998). Hills and Chen (1998) carried out ex-vivo experiments using 
bronchial epithelium (derived from porcine lungs) to prove the hypotheses that: exogenous 
surfactant can directly bind to various tissue surfaces where the adsorption of indigenous 
surfactant had been demonstrated; and how (phosphatidylgycerol) (PG) has a physiological 
role in promoting DPPC adsorption. Hills argues that, if his hypothesis is correct, then SAPL 
would already be in place, adsorbed at the alveolar epithelium in a normal mature foetus 
before delivery, then it should also be in place in a still-born human baby. To test his 
hypothesis, necropsy (autopsy) was carried out in a human foetus of 41 weeks gestational age, 
which had died from non-respiratory causes. Peripheral lung tissues were studied using 
epifluorescence microscopy.
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Figure 7: Electron photomicrograph of alveolar tissue excised from a still human foetus at 41 weeks 
gestation, taken by epifluorescence microscopy using Phospholipin E as the hydrophobic probe.
Note the SAPL lining layer bordering the potential air space as indicated by the arrow, magnification 
x300.
The results clearly show that the outermost layer lining foetal alveolar epithelium at term is 
SAPL (Hills and Masters 1998). Spectral analysis, using a scanning spectrophotometer, of the 
fluorescent light emitted from the arrow shown in Figure 7 produced a spectrum (see Figure 8, 
page 22) that was identical to the spectrum of synthetic DPPC shown by Bangham and Home 
(1964) to produce oligolamellar SAPL (liposomes) when ultrasonicated in water. This 
spectral analysis (Figure 8, page 22) is also consistent with the lamellated alveolar lining 
shown in the adult lungs and in the upper airways by Ueda et al (1985).
In order to substantiate his discontinuous model further, and to prove that alveolar surfactant 
is adsorbed on to the alveolar epithelium, Hills and Masters (1998) and Hills (1999) state that, 
if the exogenous surfactant used in the treatment of neonatal RDS spreads instantaneously at 
the air-liquid interface (as predicted by the bubble theory), why is it that improvements in gas 
exchange are noticed some 48 hours after administration? This time lapse was first reported 
by Milner (1993) and is consistent with the much slower rates for surfactant binding to solids 
than spreading over liquid surfaces (Hills 1988).
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Figure 8: Spectral analysis of the fluorescent light (from arrow in Figure 7). The spectrum is identical to 
that of synthetic DPPC transformed into its oligolamellar state as liposomes by ultrasonication in water.
Other functions for the pulmonary surfactant have been suggested, they include: Contribution 
to the host defence mechanism (McFadden et al (1994); Enhancement of ciliary beat 
frequency (Kakuta et al 1991); Role in maintaining the patency of the conducting airways 
(Enhoming et al 1996). In addition to these functions, the potential use of exogenous 
surfactant in other lung diseases such as pneumonia and bronchial asthma may be a possibility 
(Lewis and Veldhuizen 1995). The potential use of pulmonary surfactant as a physical barrier 
against asthma will be discussed later.
1.2.2.3.3 Surfactant Dysfunction
As mentioned earlier, surfactant alterations during ARDS are somewhat more complex than 
the primary surfactant deficiency noted in neonatal RDS. Typical alterations to the surfactant 
include altered phospholipid composition, where levels of PC, PG and PI are all decreased. 
There is also a decrease in the levels of SP-A, SP-B, and SPC. SP-A is known to bind lipids
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(Hawgood 1992), to aid vesicle formation, play a role in tubular myelin formation, also 
thought to be involved in defence mechanisms (Wang et al 1998). SP-B is thought to play a 
role in monolayer formation, and SP-C is believed to promote the adsorption of the 
phospholipids to the air-liquid interface (Batenburg 1995). SP-D plays a role in defence 
mechanisms (Wang et al 1998) where it activates alveolar macrophages and binds to 
lipopolysaccharides. The combined result of the alterations to the phospholipid and protein 
levels leads to a loss in the ability of the surfactant to reduce surface tension. Furthermore, 
surface activity of the surfactant is further impaired by the increased influx of serum proteins 
into the alveolar space due to the increased epithelial permeability associated with ARDS 
(Lewis and Veldhuizen 1995). Disturbance in the levels of surfactant will result in pulmonary 
airway swelling and will hence affect lung compliance and gas exchange.
1.2.2.3.4 Other Phospholipids and Liposomes
Molecules with combinations of hydrophilic and lipophilic moieties are termed amphipathic. 
Some amphipathic molecules are better at reducing interfacial free energy than others and 
these are termed surfactants (Hills 1988). Hydrophilic moieties of surfactant fall into four 
basic categories depending upon whether they carry no net charge (non-ionic), a negative 
charge (anionic), a positive charge (cationic) or both, in which case they are termed 
zwitterions. Thus, the ends of a surfactant molecule are often referred to as ‘polar’ or ‘non­
polar’ and all except the non-ionic variety are electrolytes. Phosphatidylcholines become 
cationic below a pH of 3 because this is the pK value of the phosphate group in the 
zwitterions, leaving a net positive charge on the terminal quaternary ammonium ion (Phillips 
and Chapman 1968). Lipids are naturally occurring compounds that are esters of long chain 
fatty acids, which are insoluble in water but soluble in organic solvents such as acetone, 
alcohol, chloroform or ether. Alkaline hydrolysis (known as saponification) gives rise to the 
alcohol and the sodium or potassium salt of the constituent fatty acids (Plummer 1987). There 
are four basic types of lipids- acylglycerols, phosphoglycerides (also referred to as 
phospholipids or phosphatides), sphingolipids, and waxes. These differ in the backbone 
structure to which the fatty acids are covalently bound. Neither the waxes nor the
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acylgylcerols are amphiphatic, leaving two groups that are highly surface active (Kondoh et al 
1987). The backbone of phospholipids are produced by the esterification (using phosphoric 
acid) of one of the hydroxyl groups of glycerol and both D and L forms are produced 
(Lehninger 1976), refer to Appendix 15: Structures of Lipids, page 276. The polar heads on 
the phospholipids are varied and can include choline, ethanolamine, inositol, serine, and 
glycerol. Bangham and Dawson (1959) concluded that phosphatidylcholines have a slight net 
positive charge and thus migrate to the cathode under electrophoresis, whilst, most other 
phosphoglycerides have a net negative charge.
Sphingolipids contain sphingosine (refer to appendix 15 for structures, ) as the backbone and 
are important membrane components in animals. The most abundant sphingolipids are 
sphingomyelins, produced by esterification of the primary alcohol group with phosphatidyl 
ethanolamine and the fatty acid residue is present as the acyl derivative of the amino group. 
Sphingomyelin is present in the myelin sheet, which acts as an insulator for nerve fibres.
Esters of glycerol and fatty acids are called acylglycerides or glycerides. The trihydric alcohol 
can be esterified to give mono-, di- and triglycerides. The fatty acids may be the same or 
different and, on saponification, free glycerol and fatty acid can be obtained (Plummer 1987). 
Triglycerides are the predominant form in nature, although mono- and diglycerides are known. 
The acylglycerols are uncharged molecules and for this reason are known as neutral lipids. 
They are called fats or oils depending upon whether they are solid or liquid at room 
temperature. If the fatty acids (see Table 1, page 25 for examples) substituted in positions 1 
and 3 are different the C-2 becomes a chiral centre and two streoisomers are possible, 
although most triglycerides in nature are the L form.
PG portion of SAPL contains some of the fatty acids listed in Table 1, (page 25), (see also 
Appendix 14: Additional Information on SAPL, page275). The unsaturated fatty acids in 
Table 1 contain double bonds, and introduction of these double bonds into the fatty acid part 
of an acylglycerol lowers the melting point of the compound. Thus, animal fats, which 
contain high amounts of triglycerides with fully saturated fatty acids are solid at room 
temperature, while vegetable and fish oils which have a high proportion of unsaturated fatty 
acids, are liquid at the same temperature.
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Name Type Formula Symbol
Laurie Saturated CH3(CH2)ioCOOH 12:0
Mystric Saturated CH3(CH2)i2COOH 14:0
Palmitic Saturated CH3(CH2)14COOH 16:0
Stearic Saturated CH3(CH2)16COOH 18:0
Oleic Unsaturated CH3(CH2)7CH=CH(CH2)7COOH 18:1*9
Linoleic Unsaturated CH3(CH2)4CH=CHCH2CH=CH(CH2)7COOH 18:2°9-12
Linoleni Unsaturated CH3(CH2)CH=CHCH2CH=CHCH2CH=CH(CH2)7COOH 18:3°9-12-15
Arachiod Unsaturated CH3(CH2)4(CH=CHCH2)3CH=CH(CH2)3COOH 20:4o5-8-n-14
Table 1: Some Common Fatty Acids Found in Living Organisms.
In Table 1, the first number denotes how many carbon atoms are in the chain, and the second 
number indicates the number of double bonds. The symbol and a number indicate the location 
of the double bond. Autoxidation and photo-oxygenation are two aspects of the non-enzymic 
reaction between oxygen and unsaturated fatty acids (Gunstone et al 1994). Lipids are liable 
to undergo oxidation during storage and handling, involving complex substrates and ill- 
defined reaction conditions. The primary oxidation products are often converted to secondary 
products of several kinds. Autoxidation is a radical chain process involving initiation, 
propagation and termination reactions. Photo-oxidation involves interaction between a double 
bond and singlet oxygen produced from ordinary triplet oxygen by light in the presence of a 
sensitiser such as chlorophyll. Photo-oxidation is a quicker reaction than autoxidation. A 
detailed account of the oxidation of lipids is given elsewhere (Chan 1987).
Liposomes, or lipid vesicles, are spherical, self-closed structures composed of curved lipid 
bilayers, which entrap part of the solvent, in which they freely float, into their interior (Lasic
1993). Liposomes vary in size from 20nm to several dozen pm, while the thickness of the 
membrane is around 4nm. Liposomes are made predominantly from amphiphatic molecules, 
such as lecithin, and are not water soluble, instead they form colloidal dispersions. 
Hydrophilic portions of liposomes tend to be in contact with water whilst the hydrophobic 
parts prefer to be hidden in the interior of the structures. Liposomes can be large or small and 
may be composed of several hundred concentric bilayers. A detailed account o f all aspects of 
liposomes can be found elsewhere (Lasic 1993).
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1.2.2.4 Neonatal RDS (nRDS)
In the late 1950s, it was shown that premature babies were deficient in pulmonary surfactant 
and that this was closely associated with RDS and hyaline membranes in the lungs of those 
babies who died (Avery and Mead 1959).
The foetus in the uterus makes respiratory movements, but its lungs remain collapsed at birth. 
After birth, the infant makes several strong inspiratory efforts, the lungs expand, and the 
surfactant prevents them from collapsing again. Surfactant deficiency is the cause of hyaline 
membrane disease, known as RDS, which is a serious pulmonary disease that develops in the 
newborn and premature babies bom before their surfactant system is fully functional. Surface 
tension in the lungs of babies is high and there are many areas in which the alveoli are 
collapsed (atelectasis). RDS seems to be more common in neonates with low plasma levels of 
thyroid hormones than in those with normal plasma levels. As many as 40,000 infants 
develop RDS in the US, annually (Ishisaka 1996). The incidence of the disease is inversely 
proportional to the gestational age of the neonate, and more than 70% of babies bom with 
between 25-30 weeks are affected. The symptoms, which include grunting, tachypnea, nasal 
flaring and increased oxygen requirements usually develop within six hours of birth (Ishisaka 
1996).
The standard treatment consists of nebulised surfactant being linked to the ventilation system 
in intensive care units. The different types of treatment for RDS will be discussed later.
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1.2.2.5 Treatment
At present, therapy of patients with ARDS is supportive (Spragg et al 1992) and the 
pulmonary permeability cannot be reversed directly (Watling and Yanos 1995, Bersten et al
1998). Gas exchange in patients is maintained with supplemental oxygen and mechanical 
ventilation. However, as yet, a definitive role and frequency of ventilation in the treatments of 
ARDS has not been established because large multi centre trials researching this avenue has 
not been initiated (Herridge et al 1998).
Attempts have been made to treat ARDS with the delivery of exogenous surfactant (Lachmann 
1989, Norton 1990, Nosaka et al 1990, Anzueto et al 1994, Gregory et al 1994, Spragg et al 
1994, Lewis Veldhuizen 1995, Balaraman et al 1998). Delivery has either been via tracheal 
instillation or by aerosolisation. Animal studies have shown that several factors influence the 
degree o f efficacy, these include: the delivery method; the timing of surfactant treatment over 
the course of the injury; the specific surfactant preparation used; and the dose administered. 
Each of these factors alone or in combination may affect the patient’s alveolar environment, 
and thus the effect of the treatment. Results have shown that in the early stages of injury, 
aerosolised surfactant does benefit the patient. At later stages, large quantities of instilled 
surfactant are necessary to achieve any benefit. Whether tracheal instillation or aerosolisation 
of the surfactant is the preferred treatment is still being established. Instillation delivers more 
surfactant to the injured lung over a relatively short period of time compared to aerosolisation. 
However, delivering large boluses of material into an acutely injured lung may not be optimal. 
Therefore, although surfactant therapy is possible in adults, only modest improvements in gas 
exchange are observed, which may vary from patient to patient (Nosaka et al 1990, 
Wiedemann et al 1992). One pattern which has appeared from the various forms of treatment 
is that, ARDS due to sepsis and pneumonia is associated with a high mortality rate, whereas 
ARDS secondary to trauma has better prognosis (Nolan et al 1997, Vanderzwan et al 1998, 
Raymondos et al 1999).
As mentioned earlier, unlike neonatal RDS which is caused by surfactant deficiency, the lung 
injury associated with ARDS is much more complex and therefore harder to treat. Other 
treatments, apart from surfactant therapy, have included the non-steroidal anti-inflammatory
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drugs (NSAIDs) in animal models (Messent and Griffiths 1992) and corticosteroids (Bernard 
et al 1994) in humans. NSAIDs were chosen in animals because they are able to decrease the 
inflammatory process in the lung, no human trials have been carried out. Corticosteroids also 
have anti-inflammatory properties but have shown no significant effect against the disease. In 
summary, mortality from ARDS is usually due to multiple-organ failure, rather than causes 
directly related to lung injury (Montgomery et al 1985). Studies on survivors of ARDS have 
shown that lung mechanics return to normal within one year (Elliot et al 1981, McHugh et al
1994).
Surfactant therapy for the treatment of RDS in neonates is now an established and essential 
element in the care of the preterm infant (Griese and Westerburg 1998, Lemons et al 1999). 
The therapy is divided into two categories: Surfactants derived from natural sources: artificial 
or synthetic surfactants made in the laboratory (Morley 1988). Surfactant therapy is aimed at 
premature babies <30 weeks of gestation. An improvement in lung compliance and general 
condition of the infant is apparent within 48 hours of surfactant administration. Mechanical 
ventilation strategy during RDS is characterised by positive end-expiratory pressure, increase 
in the respiratory time, and high inspiratory oxygen concentration (Fraisse et al 1998).
1.2.2.5.1 Naturally Derived Surfactants
Some examples of surfactants used in clinical trials, which are derived from natural sources 
include: Surfactant TA (Surfacten®, Tokyo Tanabe, Tokyo, Japan). Calf-Lung Surfactant 
Extract (CLSE, NY, USA), Porcine surfactant (Curosurf®, Serono Laboratories (UK) Ltd.), 
Human Amniotic Fluid Surfactant (HAFS) (currently, not in use), Beractant (Survanta®, 
Abbott Laboratories Ltd., UK), Infasurf (Forest Labs, St.Louis, USA) and Alveofact (Thomae 
GmbH, Biberach, Germany). These drugs are all administered via an endotracheal tube 
installation and are intended to replenish the reduced levels of indigenous surfactant within 
premature babies.
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Surfactant TA was developed by Fujiwara et al (1980) and is derived from homogenised 
bovine lungs and was the first efficacious surfactant used in humans. The medicine contains 
84% phospholipids, 8% palmitic acid, 7% tripalmitin and 1% SP-B and SP-C. It is a freeze- 
dried preparation and between 100-120mg is sonicated for 5 minutes in physiological saline 
(3-4ml) and administered.
CLSE is also naturally produced and is made by washing the surfactant out o f bovine lungs 
with physiological saline. It was developed in collaboration of groups from USA, UK, and 
Canada. The preparation contains 63% saturated PC, 32% other phospholipids, 4% 
cholesterol and cholesterol esters, and 1% hydrophobic protein (SP-B and SPC). Controlled 
trials of prophylactic use of CLSE have been done in infants of 24-28 weeks’ and 25-29 
weeks’ gestation (Kwong et al 1985). Mortality and morbidity was decreased significantly.
Curosurf® is obtained from minced porcine lungs by chloroform-methanol extraction and 
liquid gel chromatography. It contains 41-48% saturated PC, 51-58% other phospholipids, 
and about 1% SP-B and SP-C, without triglycerides, cholesterol or fatty acids. It is used as a 
suspension of 80mg/ml and at 200mg/kg (Noack et al 1987). Prophylaxis therapy in multi­
centre trials has shown a decrease in the incidence and severity of RDS (Egberts et al 1993).
HAFS a modified natural surfactant produced by collecting amniotic fluid from caesarean 
sections of some foetal deliveries. Amniotic fluid provides the foetus with favourable 
conditions for absorbing mechanical pressures and yet allowing freedom of movement. While 
the foetus skin is still permeable, the fluid forms an extension to the foetal extracellular fluid. 
When the skin becomes impermeable, the balance of amniotic fluid is that added by foetal 
urine and that taken away by foetal swallowing. Changes in fluid levels can give an indication 
of lung maturity in premature babies (Hallman et al 1985). HAFS was used as 60mg 
suspended in 3-5ml of 0.6% saline. This product was only used for efficacy trials and is not 
available commercially.
Survanta® is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, 
and surfactant-associated proteins. Additional DPPC, palimitic acid, and tripalmitin are added
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to improve its surface tension lowering properties. Each dose of Survanta® is 4ml/kg. Several 
randomised trials have shown the drug to be effective either prophylactically or as rescue 
therapy, with immediate improvements in gas exchange (Sehgal et al 1994).
Infasurf® is a chloroform-methanol extract of neonatal calf lung lavage without supplements. 
It contains 35mg/ml of phospholipids, 55-70% of which is saturated PC and the dose is 
3ml/kg. Infasurf contains SP-B and SP-C, but not SP-A. Since it is prepared from lung 
lavage rather than lung mince, it may contain less unwanted ingredients. Trials have shown 
the drug to increase the survival chances of infants with birth weights <1000g (Repka et al 
1992).
Alveofact is obtained from bovine lung lavage and contains up to 1% SP-B and SP-C, 88% 
Phospholipids, 4% Cholesterol, and 8% other lipids. The dosing is 1.2ml/kg and delivers 
about 50mg/kg of phospholipids. Trials in Germany have shown increased survival rate 
against a control group (Gortner et al 1992).
1.2.2.5.2 Artificially Derived Surfactants
Artificially derived surfactants for use in RDS treatment have included: Exosurf® (Wellcome 
UK), and Artificial Lung Expanding Compound (ALEC), (Britannia Pharmaceuticals). Like 
naturally derived surfactants, these too are administered via an endotracheal tube instillation.
Exosurf® (Colfosceril Palmitate) is a synthetic, protein free surfactant consisting of 85% 
DPPC, 6% tyloxapol (non-ionic surfactant) and 9% hexadecanol (cetyl alcohol) by weight. It 
comes as lyophilised powder and is administered as a suspension and contains 67.5mg/5ml of 
drug substance, which is re-constituted (108mg) with 8ml of water for injections. The 
tyloxapol and cetyl alchol facilitate the adsorption and spreading of the DPPC. In multi-centre 
trials a single dose, used prophylactically, has been shown to reduce infant mortality (Durand 
et al 1985, Stevenson et al 1992).
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ALEC (also called Pumactant) was synthesised in 1977 at Cambridge, UK, by Morley. It is 
composed of DPPC and unsaturated phosphatidylglycerol in the ratio of 7:3 (see Figure 1, 
page 13 for structures). It contains no protein and has been used in trials both as a powder and 
as a suspension (50-100mg in 1ml cold saline). The compound is a white, sterile, freeze-dried 
powder contained in vials and is ready for reconstitution. When reconstituted, the product is a 
white, creamy suspension and contains about 10.8mg of sodium. ALEC contains no 
antimicrobial preservatives and should therefore be reconstituted and used within 8 hours. It 
has been shown to reduce the severity of RDS in neonates and has few or no undesirable side- 
effects (Morley 1987). In a multi-centre trial on 328 premature babies, between 25-29 weeks 
gestation, neonatal mortality was reduced from 27% to 14%, the need for respiratory support 
was also significantly reduced (Ten Centre Study Group 1987). A follow-up study carried out 
by Morley (1990) on the same babies, three years later, showed no difference between treated 
and control groups in the incidence of mental impairment, respiratory infections, allergies, or 
hospital admissions. Precisely 57% of the treated group were still alive compared with 41% 
of the control group.
To date, over 10 000 infants have been treated in randomised clinical trials using surfactant 
therapy (Hellmann 1995). Currently, there is no conclusive data to support the routine use of 
one surfactant over another (Ishisaka 1996, Griese and Westerburg 1998). However, specific 
preparations under a specific clinical situation may be preferable (e.g. natural surfactants may 
be preferred in cases where the biological system is poorly functional). New surfactants are 
being developed and evaluated, new techniques of administration such as aerosols, are being 




Publications over the years have indicated that a dysfunction of pulmonary surfactant system 
might partially explain the pathophysiology of asthma, and COPD (Chen et al 1998, 
Enhoming et al 1996, Hills et al 1996a, 1996b, Holgate 1998, Kurashima et al 1991, Liu et al 
1995, 1996, 1997, Postle 1995, Vanderzwan et al 1998, Wang et al 1998). Some authors 
(Holgate 1998, Reddington et al 1998) have also outlined that surfactant dysfunction is 
indirectly responsible for airway inflammation and subsequent alteration of airway mechanics 
(see 1.2.1.2 The Inflammatory Process and Bronchial Epithelium, page 5). From the relatively 
few studies carried out, it has also been suggested that pulmonary surfactant may have a 
protective role against the pathogenesis of asthma by acting as a potential prophylactic agent, 
by forming a physical barrier against potential irritants that may initiate inflammation of the 
airways. A hypothesis for this barrier model will be proposed, and results of clinical trial of 
surfactant administration to date will be reviewed.
1.3.1 Potential Uses in Asthma
The concept of a partial barrier function of surfactant separating bronchial air from the 
receptors that elicit bronchoconstriction was outlined by Hills et al (1996a, 1996b) and further 
endorsed by Hohlfeld et al (1997). Hills has used his argument of surfactant binding to 
epithelium tissue (see 1.2.2.3.2 Physiological Mechanisms for the Action of Pulmonary 
Surfactant, page 14) to prove the existence of surfactant in the upper airways (Ueda et al 1985, 
Hills 1990, Hills et al 1996). This proof is in the form of electron photomicrographs of the 
epithelial cells in the airways, which are lined with multilamellar (oligolamellar) layers of 
SAPL (see Figure 9, page 33).
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Figure 9: An electron photomicrograph of bronchial epithelium, rinsed free of mucus.
Note the oligolamellar layers of surface-active phospholipid (SAPL).
These same oligolamellar layers have also been described adjacent to the taste receptors of the 
tongue (Sbabarti et al 1991) which led to Hills’ (1996a) hypothesis o f the physical barrier 
concept for the surfactant. The theory states that the function o f SAPL layers in the airways is 
to ‘mask’ smooth muscle and nerve terminal receptors and, thus, moderate the 
bronchoconstrictive reflex to any noxious stimuli or other airborne triggers, which may lead to 
airway hyperresponsiveness and inflammation (Hills et al 1996b). This theory is an extension 
of the concept derived by Pride (1989), that asthma represents a loss o f normal mechanisms 
restricting the effects of smooth muscle contraction. The source of the surfactant found in the 
upper airways are lamellar bodies (Haller 1994), which have also been observed on epithelial 
surface (Hills 1995) and in the Golgi complex associated with the cells secretory system. 
These cells are directly exposed to any noxious agents in the inspired air and they appear to be 
secreting SAPL to mask their own receptors, thus, moderating the sensitivity of the 
constrictive reflex.
The ‘unmasking’ or ‘uncovering’ of receptors as a mechanism for explaining sensitisation of a 
particular reflex is commonly used in neurophysiology. Typically, only 1-5% of the receptors 
are unmasked at any one time, and 95-99% remain masked. Knowing that phospholipids and 
phosphatidylcholines (PC) in particular are present in every cell in the body, and in their
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disaturated form (DSPC) constitute the lung surfactant. It can be argued that, surfactant 
molecules can pack together very tightly as depicted in Figure 10. Surfactant is also present in 
the stomach where DSPC has been demonstrated to be a corrosion inhibitor, proving 
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Figure 10: A diagram showing the adsorption of DSPC molecules to a receptor surface.
The above is achieved by reversible binding of the positive charge at the polar end to negative charges that 
are present on all tissue surfaces. The non-polar ends are orientated outwards and, as straight (saturated) 
fatty-acid chains, pack together to form a barrier and render the surface hydrophobic. Reproduced from 
Hills et al (1996b), with the author’s permission.
Agents which may promote or compromise the non-specific barrier of SAPL and cause 
adsorption or desorption of surfactant include the following:-
a) Physical Agents: Any layer of SAPL renders the surface hydrophobic, therefore, 
impermeable to water and resistant to fluid shifts across the epithelial surface. However, 
strong osmotic gradients could cause the barrier to be ruptured, explaining bronchial 
hyperresponsiveness to non-isotonic aerosols (Smith and Anderson 1990). With hypertonic 
aerosols (e.g. seawater spray) the outward shift of fluid from the tissue would lift the coating 
off the receptors. However, hypertonic aerosols do not strip the airways of epithelial cells, so 
a coating of adsorbed surfactant could provide a semi-permeable membrane. Fluid shifts 
across into the airways occur during increased ventilation (e.g. exercise), explaining why
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some asthmatics become more sensitised during this period (Woodcock 1992). Some airborne 
particles such as a-quartz have a strong affinity for surfactant and would, hence, compete with 
the receptors for adsorbed SAPL. This competitive adsorption could explain dust-induced 
asthma or similar forms of occupational asthma.
b) Dietary Aspects: One important aspect of the adsorbed SAPL layer is its need to be 
comprised of DSPC, so that it can form the close mosaic packing depicted in Figure 10. 
Therefore, a dietary change from a predominantly saturated to unsaturated fats could lower the 
proportion of SAPL being DSPC. This would result in a less-effective masking agent, which 
may explain the link in switch from butter to margarine over the last decade, which has 
coincided with a ten-fold increase in childhood asthma over this period (Hodge et al 1994). 
Claims have also been made that consumption of fish oil, rich in saturated lipids, leads to 
lower incidences of asthma (Hodge et al 1995).
c) Chemical Agents: If the gastric mucosal barrier theory is correct, then agents which 
compromise the barrier and lead to ulcers should also provoke asthma. One such agent is bile, 
known to induce heartburn if present in gastro-oesophageal reflux. There are suggestions that 
bile in its aspirated form may travel up the airways and potentiate asthma (Urschel and 
Paulson 1967). Some enzymes which can potentially break down the surfactant barrier are 
contained in the faeces of house dust mite, known to cause asthma (Voorhorst et al 1967). 
Leakage of plasma proteins into the airways during the inflammation process (as described in 
1.2.1.2 The Inflammatory Process and Bronchial Epithelium, page 5) have been shown to be 
reduced by surfactant secretion, thus, preserving the adsorbed SAPL layer (Robertson and 
Taeusch 1980).
d) Other Agents: Steroids have been shown to promote the secretion of SAPL in the lung 
(Torday et al 1975), thus replenishing the SAPL barrier resulting from inflammation. Mucus 
may have an important role in stabilising the hydrophobic layer of the SAPL barrier by 
reducing its interfacial energy with bronchial fluid, thus, SAPL deficiency could be linked to 
viscid mucus plug found in the airways of asthmatic patients (Barnes and Thompson 1992). 
Prostaglandin (PGE2) has been shown to have an inhibitory effect in the airway nerves, 
reducing the bronchoconstrictor response. PGE2 is also known to be involved in surfactant 
synthesis (Lichtenberger et al 1985). P2-agonists are known to invoke an immediate and
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dramatic release of airway surfactant when administered, so they help in the replenishment of 
the barrier (Enhoming 1989).
e) Asthma Challenge Agents: Histamine or Methacholine are used in diagnostic challenge 
tests in asthma. These substances test the integrity of the SAPL barrier by competing with 
SAPL for adsorption sites on the epithelium receptor surfaces. Methacholine and its isomer, 
acetylcholine, both posses a quaternary ion, which as a positively charged group, enables 
SAPL to bind to negatively charged epithelium. Hohlfeld et al (1997) has suggested that 
surfactant aerosol may prevent acetylcholine from reaching the airway smooth muscle.
Use of exogenous surfactant to treat asthma was first carried out in a pilot study undertaken by 
Kurashima et al (1991). Exosurf® was administered via nebulisation (lOmg/ml dose) to 
eleven volunteers with allergic asthma. Results showed marked improvements in respiratory 
functions including improvements in: Forced Vital Capacity (FVC), Forced Expiratory 
Volume in 1 second (FEVi), Maximal Mid-expiatory Flow (MMF), and improvements in gas 
exchange. Since Kurashima’s pilot study, published papers indicate that surfactant 
aerosolisation has either led to improvements in or has an important role in the following:-
a) Maintaining the patency and stability of the small airways- as shown by (Enhoming et al 
1995, 1996, Hohlfeld et al 1997, Liu et al 1991, 1996, and Vanderzwan et al 1998).
b) Improvements in Bronchial Clearance- as shown by Schurch et al 1990.
c) Modulation of the function and repair mechanisms of respiratory inflammatory cells- (Van 
Iwaarden 1992, Holgate 1998, Hoymann et al 1998).
d) Increase in airway hyperresponsiveness, a decrease in surfactant production and activity in 
asthmatics due to plasma protein leakage into the airways or other factors- (Hoymann et al 
1998, Kurashima et al 1997, Lemarchand et al 1992, Liu et al 1995 and 1997).
e) Improvements in Pulmonary Function- (Anzueto et al 1997, Kurashima et al 1991)
Future investigations are likely to concentrate on:-
a) Attaining a better understanding of the role of the surfactant in the inflammatory process, 
both in-vitro and in-vivo.
b) Attaining more human data on the effect of aerosolised exogenous surfactant on asthma.
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c) Definitive elucidation of the pathogenesis of asthma with respect to the pulmonary 
surfactant.
d) Mechanisms and pathways leading to increased secretion of indigenous surfactant.
1.3.2 Potential Uses in Non-Respiratory Disorders
The potential use of surfactant therapy in areas other than respiratory disorders have been 
outlined by a number of authors (Hills 1984, Fomadley and Bums 1994, Nemechek et al 
1997, Yamanaka 1991). Interest in this area has arisen because of the discovery of the 
existence of surfactant producing (lamellar body) secreting cells in extrapulmonary sites 
(Dobbie and Anderson 1996). These sites include the serosal mesothelium (peritoneum, 
pluera, and pericardium), and joints (type A and type B synovocytes). Thus, research into 
non-respiratory, systemic conditions has intensified, where for the first time an organelle and 
associated proteins (i.e. SP-A and SP-A like proteins) provide a link between diverse tissues 
affected by a common substance (i.e. surfactant).
1.3.2.1 Intraperitoneal Postsurgical Adhesions
The presence of surface active phospholipids (SAPL) has been demonstrated to be present in 
the pleural surfaces of dogs as far back as 1982 (Hills et al 1982). Hills postulated that SAPL 
might have effects such as lubrication and conferring of water repellency to surfaces. 
Furthermore, he went on to say that phospholipids adhered to both parietal and visceral pleural 
surfaces, held in place by the attraction of the positive charge of the choline head group to the 
negative charge of the pleural surface. Grahame et al (1985) made the implications of these 
findings to patients with adhesions. Since then, some authors have reported that 
phosphatidylcholine (PC) reduces post-surgical adhesions in animal models (Rozga et al 1990, 
Rajab et al 1991, 1995, Hills 1992a, 1992b, Hills et al 1996c, 1998, Kappas et al 1992, Snoj et 
al 1992). More recently, lamellar bodies have been shown to be present in the human 
peritoneum in a detailed study carried out by Dobbie and Anderson (1996). Hills et al (1996c)
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further proved the existence of SAPL as oligolamellar layers adsorbed to pleural mesothelium. 
He postulated that SAPL probably lubricates pleural sliding, and this concept has been 
transposed to the peritoneum where SAPL has been detected in the dialysate fluid following 
continuos ambulatory peritoneal dialysis. Heu et al (1997) confirmed the presence of PC in 
the peritoneum along with surfactant proteins SP-A, SP-B and SPD. It is proposed that the 
SAPL is very similar in composition to surfactant on the alveolar surface of the lung. 
Postoperative adhesions (after laparotomy) are a common and serious surgical problem 
resulting in considerable morbidity and economic loss (Beck 1997). In a British study carried 
out in 1990 and 1993, adhesions were found in -24,000 patients, 93% of patients who had 
undergone abdominal procedures (Menzies and Ellis 1990, Scott-Coombes et al 1993). Whilst 
in the USA over 400, 000 surgeries were performed for adhesiolysis in 1993 (Beck 1997). 
The average hospital stay for adhesion patients is -15  days, with the cost o f hospitalisation and 
subsequent care running into millions of pounds and dollars.
Figure 11: An example of a real adhesion operation in the clinic
Adhesions are the main cause of mechanical small bowel obstruction and female infertility 
(Ellis et al 1999, Rajab et al 1991). Furthermore, the presence o f these adhesions makes re­
operation difficult. Treatment and prevention of adhesions have included the use of 
mechanical barriers, topical agents, anti-inflammatory drugs, physical agents, anticoagulants, 
fibrinolytic agents and enzymes (Rajab et al 1991). Osada et al (1999) have reported the use 
of a haemostatic and anti-adhesion preparation to prevent post-surgical adhesions.
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TachoComb, an experimental product, consisting of equine collagen in a sponge-like form 
coated on one side with human fibrinogen and bovine thrombin was used as a haemostatic and 
a physical barrier to inhibit post surgical adhesions. However, as yet, there is no established 
treatment. The use of SAPL in the treatment of adhesions is a real possibility.
1.3.2.2 Otitis Media with Effusion (Glue Ear)
Persistent otitis media with effusion (OME), or glue ear, is the most common cause of hearing 
loss during childhood, and the most frequent cause for elective surgery in children (Maw et al 
1999). If left untreated, glue ear can lead to impairments in language and speech 
development. In the short term, the hearing deficit due to effusion in the middle ear is 
correctable by insertion of a ventilation tube (grommet). In the long term, hearing gain after 
ventilation tube is not maintained. Whilst effective, ventilation tubes do carry the risk of 
allowing water (and thereby infection) into the ear and therefore the patient must keep their 
ears dry for the duration that the tube is in place (8-12 months). Ventilation tubes also carry 
the additional risks of causing: 1) infection by acting as a nidus and 2) residual perforation of 
the eardrum after the tube has been extruded.
Under normal physiological conditions, the middle ear (an air filled cavity) opens via the 
auditory (Eustachian) tube into the nasopharynx and through to the exterior. The tube is 
usually closed, but during swallowing, chewing, and yawning it opens, keeping the air 
pressure on both sides of the eardrum equalised. However, glue ear in children may develop 
as a result of viral, bacterial, or allergic agents that cause fluid accumulation. As a result the 
mucous membranes at the aural end of the Eustachian tube have been described as been ‘glued 
together’, which in turn prevents the normal flow of gases (Pearlman 1967).
It has been hypothesised that SAPL plays a role in normal Eustachian tube function, and in- 
vivo animal studies have shown that surfactant treatment by direct, topical application of drug 
to the middle ear may be a viable alternative to surgery (Hills 1984, 1992a, Fomadley and 
Bums 1994, Nemechek et al 1997). SAPL found in the Eustachian tube has essentially the 
same physical and chemical properties as surfactant present in the lung (Birken and Silen
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1973). Middle ear exudate contains an appreciable amount of proteins (Juhn and Huff 1976). 
Proteins are very effective adhesives and serous otitis media is a condition in which the 
luminal surfaces of the Eustachian tube become very adhesive due to serous effusion resulting 
in poor middle ear ventilation and fluid accumulation leading to hearing difficulties. The 
SAPL identified in the Eustachian tube are absorbed to the epithelial cells lining the walls of 
the tube where they form a protective barrier and oppose the strongly adhesive nature of these 
proteins (Hills 1984). It has been shown that indigenous SAPL recovered from irrigation of 
the Eustachian tube with saline is an excellent release agent, reducing the force of adhesion 
between two surfaces glued by albumin by 94% (Hills 1984). This implies that applying 
exogenous surfactant (i.e. SAPL) to the Eustachian tube would facilitate tubal opening and, 
thus, reduce the risk of serious otitis media.
1.4 Aerosol Characteristics
The use of inhaled therapeutic aerosols is a common and established method for the treatment 
of lung diseases such as asthma and irreversible chronic obstructive lung disease.
An aerosol is defined as a relatively stable colloidal suspension of solid or liquid particles in a 
gas, usually air (Byron 1990). The aerosols may either be in the form of a pressurised metered 




The efficacy of the inhaled aerosol depends upon some factors regarding the particles that 
comprise the aerosol. The aerosol must be able to reach the desired site of action in the 
respiratory tract (i.e. pulmonary region). Effective, therapeutic concentrations of the aerosol 
must be delivered within a small number of breaths for a device or formulation to be practical. 
The aerosol particles must be capable of releasing the drug particle at the site of action, before 
clearance mechanisms carry the compound away from the deposition site.
1.4.2 Dry Powder Formulations for Inhalation
Dry powder formulations can consist of: drug particles with no other components, drug with a 
coarse carrier particle (a binary blend), drug and carrier particle plus other excipient(s) 
(ternary blend), or even more complex systems involving carrier particles of different sizes 
and excipients as well as the active compound. A variety of terms (e.g. ED, FPF, FPD) are 
used to describe the aerosol performance, in-vitro. These terms are defined in Table 5, page 
70.
In order for a drug particle to reach the lung, it must have an aerodynamic size range of 1-5 pm 
(density ~1 ±0.5 g/cm3), termed the respirable fraction. However, recent publications by 
Edwards et al (1997, 1998a, 1998b) have argued that large porous particles of insulin with 
mass density <0.4g/cm3 and aerodynamic diameters of >5pm are also respirable. Edwards has 
shown that these particles escape the clearance mechanisms of the lung by virtue of their size, 
and that delivery of insulin to the systemic system resulted in elevated levels of the drug for 
up to 96 hours. In-vitro studies showed a fine particle fraction (FPF) o f 50 ±10%. In-vivo 
studies in rats showed that tracheal deposition of the porous particles were 46% compared 
with 79% for non-porous particles. The percentage porous particles reaching the rat lung were 
an order of magnitude higher than the non-porous material.
To get the desired size range, techniques such as milling and spray-drying may be employed. 
To aid dispersion of the small drug particles and increase the emitted dose from a delivery
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device, coarse and / or fine carrier particles (usually lactose) may be used in the formulation. 
In addition, the various physical forces that govern particle aggregation and adhesion must be 
well understood.
1.4.2.1 Particle Size
Particle size is the most important parameter for characterising the physical behaviour of 
aerosols (Colbeck 1998). Aerosols can have a wide variety of shapes and size (termed 
polydisperse). The particles in question may be spherical, fibrous, or aggregates of small 
particles of similar or different shapes. Consequently, it is difficult to describe an aerosol 
using a single number. The term aerodynamic diameter (D a) is one way of describing size of 
a particle and is related to the settling velocity of that particle in air. Da is the diameter of a 
perfect sphere of unit density (1 g/cm3, equivalent to 103 kgm'3 in S.I. units) that has the same 
terminal settling velocity in air as the particle in question (Byron 1990).
To describe an aerosol, precisely, one needs to describe the size of the particles in terms of 
some measure of the shape of the distribution. The most popular size distribution of physical 
phenomena is the normal (Gaussian) distribution (Colbeck 1998). This distribution can be 
described by the mean value and the standard deviation. However, this type of distribution is 
not seen in aerosol science except in cases where particles are monodisperse. Aerosols exhibit 
a skewed distribution due to their polydispersity, with a long tail in the distribution curve that 
extends out to relatively large particles. These types of distributions are often described as 
being log-normal. Therefore, geometric mean (GM) value and geometric standard deviation 
(GSD) are used to describe the distribution. GM and GSD are obtained from count or mass 
distributions. The median diameter (which for a log-normal distribution equals the geometric 
mean) is termed the count median diameter (CMD) or mass median diameter (MMD). 
Therefore, CMD is equivalent to the particle diameter at which 50% of all particles in a 
polydisperse, log-normally distributed, systems have a larger diameter than this value.
MMD is the particle diameter above which 50% of the aerosol mass is contained. Area 
median diameter (AMD) is the particle diameter above which 50% of the aerosol surface area 
is contained. The GSD and GMD can be used to calculate the MMD and AMD in a log­
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normal aerosol distribution using the equations first derived by Hatch and Choate in the 
1920s. Mass median aerodynamic diameter (MMAD) can be calculated by first calculating 
the MMD and then manipulating the figure to take account of the particle density. MMAD is 
the particle diameter at which 50% of the aerosol mass is contained in particles above that 
diameter and 50% is contained in particles below that diameter (Brain and Blanchard 1993).
1.4.2.1.1 Methods for Altering and Controlling Particle Size
Coarse powders can be made respirable by milling, types of which include ball milling, 
colloid milling, hammer milling, and air-jet (also called fluid energy or attrition) milling. The 
majority of inhalation powders are prepared by jet milling employing a process known as 
micronisation. This and the other types of milling are destructive in the sense that solid 
particles are shattered, and reduced in size due to collision or grinding (Johnson 1997). 
Constructive methods of particle reduction also exist, they are spray-drying, freeze-drying 
(lyophilisation), and supercritical fluid particle generation (Sacchetti and Van Oort 1996).
The type of milling employed generally depends on the required products. Hammer and ball 
milling generally reduce particle size to -5 0 pm, although smaller particles can be obtained 
depending upon how brittle the sample is. Ball milling has been around for about 100 years, 
and utilises the motion of tumbling bodies (usually spherical stainless steel balls) within a 
closed container which rotates (Prior et al 1990). When the sample is introduced, direct 
pressure is applied by impaction or shear to pulverise and grind the material.
Colloid mills are wet mills that consist of high-speed, profiled, disc-shaped rotors, which force 
the suspension, under high pressure, through narrow gaps into a housing. The particle size 
reduction is dependent on the size of the gap and the rate at which the material is forced 
through it.
Hammer mills reduce particle size by applying impact stress on the solid surface, from 
implements that swing from a rotor. The velocity of the rotor and the grinding action of the 
implements allow for continuous milling, limited only by the feed rate of the sample. There 
may also be a grate or a screen, and the perforations on them determine the final particle size.
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In air-jet milling, size reduction is obtained by particle-particle collision and attrition 
(Carstensen 1993). Particles are carried on a high-velocity air jet in a direction opposed by an 
equally large opposing jet. The resulting turbulence causes particles to collide at high speed 
and to fracture into smaller ones. The gas stream moves in a spherical path and smaller 
particles exist near the mill’s centre (cyclone) and are directed into a collection vessel. Large 
particles are forced to the periphery by centrifugal forces and stay in the cyclone to undergo 
more inter-particle collisions, until they are small enough to be directed into the collection 
vessel. Crystalline or friable material can be micronised to <5pm, ductile materials are 
unsuitable for micronisation and may require chilling or immersion into liquid nitrogen in 
order to make them more brittle. The rate of micronisation depends upon the dimensions of 
the feed hopper and the nature of the sample.
These destructive methods of milling although good at reducing particle size, have some 
disadvantages, they include: sample charging, production of cohesive products, being 
unsuitable for some products (e.g. micro-crystalline cellulose), loss in crystallinity and scale- 
up problems (York and Hanna 1997).
The constructive methods for altering and controlling particle size include freeze-drying, 
spray-drying, and supercritical fluid technology. Freeze-drying or lyophilisation is used 
extensively in the preparation of protein and peptide formulations. However, one cannot 
control the size or morphology of the particles, and powders produced are often coarse / 
amorphous and require milling or spray drying for reduction in size (Johnson 1997). Spray 
drying is a one-step process that converts a liquid feed to a dried particulate form (Sacchetti 
and Van Oort 1996). The feed can be a suspension / slurry, colloidal dispersion (e.g. 
emulsions, liposomes etc.), or paste. The fluid is atomised to a spray form which is incontact 
with a hot gaseous medium. The large surface area of contact results in rapid evaporation of 
the droplets to form dried solid, often spherical, particles. Application of spray-drying to 
powder formulations for inhalation is increasing. In particular, pulmonary delivery of 
peptides and proteins (by spray drying) and subsequent powder formulation has been 
demonstrated, amongst others, by Lucas et al (1997). The main advantage of spray-drying 
with respect to pulmonary drug delivery are the ability to manipulate and control particle size, 
size distribution, particle shape, and density in addition to macroscopic powder properties 
such as bulk density, flowability, and dispersibility.
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Supercritical fluids (SCFs) have been in use in analytical chemistry for many years. However, 
it has recently been applied to powder technology for its potential to produce uniform particles 
where the size distribution and morphology can be controlled (York and Hanna 1997). Above 
a fluid’s critical point, a solute’s solubility can be altered considerably by small changes in 
pressure. A rapid de-pressurisation of a SCF containing a solute causes supersaturation, 
which leads to high nucleation and crystal formation. Carbon dioxide is used as a solvent in 
SCF applications where it is dissolved in organic solvents. The dissolved gas expands the 
liquid phase, which decreases its cohesive energy density and causes a solute to precipitate 
(Johnson 1997).
Once the desired particle size is obtained by using one or more of the methods described, it 
may be fractionated using sieving methods. The two most commonly used techniques are 
mechanical sieve analysis and air-jet sieve analysis.
1.4.2.2 Agglomerated and Carrier-Based Systems
Drug-only formulations for inhalation which consist of the active compound, and no other 
excipient, may be processed using the techniques described previously to achieve the particle 
range (l-5pm) necessary for deep and peripheral lung penetration. However, powder 
formulations usually utilise carrier particles (lactose, occasionally dextrose) as bulking agents. 
The carrier particles are introduced to the drug by various mixing techniques. These small 
particles associated with the carrier are inherently cohesive, thermodynamically unstable due 
to excessive levels of surface free energy, and have poor flow properties. Cohesion and 
adhesion of the particles to form agglomerates, and to adhere to surfaces of carriers serves to 
lower the surface-free energy and to produce more stable, ordered units that should be more 
free flowing (Lord and Staniforth 1996). These agglomerates are intended to break-up on 
delivery and inspiration to produce discrete particles for inhalation.
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1.4.2.2.1 Mixing Theory
Various types of mixing include random mixing, non-random mixing, ordered mixing, and 
total mixing. Staniforth (1982) and Travers (1988), amongst others, have extensively 
reviewed the theory and the mechanisms involved in each case. Briefly, random mixing was 
described by Yeung (1979) as a statistical process by which the bed of particles is repeatedly 
split and recombined until there is an equal chance of any individual particle being at any 
given point in the mix at any one time. The mechanisms of random theory, which include 
shear mixing, diffusive mixing, and convective mixing were outlined by Lacey (1954).
In practice, pharmaceutical powders are never random, and the theory of non-random mixing 
states that the probability of finding any constituent particle in a mix is not equal (Williams 
1969).
In order to produce a solid-solid mix, which may typically contain coarse and fine particles as 
described above, work must be done overcome the influence of gravity on the particles 
(Staniforth 1982). The system produced by mixing coarse and fine powders has been 
described as interactive or ordered. Such a system was first described by Hersey (1975). 
Ordered mixing depends upon the adhesion or cohesion of fine particles onto a host or carrier 
particle. Travers and White (1971) were the first to note that adsorption of fine particles onto 
the carrier crystal prevented the segregation normally associated with differences in particle 
size predicted by the theory of random mixing. Travers (1975) later stated that some sites in 
an ordered mix were more strongly binding than others. This was confirmed and enhanced by 
the findings of Lai and Hersey (1979), who proposed that competition for binding sites existed 
when a third component was added to the mix. Kassem and Ganderton (1990) found that low 
surface rugosity appeared to allow redispersion of the drug particles more effectively than 
carriers with high surface rugosity. More recently, Staniforth (1997) used atomic force 
microscopy (surface topography studies) to prove that there were high and low energy binding 
sites on the surface of carrier lactose particles. Furthermore, it was suggested that these high- 
energy sites adversely affected the fine particle fraction (FPF) in formulations, because the 
force of deaggregation does not exceed the force of adhesion of the drug particles to the 
carrier surface. Staniforth (1997) proposed that these high energy sites on coarse lactose
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particles may be rendered inactive by pre-blending with fine lactose particles (FPLs), leaving 
the more passive sites available for drug adhesion. As a consequence, the FPF of subsequent 
formulations treated in this way were higher than the untreated lactose carriers. In addition to 
this, Lucas et al (1997) showed that addition of FPLs to a coarse carrier not only inactivated 
high-energy sites, but that FPLs also existed as individual particles or fine particle multiplets 
(FPMs). When the drug component was added to the mix, it was shown that the drug was 
associated with the FPMs as well as adhering to sites on the coarse carrier. It was proposed 
that the liberation of the drug particles from the FPMs occurred more readily than from the 
coarse carrier. In conclusion, it was proposed that distribution of the FPL and the ternary drug 
compound on the surface of the carrier was not uniform, and combinations of FPL-FPL-Drug, 
FPL-Drug-Carrier, and Drug-carrier aggregations were present in the formulations. Staniforth 
(1997) also proposed the action of FPL on agglomerated powder systems. It was suggested 
that the presence of FPLs served to disturb interactions between cohesive drug particles so 
facilitating deaggregation.
Total mixing theory has been described by Staniforth (1981), amongst others. It encompasses 
both random and ordered events to produce a homogeneous final mix. Hence, it is considered 
that mixes produced for dry powder drug delivery contain particles mixed in a random, non- 
random, ordered, or partial ordered random configuration, or by any combination of these 
mechanisms (Staniforth 1982).
Segregation of particles in a mix occurs due to significant differences in particle size, shape, 
and density (Travers 1988). Segregation is most likely to occur in free flowing powders with 
large particle size distributions (Johanson 1996). Mechanisms of segregation include 
trajectory segregation, percolation segregation, and densification segregation and are reviewed 
in detail elsewhere (Staniforth 1982, Carson 1988, Chowhan 1995).
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1.4.2.2.2 Interparticulate Forces
Interparticulate forces can be broadly divided into two groups depending upon whether they 
arise principally due to electrostatic or molecular interactions. In 1982 Staniforth and Rees 
showed that during mixing, powder components could become charged due to electrostatic 
interactions, and postulated that the mixing vessel itself could influence the charging. 
Triboelectric charging (or triboelectrification) is a phenomenon, which occurs due to erratic 
movement of powder particles in mixes and other such environments, causing frequent 
collisions of particles with each other and with the surfaces of the vessel in question 
(Balachandran 1987, Vissier 1989). This leads to contact charging which occurs when there is 
an imbalance in the work functions between contacting solids (Stewart 1986). The work 
function is the difference in energy between the outermost conduction band of electrons (i.e. 
Fermi level), and some outer reference level (i.e. vacuum energy level). Therefore, an 
interfacial charge transfer of electrons takes place between two dissimilar materials, and the 
direction of the transfer depends upon which of the two materials (or material Vs surface) has 
a higher affinity for the electrons in that contact area (Fuhrer 1996). Once an electrostatic 
charge has developed, two types of interaction may contribute to the adhesion process in 
ordered mixes, namely the formation of electric double layers (formed at interface upon 
contact between two particles), and Coulombic interactions which arise due to interactions 
between charged particles and uncharged surfaces. Unlike chemical linkages, electrostatic 
interactions cannot be saturated and they play a vital role in particle cohesiveness and 
adhesion. Measurement of electrostatic forces and investigations into triboelectrification, 
charging mechanisms of lactose with different surfaces and measurement of adhesive forces 
has been extensively studies by Peart (1996)
Molecular interactions also have the nature of electrostatic interactions but with small charges 
or polarisations on the molecule or only on some atoms of the molecule that are responsible 
for the valencies of secondary bonds (Fuhrer 1996). These secondary bonds or van der Waals’ 
forces of attraction are classified into dipole-dipole or van der Waals’-London interactions. 
These forces are effective at short distance (0.2-lnm), when two molecules are close to each 
other and decrease rapidly with distance. The effect of these forces are only noticeable when
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they are greater than the gravitational forces or hydrodynamic interactions influencing the 
powder particles.
Interparticulate forces and interactions are influenced by a number of factors, such as: particle 
size, shape, texture, drug to carrier ratio and humidity (Bailey 1984). If the primary particles 
are irregular in shape, or deviate significantly from sphericity, their aerodynamic behaviour is 
affected, hence, shape is a component in the expression of particle diameter (Hickey and 
Concessio 1997). A variety of methods are used to define particle shape including 
microscopy, Fourier analysis and fractal analysis. These methods result in dimensionless 
numbers that reflect the magnitude of particle shape irregularity. In terms of adhesion of 
particles, as sphericity decreases, contact area between particle and carrier increases, leading 
to increases in adhesion force. However, Wong and Pilpel (1988) reported that irregular 
shaped particles formed more stable ordered mixes than spherical particles. This reason for 
this was that there were fewer contact points between irregular shaped particles and carriers 
compared with spherical particles. As the contact area increases, so do the influence of 
molecular interactions and the effects of van der Waals forces. The techniques used for 
altering particle size should be considered carefully when formulating powders, since it may 
effect particle shape. Generally, micronisation leads to irregular shaped particles, whereas 
spray-drying and SCF lead to more spherical particles. In addition, as particle size increases, 
so does surface roughness, as a result, greater energy is required to remove drug particles from 
clefts on the carrier surface (Staniforth 1987, Kassem and Ganderton 1990). Therefore, a 
compromise needs to be made between the size of the carrier particles, their surface 
roughness, and shape / size of the drug particles to compile a dry powder formulation with 
adequate deep-lung deposition profile.
The effect of humidity on adhesive forces has been studied by a number of authors (Karra 
Fuerstenau 1977, Stephenson and Thiel 1980, Thiel and Stephenson 1982, Kulvanich and 
Stewart 1988). The basic conclusion is that, adhesive forces are humidity dependent and 
adversely affect the fine particle deposition from formulations (Jashani et al 1995, Braun et al 
1996). At low relative humidities (RH) (<30%), electrostatic forces of interaction are 
dominant, but as %RH increases van der Waals’ forces become more prominent. At high RH 
values (>60%), water may be adsorbed on to the surfaces, causing particle growth and liquid 
bridges at contact points between carrier and drug particles. The rate of growth and the
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formation of the liquid bridges are dependent on how hygroscopic the drug particles are. 
Drying of formulation and / or drug particles may cause the liquid (forming the bridges) to be 
evaporated off, but this may lead to the formation of solid bridges between two particles. 
Solid bridges will also influence the deposition behaviour of the formulation. Therefore, 
hygroscopic materials may need to be stored under special conditions, such as in a desiccator 
with a saturated salt solution of low RH.
1.4.3 Aerosol Deposition Mechanisms
The three, main, mechanisms by which aerosols are deposited in the respiratory tract are 
inertial impaction, sedimentation, and diffusion (Hinds 1982,1999, Byron 1990). Other 
mechanisms such as electrostatic deposition and thermophoresis (thermodiffusion) have been 
proposed (Brain and Blanchard 1993), however. These mechanisms are considered to make 
only a minor contribution to aerosol deposition. The theories underlined in this report will 
therefore concentrate on the primary mechanisms.
1.4.3.1 Inertial impaction
A particle moving in an airstream from the nasopharynx to the tracheobronchial tree has to 
negotiate the bifurcations of the upper airways. Whether or not a given aerosolised particle 
can do this depends upon its inertia (momentum), size, mass and the velocity of the particle in 
question. When a spray leaves a pMDI (see section 1.5.1 Pressurised Metered Dose Inhalers 
(pMDIs), page 54) actuator, it does so at high velocity (~100km/h) (Current Perspectives in 
Inhaled Drug Therapy 1994). The average adult inspires at a velocity of approximately 45 
km/h. Because of this linear velocity miss-match, most of the aerosol never reaches the lungs. 
Rather, inertial impaction of high velocity, high momentum particles occurs in the 
oropharynx, tongue and soft palate, accounting for some 80-90% of the aerosol that does not 
reach the lungs. This is a typical scenario for most particles greater than 5pm (Hinds 1982,
1999), although for particles less than 5pm other deposition mechanisms can prevent deep
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lung penetration. The probability of impaction in the upper airways can be calculated as 
follows:
p d 2V
Vtk =  —-------
I f ty jR  Equation 2
Where Stk= Stokes number (a dimensionless function), p= Particle density 
d= Particle diameter, V= Velocity of air, rj= Air viscosity, and R= Airway radius
The higher the Stokes number, the higher the probability that larger particles will diverge from 
airflow streamlines, particularly in the carinal bridges of bifurcations.
1.4.3.2 Sedimentation
Sedimentation due to gravity affects particles in the size range of 1-5 pm and is a time 
dependant process. Those particles that are <0.5pm are influenced by diffusion. Deposition 
via sedimentation is the main mechanism by which the aerosol particles are deposited in the 
pulmonary region (small airways and alveolar spaces), during either breath-holding or slow 
tidal breathing. However, whether or not the particle reaches this region depends upon the 
following factors:
a) Viscous forces (drag due to the airstream) acting on the vertical direction of the particle.
b) The location of the particle within the airstream and its position with respect to the 
bifurcating airways.
c) Velocity of the particle.
d) The angle of inclination of the airway with respect to the horizontal (called the zenith 
angle).
Therefore, if  the particle is located close to the walls of the lower airways and / or does not 
have sufficient velocity, or the angle of inclination is too great to be successfully negotiated, 
then the particle will sediment due to gravity. Landahl first calculated the probability of
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sedimentation in the lower airways in the 1950s. The rate of sedimentation in air can be 
calculated using Stokes settling equation as follows:
g d 2 ( P i  ~ P 2 )
U I877 Equation 3
Where u= Terminal rate of sedimentation, pi= Density of particle, p2= Density of air 
d= Particle Diameter, r\= Viscosity of air.
This equation shows that the rate of sedimentation is dependent on particle size and density, it 
is only applicable for spherical particles settling in air.
1.4.3.3 Diffusion (Brownian Motion)
Diffusion is defined as the process whereby gasses and liquids of different concentrations 
intermingle when brought into contact, so that their concentration becomes equalised 
throughout the system (Roper 1987). Brownian motion refers to the bombardment and 
transfer of energy from air molecules to other larger particles causing these particles to 
undergo random motion (Hinds 1982, 1999, Byron 1990). The theory of Brownian motion 
(diffusion) was originally deduced by Einstein and republished in the 1950s.
Aerosol particles, like gas molecules, will tend to diffuse from regions of high particle 
concentration to regions of low particle concentration. Only particles <0.5pm are affected by 
diffusion and diffusion is the main mechanism of deposition of these particles in the lower 
airways. Compared with the previous two mechanisms, diffusion probably has the least 
influence on deposition patterns of aerosols, since most therapeutic aerosols have a low 
percentage, by volume, of particles <0.5pm diameter.
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1.4.3.4 Other Mechanisms
Particles in the airstream may be subjected to other mechanisms such as interception or 
electrostatic forces. Interception affects fibrous particles and occurs when the edges of the 
particle make contact with the walls of the airways due to its relative position and trajectory in 
the airstream. Electrostatic forces may also be responsible for depositing particles in the 
airways (Balachandran et al 1991). Particles produced by high velocity dispersions of solid or 
liquid material may be highly charged and if inhalation occurs without neutralisation in the 
atmosphere, then this mechanism may influence particle deposition.
1.5 Inhalation Devices
Despite the numerous methods that can be employed to generate aerosols, only three basic 
systems have found commercial success, these are: pressurised metered dose inhalers 
(pMDIs), dry powder inhalers (DPIs), and nebulisers, (Newman 1991, Dalby and Tiano 1996). 
There is great interest in the development of new inhalation devices and delivery systems to 
make inhalation therapy easier and more reliable for patients, to develop inhalers using 
alternative propellants, and to deliver a range of novel compounds to the lungs (Newman 
1994). In order for an inhalation system to be acceptable for clinical use, it must meet certain 
criteria:
a) It must generate an aerosol with most of the drug carrying particles less than 10pm, and 
ideally in the range of 0.5-5pm, the exact size depending on the intended application.
b) It must produce reproducible drug dosing during the period of its use.
c) It must protect the physical and chemical stability of the drug from the external 
environment.
d) It must be relatively portable and inconspicuous during use.
e) It must be readily used by the patient with minimal training.
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Apart from these minimal requirements, the device should ideally provide multiple dosing 
with minimal excipient inhalation. Ergonomic design, patient convenience, dose counters, an 
indication of appropriate inhalation flow rates, power-assistance, an alarm to indicate next 
dose, and other useful features are also desirable.
1.5.1 Pressurised Metered Dose Inhalers (pMDIs)
The introduction of the pMDI in 1956 allowed effective portable aerosol administration for 
the first time. The development of progressively more specific and effective anti-asthma 
therapy from the pMDI has improved the quality of life for the typical asthma patient (Clark 
1995a, Jackson 1995). This has made the pMDI the most popular form of respiratory drug 
delivery system.
A pMDI is made up of five main components: a canister, a metering valve, the liquified 
propellant with excipients, the active compound (either in a suspension or solution), and an 
actuator housing complete with the mouthpiece for inhalation (Lalor and Hickey 1998). 
Chlorofluorocarbons (CFCs) 11, 12 and 114 are used as propellants: a suspension of 
micronised drug substance, rather than solution, is preferred since most drugs are not soluble 
in CFCs (Pauwels et al 1997). Formulations also incorporate co-solvents such as ethanol to 
improve the solubility of the drug and / or help control the particle size of the aerosolised 
cloud. Flavours (such as dissolved mint extract) and suspended sweeteners (e.g. saccharine) 
may be used to mask the taste of the drug deposited in the throat. To enhance the stability, 
antioxidants (e.g. ascorbic acid) may be used in formulations where the drug is dissolved. In 
addition, surfactants (soya-derived lecithin and sorbitan trioleate) are added to the formulation 
to improve the dispersion of suspended particles or dissolution of a partially soluble drug. 
Surfactants also maximise aerosolisation (and increase fine particle fraction) of the drug and 
on release lubricate the valve mechanism of the canister. The canister design has changed 
very little since the first pMDI. However, great advances have been made in the metering 
technology, which has led to increased control of particle size of the aerosol as well as the fine 
particle fraction (Meakin 1998).
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Although pMDIs are small, portable and unaffected by the external environment, they 
nevertheless have a number of disadvantages, which include:-
a) Co-ordination problems: co-ordination between actuation and inhalation by the patient is 
essential for effective lung deposition (Crompton 1982). However, many patients cannot 
achieve this requirement, even with training; the importance of patient training has been 
underestimated (Amirav et al 1994). Breath-actuated pMDIs were developed to overcome co­
ordination problems. The canister in such devices is spring-loaded and is balanced on top of a 
flap valve. When the patient breathes through the mouthpiece, the valve opens and the 
canister is automatically depressed, delivering drug at the ideal time, just at the start of the 
inspiratory effort. Studies have shown that patients handled breath-actuated pMDIs better 
than conventional pMDIs and required less training. The use of spacing devices another way 
of improving co-ordination in pMDIs (Chapman 1994). Spacers force patients to breathe at a 
distance from the canister orifice, where the spray front is moving much more slowly
b) Incorrect inhalation: Some patients stop inhaling when they feel the aerosol cloud in their
mouth, thus failing to inhale it into the lungs.
c) Adverse effects: The propellant / surfactant mixture may cause initial bronchoconstriction. 
This effect has been reported, using both active and placebo inhalers (Yarborough 1985, 
Jackson 1995).
d) Humidity problems: High humidity may pose problems in the use of pMDIs (Miller 1990), 
and they cannot be used effectively in temperatures <5°C (41°F).
e) Residual drug content: There is insufficient information about the quantity of drug 
remaining in a pMDI. The device may become suddenly and unexpectedly exhausted, thus
failing to dispense the required dose (Williams et al 1993).
f) Propellant effect: CFC gases (Freon) are harmful to the ozone layer and are the subject of 
an international treaty (Montreal protocol, 1987) of limitation. Under the latest upgrading of 
the Montreal protocol, CFC production was banned as of 1st January 1996 and in the 
European Union the ban took effect on 1st January 1995. At present, developing countries are 
excluded from the ban for a further 10 years. Current research is in progress on pMDIs that 
can be operated by hydrofluoroalkanes (HFAs): 134a (Dymel®) and 227 (Solkane®). Please 
refer to Appendix 1: Summary of the Physical Properties of Hydro Fluoro Alkane (HFA) 134a 
and 22 7
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3M Healthcare was the first company to market a non-CFC MDI (Airomir™) in 1995, and 
studies have shown the efficacy of this product to be better than the original CFC formulation 
(Purewal 1998). A recent presentation (Meakin 1998) showed that a solution-based pMDI for 
the delivery of Beclemethasone (using HFA 134a) produced uniform dose delivery in in-vitro 
studies. Furthermore, the study showed that drug stability was not an issue, and a greater 
control in particle size of the aerosol was attainable using advanced valve systems.
Complete transition from CFC based formulations to HFAs, in America & EU, is expected in 
the first half of the next decade.
1.5.2 Dry Powder Inhalers (DPIs)
The first, modem DPI marketed was the Spinhaler™, designed and used exclusively for the 
inhalation of disodium cromoglycate (DSCG) (Crompton 1991). Today there are over 20 
existing devices and at least 30 currently known to be under development (Anderson 1998). 
Examples of these devices are given in Table 2, page 58. Early DPIs showed an equivalence 
to MDIs, more recently, advances in device and formulation changes have shown an 
enhancement over MDIs (Nichols 1997).
In 1976, it was reported that patients who could not use conventional pMDIs were able to use 
the Spinhaler (Patterson and Crompton 1976). With most inhalers, like the Rotahaler , the 
active compound is mixed with a carrier-powder (usually lactose). The drug particles adhere 
to the carrier as a result of surface electrical interactions mediated by an electrostatic 
mechanism, and become separated from the carrier at the time of actuation (Dunbar et al 
1998). With single-dose inhalers, a capsule is loaded into the inhaler, and subsequently, 
mechanically punctured or opened in the device using a blade or pin and the dose emitted is 
inhaled by the patient’s inspiratory effort. All currently marketed DPIs are both inspiratory 
flow-driven and inspiratory flow-actuated (Clark 1995a, Nichols 1997,).
Multi-dose DPIs were developed for the inhalation of bronchodilators and steroid drugs, and 
to be able to deliver large numbers of metered-doses from reservoirs (e.g. Turbuhaler™) or a 
set number of deliveries from pre-packaged foil blisters (e.g. Diskhaler™). DPIs were 
intended to deliver the drug both accurately and precisely, but this point is subject to debate
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since the Turbuhaler™ varies considerably in its performance. However, multi-dose DPIs are 
easier to use than the original, single-dose inhalers (e.g. Rotahaler™), which is another reason 
for their development.
As a result of the decline in the popularity of the pMDI on the part of manufacturers, as well 
as the realisation that systemic delivery of drugs (e.g. peptides and proteins, Johnson 1997) 
could be achieved via the lung has led to increased research into DPIs. By delivering systemic 
drugs to the lung ‘first-pass’ hepatic metabolism as well as enzymatic and chemical 
degradation in the GI tract can be avoided, and the lung can be used as a portal of entry to the 
body (Newman 1996a). Thus, lower doses would be needed to achieve a therapeutic effect 
due to advances in DPI drug-deaggregation technology, which has led to increases in the fine 
particle dose delivered to the patient.
Table 2, page 58, shows some of the DPIs currently available or in development. The active 
compound delivered by each DPI has been omitted, because in most cases the devices are 
universal (i.e. capable of delivering more than one type of drug). The metering and dispersion 
mechanisms have been simplified, and multiple numbers of doses is denoted in cases where 








Accuhaler P Cvclone Svstem Blister Roll 60
Airboost A Comnressed Air Reservoir M
Biohaler A Comoressed Air Blister Cartridee 7
Bulkhaer P Cvclone Svstem Reservoir 200
Clickhaler P Soiral Svstem Reservoir 200
Cvclohaler P Deaeereeatine Mesh Caosule Sinele
Diskhaler P Cvclone Svstem Blister Cartridee M
E-Haler (Ecliose) P Cvclone Svstem Caosule 4
Flow Cans P Cvclone Svstem Caosule 8
Omnihaler (Kohlerhaler) A Vacuum Reservoir M
Miat-Haler I P Soiral Svstem Reservoir M
Mikro-Haler P Cvclone Svstem Reservoir 200
Prohaler A Comoressed Air Reservoir 100
Pulvinal P Swirl Chamber Reservoir M
Rotahaler P Deaeereeatine Mesh Caosule Sinele
Seroracor P Venturi Princiole Blister Cartridee M
Soinhaler P Soiral Svstem Caosule Sinele
Soiros A Fan assistance Blister Cartridee 30
Taifun P Cvclone Svstem Reservoir 200
Taoe Device A Hammer Assistance Disoosable Cassette M
Technohaler A Vacuum Disoosable Cassette M
Turbosnin P Cvclone Svstem Caosule M
Turbuhaler P Soiral Svstem Reservoir 60-200
Ultrahaler P Cvclone Svstem Reservoir 100+
Table 2 Examples of DPIs currently available or in development. 
Key: A (Active), P (Passive), and M (Multiple).
1.5.2.1 Device Design
All DPIs have four basic features: A dose metering mechanism, an aerosolisation mechanism, 
a deaggregation (dispersion) mechanism, and an adaptor to direct the aerosol into the patient’s 
mouth (Clark 1995a, Prime et al 1997). All these features vary from inhaler to inhaler.
Design and engineering of DPIs is an evolving process (Bell and Treneman 1994). The most 
difficult problems to overcome are reproducible dose metering and acceptable dispersion of 
the powder. For this reason, the DPIs on the market or in development have either employed 
pre-filled capsules (e.g. Spinhaler™), multiple depression aluminium blister packages (e.g.
f p w    T X / f
Diskhaler ), or metering of a specified mass of powder from a reservoir (e.g. Turbuhaler ).
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Metering of powders is a mechanical process and varies from inhaler to inhaler, and is 
affected by particle size and associated factors discussed previously (section 1.4.2 Dry Powder 
Formulations for Inhalation, page 41).
The advantages of a pre-metered dose are: firstly, precision in which the dose can be metered 
in the factory is superior to that which can be achieved by the device alone, and secondly, 
sealed / protected pre-metered doses can be better protected against the environment. The 
second point is less of an issue than the first since most modem DPIs offer adequate protection 
from the environment (Prime et al 1997). The advantage of a reservoir metering system is the 
relative ease and cost of manufacture, since these devices can be bulk-filled with high 
throughput.
As Table 2, page 58 shows, the dispersion principles used by the various inhalers vary 
considerably. The Bernoulli, or Venturi effect has received some attention (Cheng et al 
1989), as well as gas propulsion (Jager-Waldau et al 1994), negative vacuum aerosolisation 
(Nichols 1997), and external mechanical assistance in the form of a battery driven motor. In 
addition, cyclone and spiral systems utilise the flow path of the incoming air to spin the 
capsule or subject the drug to a deaggregating mesh / grill to aid dispersion. Devices that use 
a mechanism of dispersion additional to the patient’s inspiratory breath are termed ‘active 
devices’ (e.g. Spiros™). These devices are activated during the inspiratory cycle and provide 
‘power-assisted’ inhalation to the patient. Devices that do not have an additional dispersion 
feature, rely solely on the turbulence created by the patient’s breath to deaggregate drug 
particles and are termed ‘passive’. Currently, the majority of the devices are passive, but 
development trends point in favour of active devices. Flow path of the incoming air and the 
design of the mouthpiece (e.g. Turbuhaler™) can be utilised to create maximum turbulence 
within a device and further aid dispersion. The Accuhaler™ (Diskus device) has an extremely 
short flow path (Prime et al 1997) and as a results drug losses within the device are 
minimised. The flow path of the Turbuhaler™ on the other hand is long, specifically designed 
to maximise turbulence through the spiral channels in order to generate shear forces that 
would disperse the drug aggregates, and produce good fine particle mass (Wetterlin 1988). A 
disadvantage with a long flow path is increased device resistance. Higher the resistance, the 
greater the effort needed by the patient in order to achieve a given flow rate, which may hinder
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device performance (Clark and Hollingworth 1993). An in-depth review of device resistance 
and implications for testing is given elsewhere (Peart 1996).
1.5.2.2 General Advantages and Disadvantages of DPIs
a) Ease of use: a comparison of the ease of use of the Turbuhaler™ compared with a pMDI, 
showed that a majority of patients (84%) who had never seen any form of inhalation device 
could use the DPI after reading the instruction pamphlet, and all could be taught to use the 
device by verbal instruction (Duncan et al 1990).
b) Absence of additives and propellants: the original, single-dose, DPIs (e.g. Rotahaler™) 
used lactose as a carrier for micronised drug. However, new multi-dose DPIs, may only 
contain micronised drug, leading to less complicated formulations and cheaper DPIs in the 
future. DPIs do not contain harmful propellants like CFCs, therefore, they are more 
environmentally friendly.
c) Dosage Control: by giving them a device that has a limited number of actuations, 
physicians can control the number of doses a patient receives over a period of time. This may 
be an advantage in patients with low compliance.
The potential disadvantages of DPIs are:
a) Device loading: loading the single-dose inhalers may be too difficult for some patients, 
therefore, they may need training.
b) Loss of delivery sensation: if the device delivers a small dose (e.g. Turbuhaler™, 0.5mg) 
the patient may not get the sensation of having inhaled anything, which is not the case with 
pMDIs. Therefore, the patient may stop inhaling causing a reduction in efficacy of the device.
c) Peak inspiratory flow (PIF) / Device resistance: the PIF required to obtain a therapeutic 
dose from a DPI may not be attainable by patients suffering from acute severe asthma.
In summary, DPIs are unlikely to completely replace MDIs, but increased research and 
development of DPIs can only serve to increase their use.
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1.5.3 Nebulisers
Nebulisers are devices designed to convert a drug solution or suspension into a therapeutic 
mist or cloud consisting of aerosolised droplets (Horsley 1988). There are two methods of 
producing a fine mist from a nebuliser, one is jet nebulisation and the other is ultrasonic 
nebulisation.
Jet nebulisers are by far the most commonly used and work on the Venturi effect produced by 
a Bernoulli nozzle. When air is forced through a fine nozzle it forms an area of negative 
pressure when the high-speed jet of gas emerges. If a tube is placed in this area with the other 
end in a pool of liquid, the liquid is drawn up, mixed with the high-speed jet and blown out as 
a cloud of particles. The baffle traps any large particles and they coalesce to fall back into the 
solution reservoir. The particle size distribution and the density of the aerosol produced 
depends upon the type of baffle used (Steventon and Wilson 1986).
Ultrasonic nebulisers use a piezo-electric crystal to generate the aerosol. By varying the 
voltage or current applied across the crystal, one can influence and change the shape of it. 
The high frequency source is matched to the resonant frequency of the transducer, causing a 
wave pattern that breaks up the solution above into fine aerosol particles. The particle size 
produced depends upon the resonant frequency of the transducer, and variations in its 
amplitude determine the rate of aerosol production (Taylor and McCallionl997).
The aerosol produced may be inhaled either by a facemask or a mouthpiece. Generally, a 
facemask is considered to be less satisfactory in delivering the aerosol than a mouthpiece, as 
less drug is deposited in the lung and some is deposited on the mask itself (Dalby and Tiano 
1996)
There are three main reasons why nebuliser therapy is effective:
a) The patient requires minimal co-ordination or even co-operation, drugs may be inhaled 
during normal tidal breathing (McCallion et al 1996).
b) The vehicle used (normal, physiological saline) tends to soothe the airways.
c) The dose of the drug administered is large, often 10 to 20 times that received from a pMDI 
or DPI. Therefore, drugs that do not formulate well in MDIs and DPIs can be delivered.
A variety of nebulisers, operated by electric compressors or by air cylinders are used in 
hospitals and homes (Flament et al 1995). Although nebulisation therapy can be effective in
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dealing with asthma, it is nevertheless not without problems and hazards. In hospitals, and at 
home, problems may arise because of a lack of understanding of administration parameters 
that affect the performance of the nebuliser and, thus, affect the dose received by the patient. 
The flow rate of the gas which drives the nebuliser and the fill-volume are of utmost 
importance in the performance of the device. The fill-volume is important because all 
nebulisers have a ‘dead-volume’ (i.e. a residual volume of solution which remains in the 
device). Therefore, the greater the fill-volume, the greater the fraction of drug released, and 
the greater the dose received. To avoid problems such as this, training, especially for home 
use, is essential. Another problem, associated with nebuliser use in hospitals, is that the 
solution used for nebulisation should be as near isotonic as possible. If a solution for 
nebulisation needs to be diluted, water should never be used, since this would cause 
hypotonicity and when nebulised, it could provoke bronchospasms and hence an asthma 
attack.
The amount of aerosol reaching the lungs from a jet or ultrasonic nebuliser is ~ 10-20% of the 
dose placed in the reservoir of the device (Hardy et al 1993). However, Knoch and 
Wunderlich (1994) reported fine particle fractions of 30-35% in-vitro, which is about twice 
the conventional delivery.
Studies have shown great variability in the amount deposited from various nebulisers 
(Newman 1993a), there are several factors which influence deposition:
a) The type of nebuliser: ultrasonic nebulisers tend to have higher droplet size values (MMDs) 
than jet nebulisers, but this is not an invariable rule, since the size also depends on flow rate of 
the compressed gas in the case of the jet nebuliser and the frequency of the signal fed to an 
ultrasonic nebuliser (Clay and Clarke 1987).
b) Inhalation rate affects particle size and, thus, deposition of the aerosol. If people do not 
breathe normally, rapid inhalation rates can lead to the formation of larger particles which 
would normally fall back into the nebuliser reservoir by gravitational forces, but may be 
drawn up into the inspired aerosol, increasing the MMD values. Humidity of the air, drawn 
into a nebuliser to provide the auxiliary air necessary for inspiration, may also affect particle 
size, and hence, deposition. The MMD values increase with increasing % relative humidity 
values. This is because, when the inspirate is unsaturated, evaporation readily takes place 
leading to a rapid decrease in particle size (Lewis et al 1981).
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1.6 Aerosol Testing and Characterisation
A variety of methods and models are available for characterising aerosols, both in-vitro and 
in-vivo. The in-vitro methods mainly comprise of impaction and impingement, whereas in- 
vivo evaluation and assessment focus on gamma scintigrapghy and pharmacokinetic 
techniques. This section will review the test procedures and methods used to evaluate:
a) Pharmacodynamic performance (Stevens and Kochuyt 1984, Timsina et al 1994, Van Oort 
1996, and Hindle and Byron 1996).
b) Pharmacokinetic assessment (Borgstrom et al 1996).
c) Gamma scintigraphy (Wilding eta l 1991, Newman 1993, and Conway et al 1997).
1.6.1 Testing Protocol
In-vitro testing of pharmaceutical inhalers has been going through a state of change and 
harmonisation. There has been a steady effort to standardise the testing conditions across the 
various pharmacopoeias. The need for change was brought about by the increasing number of 
DPIs on the market all with varying device resistance. Newman et al (1989, 1994a), and 
Vidgren et al (1988) had shown that the flow rate at which a patient inhales through a powder 
inhaler significantly affects the amount of drug reaching the lung. Clark and Hollingworth 
(1993), Olsson and Asking (1994) and Hindle et al (1994) carried out a series of experiments 
to determine the relationship between device resistance and the maximum inhaled flow rate. It 
was found that the maximum pressure drop developed by the chest muscles of adults with 
respiratory disease, when inhaling through a DPI at peak inspiratory flow rate was in the 
region of 4kPa (40.8cm H20). The following equation was proposed by Clark and 
Hollingworth (1993): -
V A P  — Q d . R d Equation 4
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Where, AP is the pressure drop across the device, QD is the flow rate through the device, and 
R d  is the device resistance. Further detail on the testing procedure is given by Ganderton 
(1996), Olsson et al 1998a, Medicines Control Agency (1998) and EP supplement (1999). 
Hence, drug delivery from DPIs should be determined at an airflow rate equivalent to a 4kPa 
pressure drop across the device. If the flow rate (required to produce a pressure drop of 4kPa) 
is greater than lOOLmin'1, as is the case for low resistance inhalers, then the test should be 
performed at lOOLmin*1. Figure 12 and Figure 13 show some of the typical experimental 
apparatus used to carry out such tests. These apparatus were used in the in-vitro aerosol 
investigations undertaken in this study. Some of the investigations were performed at 
60Lmin_1, which was considered representative of flow rates achievable by patients (BP 
1993). Other tests were performed according to the procedures described above.
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Figure 13: Dose unit sampling apparatus (DUSA) for measuring the uniformity of delivered dose from 
DPIs.
SV: solenoid valve NV: needle valve F: pump protection filter 
MPA: mouth piece and adaptor
PI: Pressure reading for determination of test flow rate (determined using the Hastings Mass 
Flow Meter, HFM 201, Teledyne Brown Engineering, Hastings Instruments, VA, USA) with a 
differential pressure transducer (Digitron Instrumentation, Technology House, Herts., UK). 
Flow rate is adjusted with a needle valve so that PI is 4kPa.
P2/P3: Pressure reading points for critical flow examination with an absolute transducer 
(Digitron Instrumentation, Technology House, Herts., UK). The ratio o f P3/P2 should be <0.5 
for critical flow.
LI, L2, and L3: are vacuum tubing with internal diameters o f at least 10mm. LI and L2 
should be as short as possible whereas L3 should be 30-40cm in length.
1.6.2 In-Vitro Methods
In-vitro methods of aerosol characterisation are primarily used to evaluate prototype or new 
delivery systems, prior to first human use. Testing is rapid, when compared with in-vivo 
assessments and provides vital information on device / system performance and gives a good 
indication as to how the device / system in question will fair in clinical trials. The techniques 
used are wide and varied and the models / instrumentation utilised is based on the anatomical
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structure of the human airways, be it loosely in some cases. The two methods used throughout 
this study were the TSI and the MSLI.
1.6.2.1 The Twin-Stage Impinger (TSI)- BP Apparatus A
The TSI is Apparatus A of the British Pharmacopoeia (BP) (1998), Appendix XVIIC, and is a 
glass, two-stage separating device developed by Hallworth (1987). The TSI was based on the 
multi-stage liquid impinger (MSLI) developed by May (1966). Stage 1 contains 7ml of test 
solution (often, mobile phase for HPLC analysis), and stage 2, contains 30ml of test solution. 
The apparatus is usually calibrated for operation at 60L min'1 although higher flow rates may 
be used. The first impaction point is the glass throat. The particles that do not impact on the 
throat remain entrained in the air-stream and enter stage 1 o f the device, which has a cut-off 
diameter of 6.4pm at 60L min'1, with a jet diameter of 14mm. The cut-off diameter is 
predicted by the following equation: -
w m
ECD5Q% — X  p V2 Equation 5
Where: ECD= effective cut-off diameter (i.e. the particle size for 50% retention of unit density 
spheres of equivalent settling rate in air), X= a constant, 30 for TSIs, W= Jet diameter in cm, 
F= Flow rate (L min'1).
The above equation developed by Hallworth (1987) can be used to calculate the ECD at other 
flow rates and jet diameters. Therefore, as jet size increases the cut-off diameter decreases.
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Stage 1 Jet Diameter (mm) Calculated ECD5o% 
(nm)
As measured by AEA Technology 
(pm)
3.9 1.33 (a), 30L min'1 1.3
6.9 3.14 (a), 30L min'1 3.2
9.7 5.20 (a), 30L min'1 6.6
10.9 6.23 (a). 30L min'1 7.3
11.6 4.80 (a), 60L min'1 5.3
13.4 5.20 (a), 80L min'1 5.37
14.0 6.42 (a), 60L min'1 N/A
Table 3: Table showing stage 1 jet-diameter versus TSI cut-off diameters at various flow rates
Particles <6.4 pm impact on to stage 2, and constitute the respirable fraction. The result is 
expressed as the amount of drug collected in stage 2 as a percentage of the total amount of 
drug emitted from the device.
Although originally developed for pMDIs, the TSI can also be used for DPIs. The advantage 
of the TSI is that analyses are quick, easy and informative. However, the disadvantage is that 
the TSI only separates the aerosol into two size ranges, and hence the information concerning 
aerosol cloud quality is not as detailed as the Andersen impactor or the multi-stage liquid 
impinger.
1.6.2.2 The Multi-Stage Liquid Impinger (MSLI)
The original MSLI was constructed by May (1966) and later modified to a glass 4-Stage 
impinger for pharmaceutical use by Bell et al (1973). The underlying principles and the mode 
of action of the MSLI is essentially similar to the Andersen cascade impactor. The 4-stage 
impinger consists of three stages and an after-filter (stage 4) with cut-off diameters of 13, 6.8, 
3.1, and <3.lpm respectively, when operated at 60L min'1. Until 1995, the glass 4-stage 
impinger together with a glass / metal throat was the only model in use, but Olsson (1995), 
introduced an extension to the apparatus by the addition of a new stage. This additional stage 
has a cut-off diameter of 1.7pm at 60L min'1 flow rate and is inserted between stage 3 and the
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after-filter of the original 4-stage apparatus. The 5-stage impinger’s cut-off diameters are 
shown in Table 4 (Olsson 1995).
Cut-Off Diameters (pm)
Flow Rate Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 (After-filter)
bOLmin'1 >13.00 6.80 3.10 1.70 0.00
90Lmin'1 >10.61 5.55 2.53 1.39 0.00
lOOLmin'1 >10.07 5.27 2.40 1.32 0.00
Table 4: MSLI cut-off diameters at different flow rates.
An ideal impaction stage has an inverse square root function of the flow (Lodge and Chan 
1986).
ECD50o/o.q= a(Q/60)b Equation 6
Where Q= flow rate (L min'1), a= ECDso% at 60L min'1) and b= an exponent describing the 
power of the flow rate dependency. The equation can be simplified since the estimation of b 
is close to the theoretical value, -1/2 (i.e. inverse square root). Therefore the equation 
becomes:
1
50%e “  a j o m  Eq,u,tion7
The addition of the extra stage was necessitated by the fact that percent cumulative undersize 
plots obtained via the 4-stage apparatus had only two points on the graph in the respirable 
fraction particle size range, whereas with the 5-stage impinger, stages 3,4, and 5 are all part of 
the respirable fraction (therefore three points on the curve) and contain size ranges of particles 
capable of deep-lung penetration. Hence, the 5-stage impinger offers better discrimination 
between particle sizes and provides more comprehensive aerosol data and characterisation. 
The collection plates at each stage are made of sintered glass, which is wetted with 20ml of 
mobile phase, prior to aerosol actuation. Upon actuation air passes through the nozzles, over 
the collection plate and onto the next stage. Particles which impact on the collection plate are
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retained. The airflow through the device is usually at 60L min"1, although other flow rates can 
be used, provided the apparatus has calibration data for those flow rates or the cut-off diameter 
data is accepted. Once the desired number of actuations have been made, the after-filter is 
removed and sonicated in 20ml of mobile phase. An additional 5ml of mobile phase is used to 
wash the jet leading to stage 1. This ensures that any particles on the inside of the jet are 
washed into stage 1. Therefore, stage 1 usually contains a total of 25mi of mobile phase. The 
impinger is then swirled for 10 minutes to ensure that all particulate matter is removed from 
the walls of the apparatus and that all drug particles are in solution. The ceiling of each stage 
is also wetted by the mobile phase to collect any particles which may have ‘bounced-off the 
collection plate and impacted on the surface above. Once all of the described procedures are 
complete, an aliquot from each stage (and also an aliquot from the solution used to rinse the 
glass throat) is taken and analysed for drug content, usually using HPLC along with an 
internal standard. If an internal standard is not used then it is necessary to wash all the drug 
out of each stage.
Although the 5-stage impinger is robust, reliable, produces more data, and provides more 
complete aerosol characterisation, it does have the following potential disadvantages:
a) The instrument is expensive to purchase and requires maintenance.
b) The analysis procedure is time consuming and labour intensive.
c) When sonicated, the solution in stage 5 usually becomes cloudy and needs to be filtered, 
prior to HPLC analysis.
d) The grade efficiencies for successive cut-off diameters are lower than between stage 1 and 
2 of the TSI.
e) When analysis is complete, the instrument needs to be washed in water, rinsed with 
methanol and left to dry in an oven, which is time consuming.
1.6.2.3 Other In-Vitro Methods
Other Methods of testing include the Andersen Cascade Impactor (ACI), The Marple-Miller 
Impactor (MMI) and apparatus B (BP (1993), Appendix XVIIC)-the Metal Impinger. These 
instruments are outside the scope of this report, as they were not used in the study of SAPL.
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1.6.2.4 Parameters Used to Describe In-Vitro Aerosol Performance
The following parameters are used in this report to describe the performance of an aerosol 
during in-vitro testing.
Parameter Explanation
Emitted Dose (ED) Can be expressed as a mass or percentage and refers to the 
amount of drug expelled by the device and recovered from 
the sampling apparatus.
Fine Particle Dose (FPD) Expressed as a mass, and refers to the portion of the 
emitted dose which is potentially in the respirable range (1- 
<5 pm).
Fine Particle Fraction 
(FPF)
Expressed as a percentage, calculated by dividing the FPD 
by the emitted dose. Stage 2 of the apparatus A and stages 
3,4, and 5 of the MSLI usually comprise the FPF and FPD.
Table 5: Table describing the various in-vitro aerosol performance parameters.
1.7 In-Vivo Methods
Prototype or new delivery systems can be tested in-vitro using the techniques described 
earlier. However, it is critical that characteristics of new devices or drug presentations be 
assessed using in-vivo lung deposition and / or drug release studies. To some extent, animal 
models aid the in-vivo evaluation of new systems / drugs (Current Perspectives in Inhaled 
Drug Therapy (1994). However, over the past decade, there has been a growing tendency for 
new delivery systems to be tested in human subjects, where possible, in phase I clinical trials 
(Newman 1993, and Davis 1991). This trend is a direct result of companies wanting to get 
their product on the market as quickly as possible, or to make early cost-saving decisions on 
products and drugs which will not reach the market.
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In-vivo techniques include gamma scintigraphy, Positron-Electron Tomography (PET), and 
Magnetic Resonance Imaging (MRI). These techniques are outside the scope of this report 
and further details can be found elsewhere Newman 1993, 1995, 1996, Gerrity 1994, Conway 
et al 1997.
1.8 Aims of the Study
On the outset, the aim of the study was to develop a system for delivering SAPL as a dry 
powder for the treatment of ARDS and neonatal RDS. The conventional system at the time 
had consisted of administering SAPL as an intra-tracheal suspension and a powder alternative 
was investigated. However, the direction of the research changed dramatically in early 1997, 
when a number of publications indicated that surfactant therapy might be applicable in 
asthma. As a result, encouraged by these findings, a development program was undertaken to 
test the hypothesis that surfactants may be therapeutic in the treatment of asthma. Thus, 
research focussed on characterisation of SAPL powder and investigation of various 
formulation and delivery avenues. More specifically, the objective was to evaluate the 
potential of various types of SAPL powder (ranging from a freeze-dried sterile product to a 
non-freeze-dried micronised material) as dry powder formulations. Deposition profiles of 
various powder formulations were obtained using conventional capsule technology and 
delivery systems. These profiles were compared against those obtained from novel delivery 
systems, developed during the course of this research with the aim of selecting a definitive 
system that may be used in clinical trials. These new delivery systems included: a dry powder 
aerosol generator and an inhalation system designed to deliver large quantities of SAPL into 
the lungs.
Publications indicating the possible use of surfactant in the treatment post-surgical adhesions 
in adults were also prominent, with some dating back to early 1980’s. Thus, the secondary 
aim of the project was to develop a concept system whereby SAPL could be used for this 
indication. This delivery system utilised pressurised medical grade carbon dioxide as a 
propellant to aerosolise and expel freeze-dried SAPL from a pre-filled vial. The ultimate aim
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Materials and General Characterisation
2 Materials and General Characterisation
Characterisation of SAPL and the various materials used throughout the study is given below.
It must be stressed that various different types of SAPL were used:
a) Freeze-dried, sterile SAPL (abbreviated to FDS) packed into small crimped vials with a 
nominal weight of lOOmg - As described in the section 1.2.2.5.2 Artificially Derived 
Surfactants), page 30.
b) Micronised and unmicronised SAPL (abbreviated to MS and UMS respectively), sterile, 
received in glass containers as bulk powder, manufactured without the freeze-drying 
process. SAPL was micronised at Micro-Macinazione SA (Micro-Grinding Ltd), 
Switzerland, using their patented Chrispro®-Jetmills. The details of the micronisation 
procedure are given in section 2.2.6.1 Micronisation of SAPL), page 113.
c) FDS labelled with a fluorescent probe (see section 3 Fluorescent Labelling of FDS, page 
121). Micronised and unmicronised, labelled forms o f FDS are abbreviated to MLFDS and 
UMLFDS respectively. A control was also used during the labelling process, abbreviated 
to CFDS. The micronisation of the labelled material (MLFDS) was done so by fluid- 
energy milling using the Gem-T air pulveriser, Glen-Creston, Stanmore, UK. (see section 
page 116).
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Borculo Whey Products Ltd., Chester, UK
Dansyl Chloride Sigma Chemical Co., Poole, UK.
Dichloromethane (GPR) Fisons Scientific Equipment, Loughborough, UK
DL-a-Phosphatidylcholine, 
Dipalmitoyl (DPPC)
Sigma Chemical Co., Poole, UK.
Hard Gelatine Capsules Davcaps Ltd., Herts., UK
Lecithin The Lecithin People, Clwyd, Wales, UK
L-a- Phosphatidyl-DL-Glycerol 
(PG)
Sigma Chemical Co., Poole, UK.
Methanol and Chloroform 
(HPLC grade)
Fisons Scientific Equipment, Loughborough, UK
Magnesium Sulphate (GPR) BDH Chemicals
n-Octadecyl dansylamide Synthesised at Bath University
Octadecylamine (Stearylamine) Sigma Chemical Co., Poole, UK.
Phosphorous Pentoxide BDH Chemicals
Propan-2-ol and Cyclohexane Fisons Scientific Equipment, Loughborough, UK
Sorbolac 400 (fine lactose) 
(Microtose)
Meggle, Germany.
Triethylamine (GPR) Sigma, Poole, UK.
Table 6: List of the various materials, powders and solvents used throughout the study.
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2.2 Characterisation of Materials
The general characterisation tests for the materials to be used throughout the study are 
outlined below.
2.2.1 Particle Size Analysis
Particle size analyses of all materials were carried out using two different types of equipment. 
Firstly, the Malvern Mastersizer X (Malvern Instruments Ltd., Malvern, UK) was used to 
characterise powders in various solvents or using the dry powder option available on the 
machine. Secondly, the Amherst Process Instruments (API) Aerosizer® (mach2 V6.04) 
powder analysis system fitted with API Aero-Disperser™ accessory was used to characterise 
all the powders used throughout.
2.2.1.1 Malvern Analysis (Laser Light Diffraction)
Introduction
Low Angle Laser Light Scattering (LALLS) methods involving laser light scattering are 
available to give information about particle size distributions of therapeutic aerosols. The 
physical principle of LALLS particle size analysis uses the light scattered in the near forward 
direction (Fraunhofer or Mie diffraction) with respect to the incident light (Kraut et al 1990, 
Kaye 1999). Fraunhofer diffraction theory (Annapragada and Adjei 1996) can be applied to 
particles that are significantly larger than the wavelength of illuminating light. By also 
incorporating Mie diffraction theory (Diffraction Training Manual (1993), Malvern 
Instruments Ltd., Malvern, UK), which relates to light scattered by large molecules and nano­
particles at right angles to the incident beam, the particle sizing instruments can measure, 
accurately, particle sizes between 0.1 -2000pm. Particle sizing of DPI devices and powders 
can be carried out using a special dry powder feeder with an external de-agglomerating
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accessory. In order to measure particle size distributions in saturated suspensions, pMDIs and 
nebulised solutions, the refractive index and density of the test material need to be inputted 
into the instrument, before a meaningful answer can be attained. The problem with LALLS is 
that a lot of material is often needed to generate a result, this may not be viable if material is in 
short supply. Clark (1995b) has shown laser diffraction to be a more reliable and accurate 
measure of testing aerosol clouds generated by medical nebulisers. The results obtained using 
a Malvern Mastersizer X (Malvern Instruments Ltd., Malvern, UK), were correlated with 
published and empirical deposition models. The results showed that the diffraction technique 
measures size parameter relevant to clinical performance of the nebuliser, and that the 
correlation between the published and the attained data was high.
This section outlines the methods used to characterise the various forms of SAPL and the 
Lactochem-lactose used throughout the mixing studies. Results are tabulated with the 
conditions per analysis given at the bottom of the table.
Method l:Use o f a Dry Powder Feeder
A small spatula full of the sample was introduced into the apparatus via a glass adapter, 
mounted at the inlet leading to the lens. A high-powered vacuum cleaner capable of achieving 
approximately ISOLmin'1 flow rate was attached to the outlet at the back of the Mastersizer X. 
Once switched on, the instrument took both background and electrical readings before 
measuring the size of the powder entrained into the air-stream. The amount of sample added 
was just adequate to give an obscuration value of between 3-25% and the particle size, by 
volume, was calculated. A total of 10 measurements per sample were taken and the particle 
size, by volume, calculated and transported to a spreadsheet via the use of a macro program.
76
Method 2:Use o f a Small Volume Stirred Cell
The liquid apparatus (MSX1 small volume unit) had a capacity of 20ml. A suitable dispersant 
with or without a suspending agent was added to the cell, and circulated via a small magnetic 
flee. Both background and electrical readings were taken before a filtered, saturated 
representation of each sample was introduced into the cell, drop-wise using a Pasteur pipette. 
Sonication of some samples was necessary to reduce or eliminate agglomeration. A 0.1% w/v 
solution of lecithin in cyclohexane was used as the suspending agent and dispersant 
respectively. The other solvent used during the measurements was acetone. For sonication 
times, temperature of the sonic bath, and other details, refer to the experimental conditions 
outlined in the individual tables.
Operating Conditions and Results
Particle Size: Calculated by Volume. Model used: Polydisperse.
Air-Supply: vacuum cleaner, Dyson, Model DC01.
Measuring Vessel: Small volume stirred cell (MSX1), manual dry powder feeder.
Lens Used: 100mm diameter (measurement range: 0.2-180pm) or 300m diameter (range: 1.2- 
600pm). Typical Laser Obscuration: 17-25%.
Particle Size (pm)





Lactochem Lactose (63- 








Table 7: Particle size analysis results for lactose using the dry powder feeder n=10. 
Values in brackets indicate standard deviation.
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Detailed tables can be found in Appendix 2: Detailed Particle Size Analysis Tables of SAPL 
Powders by Laser Light Diffraction (Malvern Analysis), page 252. Table 8, below shows a 
summary of the results obtained.
Particle Size (pm)
/
Sample ID Dispersant or Solvent Sonication Time D(0.1) D(0.5) D(0.9)
FDS Cyclohexane 2 min 3.09 18.6 39.9
Acetone 2 min 7.27 33.7 66.9
Air N/A 25.9 83.3 164.7
UMLFDS Cyclohexane 2 min 1.51 12.4 64.9
Acetone 2 min 4.28 53.1 164.6
Air N/A 21.2 64.9 140.2
MLFDS Cyclohexane 2 min 1.61 4.12 8.51
Acetone 2 min 2.26 19.3 62.4
Air N/A 17.8 99.2 168.4
UMS Cyclohexane 2 min 2.61 13.4 28.2
Acetone 2 min 8.64 31.6 68.9
Air N/A 14.3 78.7 160.9
MS Cyclohexane 2 min 1.28 2.39 7.62
Acetone 2 min 4.83 12.7 24.6
Air N/A 10.4 61.9 147.8
Table 8: Summary particle size analysis table for various SAPL powders using the Malvern Mastersizer 
X.
Discussion
The particle sizes of the various SAPL powders have been determined. The general trend is 
that the particle size measured is dependent on the solvent / dispersant used, sonication time 
that the sample is subjected to, and the temperature of the sonic bath. Smaller VMDs are 
obtained for all samples when cyclohexane in combination with lecithin are used compared 
with solvent alone or samples suspended in air. Presumably, this is because samples are better 
dispersed in a solvent containing a suspending agent. SEM photos of samples show particle 
size to be more concordant with results obtained for cyclohexane (with suspending agent) than 
with acetone. Sonication time of 1-2 minutes seems to optimal to break up the agglomerates 
of powder.
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2.2.1.2 Time-of-Flight Aerosol Beam Spectroscopy (TOFABS)
Introduction
When carrying out Fraunhofer diffraction in liquid media, the particles may be prone to size 
distribution changes because of dissolution and / or growth during sample preparation (Hindle 
and Byron 1995). To overcome this problem, powder dispersion equipment capable of 
dispersing a sample in a gas stream prior to sizing has been developed. This system is 
commonly called the time-of-flight aerosol beam spectroscopy (TOFABS), one such example 
is the Aerosizer® (Amherst Process Instruments, MA, USA). This is a laser-based system 
which measures the time-of-flight of a given particle across a measurement zone, and 
determines size distributions according to the aerodynamic principles described by Niven 
(1993). Powder is first fluidised by a combination of pulsed jet air and carrier gas. Particles 
are transported to a computer-controlled disperser and mixed and further diluted by sheath air 
and subjected to a pressure drop. The resultant shear force assists in particle de-aggregation 
and the particles are fed into the Aerosizer® for time-of-flight analysis. The time taken for 
particles to traverse two laser beams is measured. The data collected can be converted to 
either volume or number based frequency distributions and can be displayed as functions of 
aerodynamic or geometric diameter
Method
A small amount of powder, approximately lOOmg was placed into the disperser cup. 
Combinations of pulsed jets of air from an external power source and carrier air were used to 
fluidise the powder. Once fluidised the samples were de-agglomerated within the Aero- 
Disperser™ and fed into the Aerosizer® for time of flight analysis. The parameters in Table 9, 
page 80 have been investigated by Niven (1993), and Hindle and Byron (1995) and have been 





Controls duration of powder de-agglomeration and particle counting.
Shear Force Controls shear force applied to particles within the Aero-disperser™ 
before being fed into the Aerosizer®.
Feed Rate Controls and maintains the target count rate.
Pin Vibration Causes the pin to dither so as to prevent power accumulation
Deagglomeration Selects airflow pattern carrying powder from sample cup to disperser.
Table 9: Showing the Aero-Disperser™ variables and their functions
Operating Conditions /Instrument Settings
Shear Force range(psi): 0-5.0 Shear Tolerance: unchanged
Feed Rate range: 2000-10000particles per second Pin Vibration: On
Run Time: lOOsecs Deagglomeration: High (H) and constant.
Sum of Channels: Total number if particles counted 
Regularisation: Low Gaussian Extension: Off
Results
Table 10, page 81, shows the summary results for the various SAPL powder obtained using 
TOFABS. In each case combinations of low shear / high shear and low feed rate / high feed 






















FDS 111292 5.0 3000 H 100 7.22 18.6 38.2
FDS 142567 4.5 10000 H 100 7.95 20.0 41.9
FDS 45054 2.0 3000 H 100 11.3 44.3 63.0
FDS 82641 2.0 10000 H 100 13.1 46.6 66.2
UMLFDS 156525 4.5 3000 H 100 5.59 13.5 21.3
UMLFDS 107972 4.5 10000 H 100 7.62 24.1 39.5
UMLFDS 96161 2.0 3000 H 100 10.9 40.2 60.4
UMLFDS 23901 2.0 10000 H 100 12.7 37.9 61.7
MLFDS 323820 4.5 3000 H 100 2.59 5.02 13.9
MLFDS 134626 4.5 10000 H 100 3.42 7.54 15.7
MLFDS 84251 2.0 3000 H 100 13.4 22.6 48.9
MLFDS 36844 2.0 10000 H 100 14.8 24.3 52.3
UMS 202347 4.5 3000 H 100 9.16 18.6 33.9
UMS 168236 4.5 10000 H 100 12.8 34.0 56.2
UMS 71365 2.0 3000 H 100 18.6 50.3 85.4
UMS 51002 2.0 10000 H 100 19.2 64.2 85.4
MS 178424 4.5 3000 H 100 2.12 3.64 5.13
MS 122454 4.5 10000 H 100 2.24 4.06 6.17
MS 63889 2.0 3000 H 100 3.95 7.26 10.9
MS 49224 2.0 10000 H 100 4.34 8.69 13.8
Table 10: Particle size analysis using the Aerosizer8 coupled to the Aero-Disperser™. Results show 
volume and number based aerodynamic particle size for various SAPL powders.
Key: Sum of chan.: sum of channels, Deag H: Deagglomeration high and constant.
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Figure 14: Measured cumulative percent by volume less than stated size vs. Aerodynamic diameter FDS 
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Figure 15: Measured cumulative percent by volume less than stated size vs. Aerodynamic diameter 
LFDSU and LFDSM measured under high shear/low feed and low shear/high feed conditions.
82
100
—• — RUMA-High shear/Low Feed 
o RUMA-Low shear/High feed
—▼- - RMA-High shear/Low feed 













0 20 40 60 80 100
Cumulative percent by volume 
less than stated size
Figure 16: Measured cumulative percent by volume less than stated size vs. Aerodynamic diameter for 
UMS and MS measured under high shear/low feed and low shear/high feed conditions.
Discussion
The volume median diameters of SAPL powders have been determined. Particle size obtained 
by this technique seems to be dependent on the applied shear force, the feed rate, and whether 
or not high deagglomeration is used. Generally for cohesive powders, shear force should be as 
high as possible, and in this study the lowest VMD results were obtained when this was the 
case. The feed rate should also be as high as possible, but in this case the instrument had 
difficulties in supplying adequate sample into the aerosizer at higher feed rates, due to the 
cohesiveness of the powder. Thus, more concordant results were obtained at lower feed rates 
coupled with high shear forces. Sample run-time is of secondary importance in this case, 
since the compressor (supplying the incoming air) reaches maximum capacity before the 





Optical techniques allow for the study of particle size and shape, and have been used 
extensively in the pharmaceutical sciences for acquiring information during drug 
development. Effects of micronisation and spray drying on compounds (Vidgren et al 1989), 
surface modifications of drug particles (Hickey et al 1992), and evaluation of carried based 
inhalation systems (Lucas et al 1997) are examples of the type information that can be 
attained.
Scanning electron microscopy (SEM) was used to assess the powders used throughout the 
study. SEM analysis allowed a detail look at the raw material and the uniformity of the 
various blends made throughout the study.
2.2.2.1 Scanning Electron Microscopy (SEM)
Introduction
Scanning electron microscopy utilises a fine beam of electrons to bombard the surface of test 
materials, which cause secondary electrons to be emitted from the atoms in the sample 
surface, subsequent detection and processing of these electrons form the image (Beckett and 
Read 1986). Samples for SEM analysis need to be dry, mechanically stable, non-volatile and 
electrically conducting. However, most pharmaceuticals do not posses these properties. 
Therefore, it becomes necessary coat samples with a thin layer of gold to aid imaging and 
dissipation of electrical charge from the sample surface. If the coated surface is damaged 
during analysis due to excessive build up and accumulation of electrons, or when imaging 
hydrated or thermo-liable compounds, then sample charging can occur which leads to 
distortion and subsequent loss of resolution of the image (Beckett and Read 1986). To 
overcome these difficulties, variants of SEM have been developed namely, low-temperature
84
(LTSEM) and Environmental (ESEM). LTSEM allows imaging of the sample under reduced 
temperatures while maintaining the integrity of hydrated or delicate materials (Babic et al 
1996). With ESEM, samples may be imaged in their natural state without prior sample 
preparation. This is possible because rather than operating just under vacuum (like 
conventional SEM), ESEM uses a differential pumping system to segregate the environment 
within the specimen chamber from other parts of the instrument.
This section outlines the instrumentation methods used during the acquisition of the SEM 
images of the various forms of SAPL.
Method
The powders under analysis were examined for particle shape, surface characteristics, and, in 
some cases, in evaluating the efficiency of an ordered mix using SEM. A representative 
sample of powder was mounted on aluminium specimen stubs using carbon-coated adhesive 
fixers. A thin, conductive layer of gold was evaporated onto the sample surface using a 
sputter coater for five minutes (Model: S150B, Edwards High Vacuum, Crawley, UK). The 
prepared specimens were examined using a JEOL 6310 SEM (Japanese Electron Optics Ltd., 
Tokyo, Japan). Typical Instrumentation Settings: Operating Voltage: 5-10 kV, Spot Size: 12.
Results
Figure 17 through to Figure 25, pages 86 to 89 show the electron photomicrographs obtained 
for FDS, UMLFDS, MLFDS, UMS, MS, and the label respectively. The interpretation of the 
images is given in the discussion / conclusion part of this section.
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lOOpm
Figure 17: Scanning Electron Photomicrograph of FDS at x500 magnification.
Figure 18: Scanning Electron Photomicrograph of FDS at x l500  magnification.
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Figure 19: Scanning Electron Photomicrograph of UMLFDS at x2500 magnification.
Figure 20: Scanning Electron Photomicrographs of MLFDS at x3000 magnification.
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Figure 21: Scanning Electron Photomicrographs of MLFDS at x4500 magnification.
lOOjjm
Figure 22: Scanning Electron Photomicrograph of UMS at x300 magnification.
88
Figure 23: Scanning Electron Photomicrograph of MS at xlOOO magnification.
Figure 24: Scanning Electron Photomicrograph of MS at x5000 magnification.
89
Figure 25: Scanning Electron Photomicrograph of n-Octadecyl Dansylamide (the label) at xl500 
magnification.
Discussion
The various SEM photographs of SAPL have been presented. FDS images (Figure 17 and 
Figure 18, page 86) suggest highly amorphous particles, existing as aggregates of no definitive 
size. When subjected to the labelling procedure (see section 3 Fluorescent Labelling of FDS, 
page 121) and subsequent micronisation (see section 2.2.6.1 Micronisation o f SAPL, page 
113) these particles are no longer amorphous, rather they are more defined in nature, as shown 
in the photomicrographs of UMLFDS and MLFDS (Figure 19, Figure 20, and Figure 21, 
pages 87 and 88). Photomicrographs of UMS (Figure 22, pages 88) show large, irregularly 
shaped particles, which are reduced in size upon micronisation as shown in the images of MS 
(Figure 23 and Figure 24, page 89). Photomicrographs of the label (n-ocatdecyl dansylamide, 




Powder flow properties of SAPL were assessed from Carr’s Index and Hausner ratio values 
derived from bulk and true density measurements. Bulk density (also called poured or fluff 
density), is a characteristic of a powder system, rather than individual particles. The bulk 
density of powder is always less than the true density of its component particles, because the 
powder contains interparticle pores or voids. Therefore, whereas there is only one true 
density, there can be many bulk densities, depending on the way particles are packed and the 
bed porosity.
Tapped density is also known as equilibrium or consolidated bulk density. It can be used to 
follow the change in packing that occurs when void space diminishes and consolidation 
occurs. As the powder is tapped the density increases from an initial bulk density D0 to a final 
value Df. This ratio can be used to assess the quality of powder flow. Carr’s index gives an 
indication of percentage compressibility of a powder arch or bridge strength and assigns an 
index of flowability to the sample. Hausner ratio is simply a ratio o f tapped density divided 
by the bulk density.
2.2.3.1 Tapped I Bulk Density
Method
A known weight of sample was accurately weighed into a 25cm3 measuring cylinder. The 
initial volume occupied by the sample was recorded and the cylinder was placed onto a jolting 
volumeter (Stampf volumeter STAV 2003, Rhein, Germany). The volume of powder was 
measured after 500 taps and the various parameters below in Table 12 were calculated. Three 
determinations were made for each sample.
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Calculations /  Tables
_ „ _ . Sample Wt. _ , ^ Sample Wt.
Bulk Density = --------------  Tapped Density = --------------
Initial Vol. Final Vol.
„  , T , Tapped-Bulk  . TappedCarr s Index -  ——------------- a  100 Hausner Ratio = ———
Tapped Bulk
Carr's Index (%) Hausner Ratio Type of Flow
5-15 Excellent
12-16 <1.25 Good













































































































Table 12: Bulk density and flow characteristics of various forms of SAPL.
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Mean Hausner ratio of 1.50 and a Carr’s index of 33.3 for FDS indicate poor flow. The values 




This was determined by helium pycnometry using a true density measuring apparatus 
(AccuPyc 1330 V2.01, Micromeritics, USA). A sample of SAPL was weighed into small, 
cylindrical aluminium container such that the sample occupied about two thirds of the 
container. The container was placed into the apparatus and the system was purged and 
equilibrated using a helium source. All analyses were carried out in triplicate and an average 
of ten readings per sample was taken.
Run conditions / Instrument settings:
Chamber temperature: 29.8°C Cell Volume: 12.1274cm3
Number of Purges: 10 Equilibration rate: 0.0100 psig/min
Expansion Volume: 8.3523 Number of readings per sample: 10
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Results
A summary of the true density results for SAPL is shown below in Table 13.




Density (g/cm3) Mean Density 
(g/cm3)
FDS-1 0.9573 0.8797 1.0882 1.088
FDS-2 0.9622 0.8815 1.0870 (±0.001)
FDS-3 0.9648 0.8824 1.0890
MLFDS-1 2.2279 2.0799 1.0722 1.072
MLFDS-2 2.1894 2.0642 1.0715 (±0.0004)
MLFDS-3 2.0272 2.0715 1.0719
UMS-1 2.143 2.0842 1.0784 1.077
UMS-2 2.264 2.1030 1.0749 (±0.002)
UMS-3 2.094 2.0805 1.0766
MS-1 2.501 2.4220 1.0806 1.080
MS-2 2.488 2.4125 1.0790 (±0.001)
MS-3 2.529 2.4352 1.0814
Table 13: Table showing the true density values for SAPL.
Values in brackets indicate standard deviation, n=3.




This section looks at the X-ray diffraction patterns of the various forms of SAPL to ascertain 
any differences between the samples in question. The theory is described briefly as well as 
the methods used to characterise SAPL.
2.2.4.1 X-ray Powder Diffraction (XRPD)
XRD diffraction patterns are produced when fast-moving electrons impinge on matter (Klug 
and Alexander 1974). The phenomena resulting from the deceleration of such electrons are 
very complex, and x-rays result from two general types of interaction of the electrons with the 
atoms of the target material. A high-speed electron may strike and displace a tightly bound 
electron deep in the atom near the nucleus, thereby ionising the atom. When a certain inner 
shell of an atom has been ionised in this manner, an electron from an outer shell may fall into 
the vacant space, with the resulting emission of an x-ray characteristic of the atom involved. 
Such production of x-rays is a quantum process. The phenomenon of x-ray diffraction by 
crystals result from a scattering process in which x-rays are scattered by the electrons of the 
atoms without change in wavelength. A diffracted beam is produced by such scattering only 
when certain geometrical conditions are satisfied, which may be expressed in either of two 
forms, the Bragg law or the Laue equations, explained elsewhere (Klug and Alexander 1974). 
The resulting diffraction pattern of a crystal, comprising both the position and intensities of 
the diffraction effects, is a fundamental physical property of the substance, serving not only 
for its speedy identification but also for the complete elucidation of its structure. The essential 
features of the powder diffraction technique include a narrow beam of monochromatic x-rays 
impinging upon a crystalline powder composed of fine, randomly orientated particles. Under 
these conditions all the diffracted rays from sets of planes o f spacing generates a cone of semi­
apex angle 20. A pattern of concentric rings is produced by those cones of diffracted rays that 
intersect a film placed perpendicular to the undeviated beam, a detailed account of the theory 
is given elsewhere (Klug and Alexander 1974).
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Method
Small (35mm x 35mm), square aluminium plates (1mm thick) with a 20mm x 15mm window 
towards the top of the plate, were used as sample holders. A 20mm x 25mm slide was used as 
a support during measurements to ensure the sample did not fall out. A small, representative, 
quantity of the sample was evenly placed into the window such that the entire area was 
covered, without voids. Care was taken not to compress the powder during the above 
procedure. A second slide was used to cover the powder bed, and the sample was place into 
the diffractometer (Philips PW 1820/00 computer controlled vertical diffractometer, 
PW1710/00 microprocessor diffractometer control, equipped with PW 1877 PC-APD version 
3.5b diffraction software) with for analysis. Data was generated in the Materials Science 
Department, University of Bath. Interpretation of the results was carried out in association 
with various members of the same department.
Operating Conditions / Instrument Settings
Tube Anode: Copper Generator (4kW, Philips PW 1730/00), Tension: 40kV
Generator Current: 25mA Wavelength Alpha 1 [A°]: 1.54060
Wavelength Alpha 2 [A°]: 1.54439 Intensity ratio: (Alpha 1/Alpha 2): 0.500
Divergence Slit: Automatic Irradiated Length: 12mm
Monochromator Used: None Start Angle (°20): 5.010
End Angle (°20): 89.950 Step Size (°20): 0.020
Time per Step: 0.5secs Type of Scan: Continuous
Results
Table 14 shows the results obtained and expressed as an average of three runs. Only FDS, 
UMLFDS, MLFDS, and a control sample were analysed. The purpose o f the experiment was 
to see if the labelling procedure (see 3 Fluorescent Labelling of FDS, page 121) used had 
altered the structure of the material. UMS and MS were not analysed because they had not 







a l  (A)
Relative 
Intensity (%)
FDS 6.175 4 14 301 8.5
9.165 9.6415 2.4
12.110 7.3026 1.9
20.890 4 2490 100.0
S A P!-C ontro l 6.200 4 14.244 14.7
fused dnrinp labelling) 9.335 9.4663 3.1
12.330 7.1728 3.1
21.035 4.2200 100.0





Table 14: X-ray diffraction results for various forms of SAPL.
The values are an average of three runs per sample (n=3).
N.B. Under the measured conditions the diffracted rays from different sets of planes of spacing generates 
a cone of semi-apex angle 20. A pattern of concentric rings is produced by those cones of diffracted rays 
that intersect a film placed perpendicular to the undeviated beam, a detailed account of the theory is given 
elsewhere (Klug and Alexander 1974). The d-spacing values represent the space between orders in the 
crystalline matrix of the sample. Thus, bigger the number, greater the spacing between planes of crystals.
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Figure 28: X-ray diffractogram of MLFDS.
Discussion
When the above diffractograms are compared, a characteristic main peak at (°20) ~21.0 can be 
seen. The broadness of this peak, may arise from very small crystallite size, or lattice 
distortion, or both. For a polycrystalline specimen (i.e. most organic compounds) consisting 
of sufficiently large and free crystallites, diffraction theory predicts that the lines of the
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powder pattern will be exceedingly sharp (Klug and Alexander 1974). Thus, the broad peak 
coupled with the noisy baseline of the diffractograms is indicative of the amorphous nature of 
most organic material, which tend to be semi-crystalline in nature. In addition, SAPL is a 
freeze-dried material and an artefact of the process is usually the production of amorphous 
material, which are produced as a direct result of the lyophilisation process itself, namely the 
non-discriminative way in which the water is extracted (Craig et al 1999). In addition to the 
peak at (°20) -21.0, there are also common peaks at (°20) -6 .2  and 9.2, between the raw 
material and the materials which had undergone the labelling process. The differences in the 
values between the samples can be attributed to the measurement error associated with the 
technique, typically about 10% (Klug and Alexander 1974). The only difference between the 
treated (i.e. materials which have been through the labelling process) material and the raw 
product are the peaks which can be seen at (°20) -12.2 and 36.8(for MLFDS only). These 
peaks are of low relative intensity and are possible artefacts of the labelling process, possibly 
due to the residual chloroform left from the vacuum drying employed during the procedure.
In conclusion, the labelling procedure has not produced any significant change in the chemical 
composition of SAPL.
2.2.5 Analytical Methods
The two analytical techniques used in the separation and quantification of the various forms of 
SAPL were HPLC and fluorimetry. The various experimental aspects of each technique and 
the justification for use on SAPL are outlined below.
2.2.5.1 HPLC Detection of MS
The two components of MS, Phosphatidylgylcerol (PG) and Dipalmitoylphosphatidylcholine 
(DPPC), used during the in-vitro deposition experiments were separated and quantified by 
HPLC. Professor John Harwood and his team at Cardiff University, School of Biomedical 
Sciences originally developed the method used. Thus, in order to use this method in the
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present study, site-to-site transfer of the method was instigated. Full method validation was 
not undertaken, rather, linearity and repeatability experiments were carried out to assess the 
response of the detector and the performance of the HPLC equipment. The only unusual 
aspect o f the method was the detection technique employed. A non-selective ‘universal’ 
detector (PL-ELS 1000, evaporative light scattering or mass detector, Polymer Laboratories 
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Figure 29: A picture of the PL-ELS 1000 mass detector.
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PL-ELS 1000 is a unique and highly sensitive detector for non-volatile solutes in a volatile 
liquid stream. The solvent containing the solute material is nebulised and carried by a gas flow 
through an evaporating chamber. The solvent is volatilised, leaving a mist o f solute particles 
that scatter light to a photosensitive device. The signal is amplified and a voltage output 
results. The output is directly related to the mass of the solute particles passing through the 
light, hence the name mass detector.
1 0 0
Chromatographic Conditions
Column: 250 x 4.6mm LiCN (10pm packing, Hi-Chrom Ltd, UK) with a guard column 13mm 
x 8mm (10pm packing, Hi-Chrom Ltd, UK).
Column Temp: Ambient Injection Volume: 20pl Flow Rate: l.Oml/min
Run time: 8 minutes Retention times: PG 2.7min, DPPC 3.8min
Pump: Jasco intelligent HPLC pump, model PU980 (Jasco Ltd., Essex, UK)
Sampler: Jasco intelligent sampler, model PAS950
Mobile Phase: Methanol (HPLC grade, Fisons Scientific Equipment Ltd., UK)
Software: Borwin chromatography software VI.22 (JMBS, Grenoble, France)
Detector: PL-ELS 1000, software version V l.l
Detector settings: N2 Inlet pressure: ~50psi, Evaporator Temp: 80°C, nebuliser Temp: 80°C, 
Gas Flow: 0.7 SLM (standard litres per minute), Exhaust Temp: 50°C
Standard Preparation
DPPC and PG standards were stored at -20°C, prior to use. Three stock solutions were 
prepared by accurately weighing approximately 70mg of DPPC and 30mg of PG into a 100ml 
volumetric flask to produce a solution of 700/300pg/ml of DPPC and PG respectively. Two 
sets of five dilutions were prepared from each of the three stock solutions (see Figure 30, page 
102) making sure that in each case the ratio of PG: DPPC were maintained at 0.429. This 
ratio of 0.429 is the ratio of the two phospholipids within SAPL.
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Figure 30: Stock solution dilution procedure for PG and DPPC.




Table 15: Stock solutions and weights of standards used in the linearity experiments.
Linearity Experiments
Six sets (two groups from each stock solution) of six standards were injected (5 times per 
sample) and the areas of the two components determined by integration. The integrated areas 
were then expressed as % areas and % PG was adjusted by multiplying with a correction 
factor, before the phospholipid ratio of the two components was calculated. A correction was 
employed to account for the sensitivity of the HPLC equipment to PG. This was necessary 
because in the original method development, various known quantities of DPPC and PG were 
analysed and also to adjust the % ratio of the PG and DPPC peaks so as to maintain the fixed 
ratio of 0.429 present in each of the standards.
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Mean PG Area Mean DPPC Area PG
C.F.
Mean Corr. PG 
Area
A1 1 108607±6082 553562130999 1.83 198651+11124
2 107135±5785 555014132191 1.85 198645±10727
A2 1 81152±4058 374074119826 1.68 136568±6828
2 80553±4189 376000120304 1.70 13696617122
A3 1 68941±3171 294242115889 1.58 10895515012
2 68765±2957 293126114949 1.58 10856714668
A4 1 55698+2339 223510111176 1.50 8376213518
2 55081+2203 221047111494 1.50 8283813314
A5 1 31555+1262 12383115572 1.48 4661611865
2 31543+1293 12190715364 1.46 4603511887
A6 1 13278+491 3420011402 1.07 142431527
2 13114+446 3411811365 1.08 141701482
B1 1 110468+6510 558319130149 1.82 200636111838
2 109340±6777 555942143363 1.83 199585112574
B2 1 83363±4752 376605120713 1.66 13799017865
2 84167±4798 375064124379 1.64 13776917853
B3 1 67990±2924 294734114737 1.60 10881714679
2 69008±2829 296762116915 1.59 10973114499
B4 1 54883+2415 222424112678 1.52 8319213660
2 56348+2141 223101111601 1.49 8383513180
B5 1 3174611302 12099014961 1.44 4582111879
2 3209511027 12173815478 1.44 4615011477
B6 1 130921458 3471011388 1.10 143411502
2 132421437 3546011454 1.10 146111482






Mean PG Area Mean DPPC 
Area
PG C.F. Mean Corr. PG Area
Cl 1 112064±6276 559342+42510 1.80 201422+11280
2 110967+6103 557618+47955 1.81 200576+11032
C2 1 86014±4731 378205+20045 1.62 139266+7660
2 84649±4402 376+30484 1.63 138299+7192
C3 1 69113+3387 297301+16054 1.59 109924+5386
2 68385+3146 296435+21640 1.60 109446+5035
C4 1 58135+2442 223611+12299 1.45 84524+3550
2 57946+2723 222755+15593 1.45 84210+3958
C5 1 33266+1497 122282+5992 1.40 46664+2100
2 32317+1487 121371+7040 1.43 46106+2121
C6 1 13558+420 36314+1743 1.10 14962+464
2 13256+398 35348+1661 1.10 14581+437
Table 17: Table showing the HPLC areas obtained for stock solution C, dilution sets 1 and 2.
2.5e+5
Polynomial Regression 
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Figure 32: A graph showing an example of the Binomial relationship between standard concentration and 
HPLC area.
The graph is a plot of concentration versus corrected PG HPLC area for stock A, dilution set 1.
104
Similar calibration curves were obtained for the other stock solutions and dilution sets. These
all showed a binomial relationship (y=A0+Alx+A2x2+ Etc.) with increasing standard
concentration. The parameters obtained from these graphs are summarised below. Regression 















AO-StkA 1 -3799(±2994) -7717(±11680) 2 -3449(±3297) -6015(±12171)
Al-Stk A 1 2231 (±337) 2020(±613) 2 2118(±404) 1824(±639)
A2-Stk A 1 150(±10.1) 85.5(±7.22) 2 154(±11.1) 88.4(±7.52)
R-StkA 1 0.99985 0.99971 2 0.99982 0.99969
R2-Stk A 1 0.99970 0.99942 2 0.99964 0.99938
SD-StkA 1 1473 5748 2 1623 5990
AO-StkB 1 -2668(±3159) -4967(±10243) 2 -3600(±2672) -5990(±9524)
Al-Stk B 1 1971 (±387) 1747(±537) 2 2194(±327) 1895(±500)
A2-Stk B 1 160(±9.06) 89.9(±6.33) 2 153(±8.99) 87.5(±5.89)
R-StkB 1 0.99984 0.99978 2 0.99988 0.99981
R2-Stk B 1 0.99967 0.99956 2 0.99976 0.99962
SD-Stk B 1 1554 5041 2 1315 4687
AO-Stk C 1 -2825(±3030) -4099(±10046) 2 -3280(±2614) -5306(±9782)
Al-Stk C 1 2110(±371) 1791(±527) 2 2125(±320) 1817(±513)
A2-Stk C 1 157(±10.2) 89.4(±6.21) 2 156(±8.80) 88.8(±6.05)
R-StkC 1 0.99985 0.99979 2 0.99989 0.99980
R2-Stk C 1 0.99970 0.99958 2 0.99978 0.99960
SD-Stk C 1 1491 4944 2 1286 4814
Table 18: Table summarising the polynomial relationship between standard concentration and detector 
response in the linearity experiments.
Statistics
The Bartlett test and Student’s t-test, as outlined in section 2.3, page 118, were performed on 
the binomial constants AO, A l, and A2 obtained from the graphs to ascertain inter and intra 
sample variation. The Bartlett and T-test at results obtained are shown in Table 19, page 58.
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X2'Value Degrees of Freedom Probability Significant
Difference
AO 0.427 11 >0.9999 No
A l 1.422 11 0.9997 No
A2 187.9 11 <0.005 Yes
Table 19: Table showing the Bartlett test values for binomial constants AO, Al, and A2 obtained from the 
statistical analysis of MS-HPLC linearity experiments.





Stock A-Set 1/2 8 0.079 0.470 No 0.101 0.461 No
Stock B-Set 1/2 8 0.225 0.414 No 0.073 0.472 No
Stock C-Set 1/2 8 0.114 0.456 No 0.086 0.467 No
T-value for A at p=0.05
Stock A-Set 1/2 8 0.215 0.418 No 0.221 0.415 No
Stock B-Set 1/2 8 0.440 0.336 No 0.202 0.423 No
Stock C-Set 1/2 8 0.031 0.488 No 0.035 0.487 No
T-value for A2 at p=0.05
Stock A-Set 1/2 8 0.267 0.398 No 0.278 0.394 No
Stock B-Set 1/2 8 0.548 0.293 No 0.278 0.394 No
Stock C-Set 1/2 8 0.074 0.471 No 0.069 0.473 No
Table 20: Table showing the T-test values obtained for the binomial factors AO, Al and A2 from the 
statistical analysis of MS-HPLC linearity experiments.
Repeatability Experiments
The precision of the method was measured by performing five injections of a standard 
solution (30/70pg/ml) and calculating the relative standard deviation of the peak areas 






DPPC Area DPPC Retention Time 
(Min)
1 110416 2.53 558507 3.66
2 110995 2.53 557121 3.67
3 110403 2.53 559493 3.66
4 111449 2.53 556914 3.66
5 111263 2.53 559637 3.67
Mean 110905 Mean 558334
SD 480 SD 1281
RSD(%) 0.433 RSD(%) 0.229
Table 21: Repeatability of injection for standard 1 (30/70pg/ml PGrDPPC).
Sample Measurement
Following calibration of the SAPL assay, determination of the concentration of the active in 
unknown solutions was undertaken as described below.
The six standards were prepared as described earlier. These solutions were injected in 
duplicate at the beginning of a run, prior to unknown samples. The unknown samples were 
prepared and diluted according to the methods given for the various deposition studies 
undertaken, such that they fell within the standard range. The test samples were also injected 
in duplicate. The concentrations of SAPL in the unknown solutions were calculated by 
solving the quadratic equations of the standard curves using a mathematics programme 
(Maple® V, Release IV, The Power Edition, Waterloo Maple Inc., Canada) as shown below. 
The values in the equation below are for stock solution A, dilution set 1, from Figure 32, page 
104.
y  = -3 7 9 9  + 223 IX  + 150.3X 2 Equation 8
solution:
L -  J181532995 + 1 5 0 3 0 v . ----- — J181532995 + 15030 v
1503 1503 1503 1503 ^
A B C  D
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Thus, by taking the positive values from the above equation, labelling them A, B, C and D and 
incorporating the values into a spreadsheet, equation 9 can be used to calculate the 
concentration of the unknown samples in the individual deposition profiles. Examples of this 
process as well as raw data are given in Appendix 13: MS Testing and Stability Study Raw 
HPLC Data, page 271.
Concentration= A+B*sqrt(C+D*HPLC Area) Equation 9
Discussion
Statistical analysis and the method outlined show that this technique for quantifying SAPL is 
appropriate for use in this study.
2.2.5.2 Fluorimetric Detection of LFDS
A full account of the labelling procedure, reasons for labelling and subsequent identification 
and characterisation of LFDS is given in section 3 Fluorescent Labelling of FDS, page 121. 
This section describes the fluorimetric method developed to quantify LFDS.
Standard Preparation
Three stock solutions were prepared by accurately weighing approximately 200mg of LFDS, 
containing 1% label (i.e. 2mg total weight), into a 100ml volumetric flask to produce a stock 
solution with a label content of 20pg/ml, dissolved in methanol (HPLC grade). Three sets of 
subsequent dilutions were prepared from each of the three stock solutions (see Figure 33, page 
109) to produce six standards, ranging from 0.05 to 08pg/ml from which the calibration curves 
were constructed.
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Figure 33: Stock solution dilution procedure for LFDS.




Table 22: Stock solutions and weights used in the construction of the fluorimetric calibration curve. 
Detection o f Excitation and Emission Wavelengths
The standard solutions were scanned using a Hitachi F2000 Fluorimeter, Hitachi Ltd., Japan.
The scan conditions are given below:-
Scan speed: Fast Scan step: lOnm Sensitivity: High
Excitation slit: lOnm Emission slit: lOnm Excitation scan range: 200-450nm
Emission Scan range: 400-600nm
Preliminary settings were such that a coarse scan was carried out for both excitation and
emission. The instrument was then set at a lower scan speed and both the excitation and
emission wavelengths were determined more accurately. The excitation (Ex) and emission 








Figure 34: A specimen spectrum showing the X,max obtained for n-octadecyldansylamide by fluorimetric 
Analysis.
The standard solutions were then measured at the above wavelengths and the relative 




















Al 0.05 1 6.42 2 6.44 3 6.40
A2 0.1 1 12.9 2 12.9 3 12.8
A3 0.2 1 25.7 2 25.6 3 25.6
A4 0.4 1 51.3 2 51.5 3 51.3
A5 0.5 1 63.8 2 63.8 3 63.7
A6 0.8 1 101.8 2 101.8 3 101.6
B1 r  0.05 1 6.41 2 6.41 3 6.40
B2 0.1 1 12.7 2 12.7 3 12.8
B3 0.2 1 25.5 2 25.3 3 25.5
B4 0.4 1 50.4 2 50.6 3 50.5
B5 0.5 1 63.6 2 63.5 3 63.3
B6 0.8 1 101.3 2 101.4 3 101.3
Cl
wooo I 6.41 2 6.45 3 6.42
C2 0.1 1 12.6 2 12.8 3 12.9
C3 0.2 1 25.2 2 25.1 3 25.0
C4 0.4 1 49.9 2 49.8 3 49.7
C5 0.5 1 62.3 2 62.5 3 62.4
C6 0.8 1 102.4 2 102,2 3 1024
Table 23: LFDS standard solutions and corresponding relative intensities for dilutions sets 1, 2 and 3.
1 1 0
The calibration curves for the above data all show a linear relationship with increasing 
concentration.
100 - Linear Regression 
Y = A + B * X 
Param Value 
8 0 - A  0.21316
B 127.14197
R = 0.99999 
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Figure 35: A specimen calibration plot of standard concentration versus relative intensity
Stock Dil Slope Slope SD Intercept Intercept SD Correlation
Coefficient
A 1 127.1 0.2443 0.2132 0.1047 0.99999
A 2 127.2 0.3676 0.2182 0.1576 0.99998
A 3 127.0 0.3141 0.1803 0.1346 0.99999
B 1 126.5 0.3260 0.11821 0.1398 0.99999
B 2 126.7 0.1691 0.05047 0.07247 0.99999
B 3 126.3 0.1773 0.1617 0.07601 1.00000
C 1 127.4 1.243 -0.3919 0.5329 0.99981
C 2 127.1 1.140 0.2904 0.4886 0.99984
C 3 126.9 1.200 0.2869 0.5144 0.99982




Statistical analysis on the slopes of the above results was performed using the Bartlett test as 
outlined section 2.3 Statistical Analysis, page 118. The test indicated no significant 
differences between the three standards and three dilutions per set (%2= 0.527, p= 0.9998). 
With the exception of A 1, the intercepts passed through zero within ±2 SDs and RSDs for the 
slopes were <4.4%, indicative of good linearity.
Sample Measurement
Following calibration of the SAPL assay, determination of the concentration of the active in 
unknown solutions was undertaken as described below.
The six standards were prepared as described earlier. These solutions were measured and a 
standard curve constructed for each separate analysis. The unknown samples were prepared 
and diluted according to the methods given for the various deposition studies undertaken, such 
that they fell within the standard range. The concentrations o f SAPL in the unknown solutions 
were calculated by substituting the equations of the standard curves into a spreadsheet. A 
more precise account of this process is given in the individual deposition studies profiles (see 
section 4 Deposition Studies of MLFDS, page 135).
2.2.6 General I Other Methods
This section outlines the various miscellaneous techniques used in the characterisation and 
processing of SAPL. These include micronisation, surface area analysis, and moisture 
analysis.
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2.2.6.1 Micronisation of SAPL
Micronisation of raw, freeze-dried labelled SAPL (FDS) was carried at out by fluid-energy 
milling using the Gem-T air pulveriser, Glen-Creston, Stanmore, UK. Micronisation of Raw 
SAPL (manufactured without the freeze drying process) was carried out at Micro-Macinazione 
SA (Micro-Grinding Ltd), Switzerland, using their patented Chrispro®-Jetmill.
Method 1- Using the Gem-T Air Pulveriser
Samples were fed into the micronisation chamber using a small vibrating spatula, via small 
feed-orifice located at the side of the instrument. The feed-rate was varied according pressure 
differences between the inlet and the outlet valve of the instrument. Inlet valve operating 
pressure was lOOpsi, and the outlet valve pressure was 80psi, therefore, creating a 20psi net 
pressure difference in the flow of air towards the micronisation chamber. This pressure 
difference was used to entrain the sample to the micronisation chamber. The micronised 
samples were collected in a glass collection jar, removed, weighed and the efficiency of the 
procedure calculated. Typically, the process was about 65% efficient, and sample loss was 
due to:
a) Sample adhering to the various internal components of the mill.
b) Sample loss during transfer after the micronisation process.
c) Ultrafine particles not heavy enough to fall into the collection jar being collected in the 
relief bag required for the escaping air from the system.
Method 2- Using the Chrispro®-Jetmill
Chrispro® jetmill, model MC50, was used to micronise SAPL in a class 10,00 laboratory 
supplied with filtered air. The humidity (<10%) and temperature (18-20°C) of the room was 
controlled. A glove-box was specially constructed to house the equipment and to produce 
micronised material suitable for inhalation. The procedure was carried out under a stream of 
nitrogen, filtered through a 0.2pm filter, and all air was eliminated from the system. Standard
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bacterial swab tests were carried out to ensure the conditions met the criteria necessary to 
produce inhalation quality material. The operating conditions were:
Air Consumption at 7bar: 0.41Nm3/min.
Sample Feed-Rate: 0.05-lkg/h Projected particle size range: 0.5-10pm 
Efficiency: -70%, losses due to reasons explained above.
2.2.6.2 Surface Area Analysis (BET Multi-Point)
In the pharmaceutical industry, surface area is becoming more important in the 
characterisation of materials during development, formulation, and manufacturing (Webb and 
Orr 1997). The surface area of a solid provides information about the void spaces on the 
surfaces of individual particles or aggregates of particles (Parrott 1970). This is important 
because factors such as chemical activity, adsorption, dissolution, and bioavailability of the 
drug may depend on the surface of the solid. The adsorption of inert gases onto solid 
materials represents the most widely used method for the determination of surface area. The 
Brunauer, Emmett, and Teller (BET) method is generally used for gas adsorption surface area 
measurements. The BET method is based on the monolayer adsorption of an inert gas onto 
the solid surfaces at reduced temperatures, nitrogen is used as the adsorbate gas for most 
samples. The way in which a material adsorbs a gas is referred to as an adsorption isotherm, 
and there are five typical adsorption isotherms. The isotherm shapes reflect specific 
conditions for adsorption, such as pore size and heats of adsorption, and the most common 
isotherm type is the type II isotherm (used in BET measurements). BET theory is an 
extension of Langmuir’s theory of monolayer gas adsorption on surfaces (Lowell and Shields 
1984). BET theory takes into account the formation multilayers on surfaces (Webb and Orr 
1997), and relates condensation rate of gas molecules onto an adsorbed layer and the 
evaporation rate from that layer for an infinite number of layers. The linear form of the 
relationship is called the BET equation.
P  1_ C - l
V(P0 - P ) ~ V „ C + VmC a
Equation 10
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(i.e. Y= C + mX)
where V= Volume of gas adsorbed at pressure P.
P= Partial pressure of adsorbate.
Vm= Volume of gas adsorbed in monolayer.
Po= Saturation Pressure of adsorbate at experimental temperature.
C= BET constant exponentially relating the heats of adsorption and
condensation of the adsorbate.
The BET theory assumes that all adsorption sites are energetically equivalent, which is not the 
case for normal samples. The BET model also ignores lateral adsorbate interactions on the 
surface, and assumes that the heat of adsorption for the second layer and above is equal to the 
heat of liquefaction.
Method
Samples were weighed into glass bulbs, and degassed (FlowPrep 060 Degasser, 
Micromeritics, Particle Technology Instruments, GA, USA) under the conditions given below 
to remove pre-adsorbed gasses and vapours from the solid surface. Higher degassing 
temperatures were avoided to minimise sample degradation and dehydration. Samples were 
re-weighed and the values were used for subsequent surface area measurements (Gemini 2360 
V5.00 (Micromeritics, Particle Technology Instruments, GA, USA).
Operating Conditions
Evacuation Time: lmin Equilibration Time: 5 or seconds




























































Table 25: BET parameters obtained on the Gemini 2360 V5.00 (Micromeritics, Particle Technology 
Instruments, GA, USA) for various forms of SAPL, n=3.
Discussion
Results of the surface area measurements show clear differences between the various samples 
analysed. Generally, as expected, the surface area of the micronised material is greater than 
non-micronised samples. However, the technique may be underestimating the surface area of 
the micronised material since firmly agglomerated particles may hinder or prevent nitrogen 
from penetrating the surfaces of every individual particle.
2.2.6.3 Moisture Analysis of SAPL
Method
Moisture determinations were carried out using Karl-Fischer (KF) analysis (Metrohm 684 
Karl-Fischer Coulometer, Hensau, Switzerland). A mixture of chloroform: methanol (Ratio 
1:2 v/v) was prepared and used as the solvent. 0.5ml of the solvent was injected through the 
septum of the KF chamber a total of 10 times, using a high precision gas chromatography
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syringe (Hamilton Gastight 1700 syringe, Hamilton Company, Nevada, USA). The average of 
ten readings were used to calculate the water content of the solvent in jig, and this was used as 
the blank value in subsequent measurements. Approximately 20-40mg of the sample was 
weighed and dissolved in the mixture to give 0.5mg/ml solution, of which five 0.5ml aliquots 
were injected. By multiplying the concentration of the solution with the volume, the amount 
of sample injected (in mg) was calculated. This figure was inputted into the instrument and % 
water content for the sample was obtained.
Instrument settings and Calculations
Drift (pg/min)= 0.0006, Delay (s)= 5, Extraction time (min)= 1 
M(H20-B lank)
/owater = -------      Equation 11
Sample
Results
FDS Pre-Micro FDS Post-Micro LFDS LMFDS UMS MS
% 3.40 5.20 3.25 3.43 4.18 4.42
Moisture (±0.10) (±0.14) (±0.04) (±0.05) (±0.09) (±0.15)
Table 26: Percentage moisture content values for various forms of SAPL, pre and post micronisation. 
Values in brackets indicate standard deviation, n=5.
Discussion
The results show that the indigenous moisture o f the various forms of SAPL, before any 
processing, are very similar with values of 3.40, and 4.18% for FDS and UMS respectively. 
The micronisation procedure appears to increase the moisture content slightly, but not enough 
to cause any undue concern.
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2.2.6.4 Mixing Techniques
Preliminary, geometric and ad-hoc hand blending techniques using a pestle and mortar yielded 
poor content uniformity results. Also, the mechanical stress caused by hand blending raised 
questions as to the stability of SAPL during the mixing process. Thus, this type of blending 
was discontinued. Turbulent tumbling mixing using the Turbula T2C (Bachofen, Basel, 
Switzerland) also produced blends with poor content uniformity. The probable cause of this 
was due to low shear achieved by this type of mixing. Hence, only the high-shear blending 
techniques described below was employed.
MLFDS was mixed with coarse Lactochem-lactose (63-90pm, see Figure 105, page 269). The 
powders were mixed using a rotary bladed blender (Kenwood Mini Chopper, CHI00, 
Kenwood Ltd., Hants., UK) at a constant blade speed. At various intervals (every minute) the 
mixing procedure was halted, the powder adhering to the sides of the chamber and the blade 
face was removed using a soft brush. The benefit of this procedure was two-fold. Firstly, 
constant mixing caused the blender to overheat. Thus, stopping periodically allowed the 
blender to cool-down. Secondly, adhered powder was introduced back to the bulk powder bed 
to ensure uniform mixing. When producing ternary blends of SAPL with coarse and fine 
lactose combinations, the two components were pre-blended for a period ten minutes. 
Following this, the drug was introduced to the system and the blending was continued until 
acceptable content uniformity values (i.e. <5% RSD) were obtained. The size of the blends 
varied between ten and forty grams depending upon the study. The optimum mixing time of 
each blend was determined by carrying out content uniformity experiments.
2.3 Statistical Analysis
The theory of statistics is based on probability (Bolton 1996). Probability distribution is a 
mathematical function that assigns probabilities for outcomes in its domain. The normal 
distribution is the basis of modem statistical theory and methodology. The chief reason for 
this is the central limit theorem, which shows that means o f samples from virtually all
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probability distributions tend to be normal for large sample sizes. Probability distributions 
used in statistical analyses are based on normal distribution and include the t and chi-square 
distributions.
2.3.1 Analysis of Variance (ANOVA)
This is perhaps the most powerful statistical stool and is a general method for analysing data 
from designed experiments, whose objective is to compare two or more group means. The 
statistics packaged used to analyse the results throughout this report was Minitab® for 
Windows, V 10.2, Minitab Inc., PA, USA. There are two types o f anova:
a) One-Way: only looks at the differences in group means
b) Two-Way: may look at other variables apart from means (e.g. different treatments of 
the groups).
Only the one-way anova was used to assess the results throughout this report. P and F values 
were obtained, where P was the probability and F was an indication of actual variation in 
group averages devided by the expected variation in group averages. To put it another way, F 
is the value obtained when the error within the group is divided by the error between the 
averages. Thus, F is greater than or equal to 1, and larger the F value more the error 
associated within the group.
2.3.2 Student’s t-Test
The t distribution is an extremely important distribution and is a special case of ANOVA in 
which only two means are compared. The t-test formula used in the statistical analysis 
throughout the report to to check for intra-group variability is given below:
slope  1 -  slope2
t  =  / t2 , t2 \ 1/2 Equation 12(sdi +sa2)
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at (ni+n2)-4, where ni= number of points on line 1 and n2= number of points on line 2.
2.3.3 Chi-Square (Bartlett) Test
Chi-square distribution is another important probability distribution and may be derived from 
normally distributed variables, defined as the sum of squares of independent normal variables, 
each of which has mean 0 and standard deviation 1. Thus, when more than two estimates of a 
parameter P are tested for equality, the following statistic is used:-
„ Tipi -  P)2B =  t  Equation 13
(<r)2
Where: ( o f  = n'S? +niS * n*S* Equation 14
« l + » 2 + ...........» ,
Where Si, S2 etc. are the standard deviations associated with the estimates Pi, P2 etc. and ni, n2 
etc. are the number of observations used in determining the estimates. If the estimates all 
come from the same normal distribution then the above equation will have a %2 distribution 
with N -l degrees of freedom where N is the number of estimates.
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Chapter 3 
Fluorescent Labelling of FDS
3 Fluorescent Labelling of FDS
The various sections and sub-sections below are intended to give a systematic insight into the 
properties and behaviour of SAPL powder.
3.1 Reasons for Labelling
SAPL has no UV chromophore and cannot be detected by UV analysis. Attempts were made 
to quantify the material with atomic absorption (AA), refractive index (RI) analysis, and by 
fluorescence. AA analysis was undertaken in attempt to quantify SAPL indirectly by 
measuring the levels of calcium (Ca2+) and sodium (Na+) present within freeze-dried samples. 
Samples were dissolved in methanol (0.5-10mg/ml) and measured using air/acetylene, nitrous 
oxide/acetylene, and nitrous oxide only as the fuel sources. AA was not used as the detection 
method, however, since the levels of Ca2+ and Na+ were different from batch to batch, and the 
material was poorly soluble in aqueous solutions. RI analysis (Abbe reffactometer, 
Bellingham & Stanley Ltd, London) of varying concentration (0.01-0.5mg/ml) of SAPL, 
dissolved in chloroform, showed that the technique was not sensitive enough to be used as the 
detection method. A full range scan using a fluorescence spectrophotometer (Shimadzu 
RF540, Simadzu Ltd., Tokyo, Japan) revealed a concentrated solution of SAPL to be only 
very slightly fluorescent, too small to be quantifiable in any deposition study profiles. Thus, 
in order to quantify FDS in the various deposition studies undertaken, it was necessary to label 
the material with a fluorescent agent (n-octadecyl dansylamide-l%w/w).
A full account of the synthesis of the label, the labelling procedure, identification of labelled 
material, and an experiment to evaluate the uniform distribution of the label within SAPL is 
described in this section.
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3.1.1 Preparation of the Label (n-Octadecyl Dansylamide)
The fluorescent label, n-octadecyl dansylamide, (see Figure 98, page 263 for structure and 
physico-chemical properties) was synthesised by reacting equal quantities (1.35g) of 
octadecylamine (see Figure 97, page 263) and dansyl chloride (see Figure 96, page 263), both 
dissolved in dichloromethane. Triethylamine (700mg) was used to remove excess 
hydrochloric acid (HC1) from the reaction. The presence of the final product was established 
by thin layer chromatography. A drop of all the components used in the synthesis was placed 
near one edge of the plate and their positions marked with a pencil. The sample solvent was 
then evaporated and the plate was placed in a closed glass container with one end immersed 
into the developing solvent (hexane:ethyl acetate (1:1)). The plate was then removed, dried 
and sprayed with ninhydrin to reveal the spots on the plate.
Once the final product was identified, magnesium sulphate and 1M HC1 were then added to 
remove residual water and excess triethylamine respectively. Identification of the final 
product was established using nuclear magnetic resonance (NMR) (see 3.1.3 NMR 
Identification of the Label, FDS, and FDS-Control) and hot-stage microscopy. The melting 
point of n-octadecyl dansylamide was found to be 70-72°C, this compared with 69.5-71°C, 
which was the quoted literature value for the compound, Bergbreaker (1990).
3.1.2 Labelling Procedure
SAPL (5g) and 1% w/w (50mg) of the label were dissolved in a minimum amount of 
chloroform, stirred thoroughly and filtered to remove any impurities. The solvent was 
removed using a rotary evaporator. The labelled SAPL was collected and identified via NMR 
and Mass Spectometry with the help of Dr Mike Threadgill and his group, University of Bath, 
School of Pharmacy and Pharmacology.
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3.1.3 NMR Identification of the Label, FDS, and FDS-Control
Figure 36 shows a *H NMR trace of n-octadecyl dansylamide. The trace was produced using 
the method outlined below.
The samples were dissolved in deuteriated chloroform (CDCI3) and a small amount was 
placed into NMR sample tubes for analysis. The NMR instrument used for both 'H and 13C 
analysis had field strength of 400MHz (JEOL EX 400, Japan).
Figure 36: *H NMR trace of n-octadecyl dansylamide.
The peak at Oppm is TMS (reference solvent). The singlet at 80.8-0.9ppm is due to the 
terminal CH3 group at the end of the long alkyl chain. All other CH2 groups within the 
compound are represented by the wide multiplet seen between 81-1.5ppm. The peak at 
82.9ppm is due to two methyl groups next to nitrogen at the bottom of the aromatic ring as 
well as the CH2 group next to the Nitrogen at the beginning of the long alkyl chain. The peak 
at 84.7ppm is due to the NH coupling. The peaks between 87.2 to S8.6ppm are due to the 
various aromatic protons. The reason for the wide range is that some are affected by the 
hetero-atoms far more than others.
Figure 37, page 124 shows the 13C NMR trace of n-octadecyl dansylamide. The peak at 
14ppm is due to terminal carbon on the methyl group on the long alkyl chain portion of the 
label. The peak at 22.7ppm belongs to the carbon present in CH2 groups in the alkyl chain 
portion o f the label.
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N (C H 3)2
Figure 37: ,3C NMR trace of n- ocatdecyl dansylamide.
The multiple peaks between 26.4 and 32.0 belong to other carbons, which make up CH2 
groups within the structure. The N-CH2 coupling produces the peak at 43.2. The peak at 45.4 
is due to two carbons on the Methyl groups, which are attached to the Nitrogen at the bottom 
of the aromatic ring. The multiple peaks between 76.7 and 77.3 belong to Chloroform, which 
is the solvent used to prepare the material for analysis. The aromatic carbon groups are given 
between 115.2 and 130.3. Quaternary carbons within the structure are represented by the 
peaks at 134.8 and 151.9. Figure 38, below, shows the ‘H NMR trace of FDS (see Figure 1, 
page 13 for structure) and FDS control. FDS control is material that has undergone the 
labelling procedure, but without the label being introduced into the process.
Figure 38: 'H NMR trace of FDS and FDS-Control.
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The peak at approximately 80.5ppm are due to the methyl groups from the DPPC and possibly 
from the terminal methyl groups at the end of the fatty chains attached to PG on positions R\ 
and R2 . The broad series of multiplets at 81.2 to 81.35 are due to the various CH2 groups in 
both the DPPC and PG. The broadness of the peak is due to the various environments that the 
CH2 groups are under. The peak at 81.6ppm is due to the CNC-CH2-CH2 couplings. The 
quartet at S2.4ppm is probably due to the various CNC-CH2 couplings throughout both DPPC 
and PG. The triplet at 83.3ppm is due to the N-(CH3)3 interactions. The multiple o f peaks 




Figure 39: 13C NMR traces of FDS and FDS -control
The peak at 14.1ppm is due to the presence o f end methyl groups within the structures. The 
peaks from 22.6 to 34.3ppm are due to the various CH2 groups. The peak at 54.4ppm is due to 
ternary nitrogen connected to three methyl groups. The peak at 59.4ppm is due to the CH2-N 
bond. The various peaks at 63.0 to 66.4ppm are due to the CH2 structures attached to oxygen. 
The peaks at 70.4 and 70.5ppm are possibly due to CH-OH interactions. The peaks at 77.0 to 
77.3 are due to the chloroform used in preparing NMR samples. The peak at 174ppm is 
probably due to C =0 interactions.
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Discussion
The identification of n-octadecyl dansylamide (label) has been confirmed. The identical 
traces obtained for both FDS and FDS-control show that the sample does not undergo any 
chemical changes during the labelling process.
3.1.4 Mass Spectrometric Identification of the Label, FDS, and FDS-Control
Mass spectra were recorded on VG7070 and VG Autospec instruments at the Mass 
Spectrometry Service, University of Bath. Fast-Atom Bombardment (FAB) spectra presented 
in this section were obtained using m-nitrobenzyl alcohol (m-NBA) as the matrix. 
Intrepretation of the spectra were carried out in collobartion with Dr Mike Threadgill and his 
research group, University of Bath, School of Pharmacy and Pharmacology.
In each of the spectra presented, there are two traces. The top trace shows the various positive 
fragments of the sample in question, whilst the bottom trace shows the main ions of the 
sample.
F i l e :9474 Ident:1 Mer Def 0.25 A c q :25-MAR-1998 15:33:12 +0:26 C a l :PF 
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Figure 40: Fast Atom Bombardment (FAB) of positive ions (FAB+) of the label.
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The bottom trace shows the main ions whilst the top trace shows the various positive 
fragments of the label.
Result: m/z 502.5 [(M+H)+ 100%] is the n-octadecyl danyslamide peak.
Pile:9476 Ident:1 Her Def 0.2S Acq:25-KAR-1998 16:33:52 >0:24 Cal:PF 
AutoSpec FAB* Magnet BpM:B6 BpI:480256 TIC:5527S76 Flags .HALL 
File Text:Moaydin C in »-NBA.
125.0 166.1
.8B5.4
File:9473 Ident:1 Her Def 0.25 Acq:24-MAR-1998 16:13:46 *0:36 Cal:PF 
AutoSpec FAB* Magnet BpM:184 BpI:982272 TIC:71084S8 Flags:HALL 
File Text:M0 Aydin RA in b-HBA.
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Figure 41: Fast Atom Bombardment (FAB) of positive ions (FAB+) of FDS-Control (left) and FDS (right).
The left trace can be interpreted as follows: m/z 735.1 [(M+H)+ 70%] is the DPPC whilst m/z 
793.5 [(M+H)+ 30%] is the PG. The peak at 756.6 is DPPC + Sodium, this is an artefact of 
the measuring process when sodium from the atmosphere is measured along with the main 
fragment to produce a pseudo peak. Similarly, the right trace results are: m/z 734.6 [(M+H)+ 
70%] is the DPPC whilst m/z 771.5 [(M+H)+ 30%] is the PG. The peak at 756.6 is DPPC+ 
Sodium.
3.1.5 Experiment to Prove the Uniform Distribution of the Label within FDS
The introduction of the label (n-octadecyl dansylamide) into FDS was carried out in solution, 
as described earlier. The solution was then evaporated off to leave the solid material behind. 
To assess the quantity and distribution of the label within FDS, an experiment was devised to 
evaluate the uniformity of the labelling process.
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Standard Preparation
Six standards of the label were prepared and measured by a fluorescence spectrophotometer, 
as described in section 22.5.2 Fluorimetric Detection of LFDS, page 108, to produce the table 
below. Methanol (HPLC grade) was used as the blank during measurements.








Table 27: Table showing the six standards of n-octadecyl dansylamide used to produce the calibration 
curve.
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Figure 42: Calibration curve of n-octadecyl dansylamide.
Linear Regression
Y = A + B * X









Twenty samples of approximately 20mg (~0.2mg or 200pg label by weight) of LFDS were 
accurately weighed, using a small glass weighing boat, and washed into a 50ml volumetric 
flask with methanol and adjusted to volume. This gave a 40pg/ml solution of the label that 
was further diluted with the methanol (1:10) to give a 4pg/mi test sample.
Results
The equation of the straight line of the calibration curve was taken and incorporated into Table 
28, to give the concentration of the unknown samples. The corrected intensities take into
account the fluorescence of the blank.
Sample Relative Corr. Cone. Corr. Cone. Dil. Label
Wt. (mg) Intensity (%) Intensity (%) (pg/ml) (pg/ml) Factor wt. fog)
20.27 53.84 53.42 0.415 0.410 500 204.9
19.74 50.20 49.78 0.386 0.391 500 195.5
19.68 50.15 49.73 0.386 0.392 500 195.9
19.60 50.25 49.83 0.386 0.394 500 197.1
19.77 50.85 50.43 0.391 0.396 500 197.9
19.21 50.29 49.87 0.387 0.403 500 201.3
19.53 50.10 49.68 0.385 0.394 500 197.2
19.21 50.55 50.13 0.389 0.405 500 202.4
19.10 50.15 49.73 0.386 0.404 500 201.9
19.36 49.46 49.04 0.380 0.393 500 196.3
20.45 52.62 52.20 0.405 0.397 500 198.3
20.41 52.79 52.37 0.407 0.399 500 199.3
20.62 52.76 52.34 0.407 0.394 500 197.2
20.77 55.10 54.68 0.426 0.410 500 204.9
20.22 52.36 51.94 0.403 0.399 500 199.5
19.63 51.89 51.47 0.400 0.407 500 203.6
19.27 50.09 49.67 0.385 0.400 500 199.8
20.10 51.40 50.98 0.396 0.394 500 196.8
19.66 49.99 49.57 0.384 0.391 500 195.5










Table 28: Relative intensities and corresponding concentrations for 20 samples of LFDS.
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3.1.6 Validation of the Labelling Process
In order to validate the labelling process, a solution LFDS was nebulised into a 5-stage liquid 
impinger, using a Cirrus™ nebuliser and a Nebupump™ compressor, with the set up 
employed for the deposition studies of radiolabelled SAPL (Figure 77, page 208). Since 
radiolabelled SAPL has a definitive deposition pattern within the MSLI, it can be used as a 
reference to evaluate the extent to which the label (n-octadecyl dansylamide) follows the 
actual drug particles of FDS.
Materials & Equipment
Compressor, Nebupump™ (Carri-Med Ltd, Dorking, UK), maximum output: 6.4L min'1. 
Nebuliser: Cirrus™ (maximum output: 3.8L min'1).
Pump: Gast 1023, Rotor Vein, Oil-less, (Bucks., UK).
5-Stage Liquid Impinger, Stage 5 filter: Type A/E glass fibre, 76mm diameter (Gelman 
Sciences, Mich., USA).
Digital timing unit, Mass flow meter (Hastings Mass Flow Meter, HFM 201, Teledyne Brown 
Engineering, Hastings Instruments, VA, USA).
Method
Flow rate through the MSLI was set at 60L min'1 using the mass flow meter. Each stage of 
the MSLI was filled with 20ml of HPLC grade methanol. 300mg of LFDS was weighed into a 
10ml volumetric flask and dissolved in methanol to produce a 30mg/ml solution. 3ml of the 
test solution (theoretically containing 1% label, 900pg by weight) was pipetted into the 
nebuliser. The nebuliser was connected to the MSLI via an adaptor, as shown in Figure 77, 
page 208. The compressor was connected to the bottom of the nebuliser via vacuum tubing. 
The timing unit was adjusted so that the by-pass switch was activated, which allowed the 
pump to work continuously. The pump and the compressor were switched on and the solution 
was nebulised. It took approximately nine minutes for the chamber empty to dryness. Stage 5
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of the MSLI was disconnected from stages 1 to 4 and the MSLI swirled gently to collect 
droplets that had impacted on the sides and then inverted to wash the ceiling of the apparatus. 
Stoppers from the four stages were removed and each stage was emptied into 100ml 
volumetric flasks. Each stage was further washed with methanol to recover as much of the 
nebulised material as possible and the volumetries were made up to volume using methanol. 
The metal throat and silicone adaptor were washed into the same 100ml volumetric flask and 
made up to volume with methanol. The glass fibre filter from stage 5 was placed into a glass 
crystallising basin and washed with 20ml of methanol. The solution was poured into a 100ml 
volumetric and made up to volume with further methanol. The residual liquid left in the 
nebuliser was washed into a 100ml volumetric falsk and made up to volume using methanol. 
Both the residual liquid from the nebuliser and stage 5 were further diluted (1:10) such that 
their intensity readings fell within the standard range. The procedure was carried out in 
triplicate. The standards were prepared as described earlier (see fluorimetric detection of 
LFDS, page 108). The relative intensity of the standards and the samples were measured on 








































































1000 210.1± 4.16 24.8+
0.490
Table 29: Distribution of LFDS within an MSLI at 60L min"1 flow rate, aerosolised from a Cirrus™ 
nebuliser using the Nebupump™ compressor operating at 6.4L min'1.
Since 3ml of the test solution (theoretically containing 1% label, 900pg by weight) was 
pipetted into the nebuliser, the total recovery values can be calculated as shown below in 
Table 30.
Parameter Value Obtained or Calculated
Mean Total Recovery (ug) 859.3+13.2
Mean Total Recovery (%) 95.5+1.47
Table 30: Recovery values for LFDS.
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Figure 43: Deposition profiles of LFDS compared againsts radiolabelled PG and DPPC in an MSLI at 
60Lmin~' flow rate, aerosolised from a Cirrus™ nebuliser using a Nebupump™ compressor operating at 
6.4Lmin''.
Bars represent the mean + SD of 3 determinations.
3.1.7 General Discussion
Fluorescent labelling as a technique is used in the food industry (Herbert et al 1999) as well as 
for biopharmaceutical and analytical applications, when derivatisation is required for indirect 
detection of compounds (Gatti et al 1995). These applications often incorporate wet 
chemistry and solid dosage forms are not used. Owing to the difficulties in chemically 
labelling drug molecules themselves, formulations for pharmaceutical applications are labelled 
with a gamma ray emitting nuclide like 99mtechnetium, which forms a complex of radioactive 
atoms or groups with molecules of the compound (Newman 1996). The isotope has found 
increasing use in the pharmaceutical industry in the past 10 years for in-vitro and in-vivo 
assessments of various delivery systems (Newman 1996). The isotope has a short half-life 
(6hrs) and can be administered in large doses. The techniques used for labelling DPIs are very
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similar to those for pMDIs. " mTC is used, along with a chelating agent and added to the dry 
powder in a solvent in which the drug is not soluble (e.g. with terbutaline sulphate, the solvent 
used is chloroform). The radiolabel permeates the drug particles, and the assessment of the 
distribution of the radiolabel and drug is made via in vitro analysis (such as an MSLI) coupled 
with scintillation counting (Newman et al 1991). Therefore, the drug deposition in the various 
stages of the apparatus is calculated both via scintillation and MSLI analysis (usually 
involving HPLC detection) and the two sets of data are compared. Lung deposition of 24% 
(Vidgren et al 1994) and >20% (Newman et al 1991) have been achieved using the 
Easyhaler® and Turbuhaler™ respectively with the authors claiming that " mTC behaves in the 
same way as the drug particles. A recent paper by Calmanovici et al (1999) stated that 
exogenous, freeze-dried, natural surfactant, labelled with " mTC could be used for aerosol lung 
scintigraphy. Nebulisation studies in animal models showed the biodistribution of the 
surfactant to be comparable to other radiopharmaceuticals.
A method for attaching the fluorescent label onto SAPL has been presented. The reasons for 
attaching the label have also been discussed, see page 121. The labelled material has been 
characterised using standard structure elucidation techniques, which showed that labelled 
material is not chemically different to the original drug substance. The distribution of the 
attached probe has been quantified, and deposition profiles o f LFDS with those of 
radiolabelled SAPL have validated the labelling procedure. The reason for choosing a 
physical association as opposed to chemically labelling SAPL in this study was financial. 
Adequate funds were not available to pursue the chemical-labelling route. Thus, this raises 
the question as to whether or not the label behaves in the same way as the drug in the various 
formulations, especially during the deposition studies when both the drug and label are 
subjected to high shear forces. The results from content uniformity experiments show that 
199.4jig of label are present within a 20mg sample of LFDS, with a relative standard deviation 
of only 1.6%, suggesting uniform distribution. This, coupled with the validation experiment, 
comparing the deposition profile of LFDS against chemically labelled SAPL in the MSLI 
from a nebuliser, suggest that the physical fluorescent probe is behaving in a similar fashion to 
the drug particles of LFDS.
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Chapter 4 
Deposition Studies of MLFDS
4 Deposition Studies of MLFDS
This section outlines the various deposition experiments carried out on MLFDS. The average 
particle size of MLFDS used during the deposition studies was 4.12pm, as determined by 
LALLS (see section 2.2.1.1 Malvern Analysis (Laser Light Diffraction), page 75). The 
fluorimetric technique used to quantify the material has been previously described (see section 
2.2.5.2 Fluorimetric Detection of LFDS, page 108).
4.1 TSI (Apparatus A) Deposition Profiles
A single dose capsule based device, the Miat Monohaler, was used to assess the in-vitro 
aerosol performance of MLFDS and its various blends with coarse and fine lactose. The Miat 
Monohaler was chosen for its ease of use and also because when used properly the 
deaggregating properties of the device is comparable to other DPIs (Pitcairn et al 1997). The 
size three hard gelatine capsules used to deliver MLFDS were stored in a desiccator 
containing a saturated salt solution of ammonium nitrate (RH 62-67%). This storage 
condition was chosen because, Konty and Mulski (1989) concluded that if the hard gelatine 
capsules were stored at <40%RH, they exhibited brittleness at ambient temperature. Konty 
and Mulski (1989) also concluded that at RH>85% caused the hard gelatine capsules to absorb 
moisture, thus altering their physical properties.
Method
The in-vitro aerosol investigations were performed using vacuum pumps (Gast Manufacturing 
Inc., Michigan, USA) at 30, 60, and 96.4 Lmin'1 (see Table 31, page 136). Flow rate through 
the device was adjusted via the needle valve using a mass flow meter (Hastings Mass Flow 
Meter, HFM 201, Teledyne Brown Engineering, Hastings Instruments, VA, USA). The 
device was not tested at the flow rate equivalent to a 4kPa pressure drop across the device, 
because the necessary equipment was not available to make such measurements.
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Flow Rate Stage 1 Jet 
Diameter
Cut-off Diameter (see page 66 for 
calculation)
Shot time
30.0T.min'1 9.7mm 6.60um K.Osecs
60. IT,min'1 14.2mm 6.55iim 4.0secs
96.4T,min'r 16.4mm 6.51 um 2..5 secs
Table 31: Table showing the conditions used in the TSI (Apparatus A) deposition study of MLFDS.
A size 3 hard gelatine capsule was filled to contain approximately 20mg of MLFDS (-1% 
label by weight i.e. 0.2mg). The capsule was placed into the chamber of the Miat monohaler 
(previously stored in an oven at 40°C) and pierced evenly using the four sets of pins on either 
side of the device, care was taken not to shatter the capsule. The Miat monohaler was coupled 
with a TSI, containing 7ml and 30ml of HPLC grade methanol in stages 1 and 2 respectively. 
The shot-time on the timing device was adjusted to deliver a total of four litres of air. Once 
fired, the capsule and device were washed into separate 50ml volumetric flasks with methanol 
and adjusted to volume. Stage 1 and throat (plus adaptor) o f the TSI were washed into 100ml 
volumetric with the mixture and diluted so as their intensity reading from the fluorimeter fell 
within the standard range. Stage 2 was washed into a 50ml volumetric and adjusted to 
volume, and diluted such that the relative intensities of the unknown samples fell within the 
standard range, details of the dilutions are given in individual deposition tables within this 
section. The relative intensity of the standards (see page 108 for preparation) and the samples 
were measured on the Hitachi F2000 fluorimeter, Hitachi Ltd., Japan.
4.1.1 Drug Only
Table 32 and Table 33, page 137 show the results obtained for MLFDS at 30.0, 60.1, and 
96.4Lmin'1 respectively.
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Parameter FR Capsule Device Stage 1 Stage 2
Measured 30.0 39.3±4.49 16.3+2.65 9.6+0.347 14.4+1.38
Intensity 60.1 29.3±0.175 7.60+1.19 11.2+0.100 38.9+0.912
(%) 96.4 27.7±3.25 6.48+1.34 9.09+0.344 44.3+4.48
Corrected 30.0 38.3+4.49 15.2+2.65 8.6+0.347 13.4+1.38
Intensity 60.1 28.0±0.175 6.40+1.19 10.0+0.100 37.7+0.912
(%> 96.4 26.7+3.25 5.44+1.34 8.05+0.344 43.2+4.48
Cone. 30.0 0.607+0.070 0.248+0.041 0.144+0.005 0.219+0.021
(Hg/ml) 60.1 0.410+0.003 0.089+0.018 0.141+0.001 0.553+0.014
96.4 0.426+0.051 0.095+0.021 0.136+0.005 0.684+0.070
Dilution 30.0 50 50 1000 50
Factor 60.1 50 50 1000 50
96.4 50 50 1000 50
Amount 30.0 30.4+3.50 12.4+2.05 143.8+5.41 10.9+1.05
Deposited 60.1 20.5+0.150 4.40+0.882 141.4+1.49 27.7+0.677
(ng) 96.4 21.3+2.53 4.80+1.05 135.7+5.3 34.2+3.48
(%) 30.0 15.3+1.41 6.27+1.18 72.8+2.64 5.54+1.19
Deposited 60.1 10.6+1.57 2.39+0.939 72.9+2.55 14.3+1.71
96.4 11.1+1.26 2.50+0.790 69.5+2.22 16.9+1.48
Table 32: Summary table of TSI deposition data for MLFDS at 30.0, 60.1, and 96.4L.min'1, n=10.
Table 33 was constructed from the results obtained above, in Table 32.
Parameter
Value Obtained or 
calculated @ 
SO.OLmin'1
Value Obtained or 
calculated @ 
60.1 Lmin'1
Value Obtained or 
calculated @ 
96.4Lmin’1
Mean Total Recovery 197.5ug(±8.20) 194.0ug(±3.52) 196.0ue(±4.04)
Mean Total Recovery 99.0%(±2.52) 97.3%(±2.45) 98.3%(±1.29)
Mean Emitted Dose 149.4ug(±5.44) 168.5ug(±4.81) 165.5ug(±3.94)
Mean Emitted Dose 78.4%(+1.79) 87.2%(±0.302) 86.5%f±1.56)
Mean FPD 10.6uef±2.06) 27.6ug(±2.58) 33.4ue(±3.28)
Mean FPF 7.06%(±0.570) 16.4%(±1.27) 20.2%('±1.86)
Mean Fill Weight 20.7mg(+1.10) 20. lmgf ±0.252) 20.5mg(+0.497)
Table 33: Summary table of various parameters calculated from TSI deposition data for MLFDS at 30.0, 
60.1, and 96.4 Lmin'1, n=10.
The distribution of MLFDS within the TSI as well as the mean emitted dose and fine particle 













Capsule Device Stage One Stage Two
TSI Parameter
Results @ 30.0Lmin'
Results @ 60.1 Lmin'
Results @ 96.4Lmin'
Figure 44: Distribution of MLFDS within Apparatus A at different flow rates. 
Bars represent the mean + SD of 10 determinations.
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160 - Results @ 30.0Lmin' 






In-Vitro Aerosol Characterisation of MLFDS
Figure 45: Emitted dose and fine particle dose of MLFDS at different flow rates. 
Bars represent the mean + SD of 10 determinations.
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Statistics
One-way analysis of variance on the emitted dose (ED) o f MLFDS at 30, 60.1, and 96.4Lmin'1 
showed significant differences (F=169.2, p<0.001). Fisher’s pairwise comparisons revealed 
that the ED at SOLmin"1 was significantly different from those at 60.1 and 96.4Lmin‘1. 
Significant differences were also observed (F=209.4, P<0.001) for the FPD values for MLFDS 
at the three flow rates, when one-way analysis of variance was carried out.
4.1.2 Binary Blends
Three different blends of MLFDS and lactose were prepared (as described below) using the 
rotary bladed blender (Kenwood Mini Chopper, CH100, Kenwood Ltd., Hants., UK) 
employing the mixing techniques outlined earlier (see 2.2.6.4 Mixing Techniques, page 118). 
The blends were tested for content uniformity and the optimum mixing time for each blend 
was determined. The deposition profiles of the blends were then obtained using the TSI at 60 
and 96.4 L min'1 using the Miat monohaler and size three hard gelatine capsules, as described 
on page 135. The relative intensity of the standards (see 2.2.5.2 Fluorimetric Detection of 
LFDS, page 108 for preparation) and the samples were measured on the Hitachi F2000 







Lactose (% w/w) Lactose Type
A 10« 10 90 Coarse (63-90|xm) Fraction
B 10b 10 90 Fine (Microtose) (<10um)
C 10b 5 95 Coarse (63-90um) Fraction
Table 34: Table showing the details of the various binary blends of MLFDS with coarse and line lactose.
Blends A, B, and C contain ~1% label by weight. This equates to 40jig of label (total) in 
blends A / B, and 20pg for C for a 40mg load capsule. Thus, to make the analysis easier and 
to make blend C comparable with A and B, a capsule load of 80mg was chosen for blend C. 
The scale of scrutiny of the content uniformity tests was set at 20mg due to sample shortage,
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but the final fill weight of the capsules to be tested were 40mg (blends A and B) and 80mg 
(blend C).
Content uniformity Experiments
In order to determine the optimum mixing time for each of the above blends, the blender was 
stopped periodically and ten representative samples from the blend were removed. This was 
done by first placing the whole powder bed onto a piece of paper, dividing it into nine sections 
and taking ~20mg from each section and an additional 20mg randomly. Samples were placed 
into 50ml volumetric flasks and made up volume with methanol. The results of this procedure 
are shown below. The pre-set criteria for a blend to be acceptable was that it must have had a 
corrected concentration (pg/ml) RSD of <5%. Table 35, below, summarises the results 
obtained. For more detailed results please refer to Appendix 3: Content Uniformity 
Experiments for Binary Blends of MLFDS, page 255.
Blend
ID






A 5 0.370 0.4 0.046 12.7
A 10 0.397 0.4 0.027 7.0
A 15 0.394 0.4 0.018 4.6
B 5 0.401 0.4 0.023 6.0
B 10 0.400 0.4 0.021 5.3
B 15 0.407 0.4 0.016 4.1
C 5 0.212 0.2 0.032 15.5
C 10 0.215 0.2 0.015 7.2
C 15 0.208 0.2 0.009 4.6
Table 35: Mixing time versus average concentration (n=10) values for MLFDS binary blends A, B, and C.




Figure 47: SEM photomicrograph of MLFDS binary blend B at x3000 magnification, mix time: 15min. 
Key: ASP: Aggregated SAPL Particle FPM/FPL: Fine Particle Multiplet / Lactose
SEM photomicrograph of MLFDS binary blend A at x2500 magnification, mix time: ISmin. 
Key: ASP: Aggregated SAPL Particle
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Figure 48: SEM photomicrograph of MLFDS binary blend C at x2200 magnification, mix time: 15min.
The SEM pictures above show examples o f the photographs obtained for the different blends. 
As outlined in the introduction (see mixing theory, page 46), carrier-based systems inevitably 
contain combinations of drug-drug-carrier and drug-carrier-drug associations. These 
characteristics are also exhibited in the SEMs above.
Deposition Study Method
The in-vitro aerosol conditions and method employed were the same as those outlined in 
section 4.1. Flow rates of 60 (ECDso% 6.55pm, stage 1 jet 14.2mm, shot time 4.0secs) and 
96.4 Lmin' 1 (ECDso% 6.51pm, stage 1 jet 16.4mm, shot time 2.5secs) were used.
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Results




Capsule Device Stage 1 Stage 2
Measured 60.0 A 3.43(10.546) 3.16(10.597) 21.1(10.382) 4.26(10.303)
Intensity B 1.85(±0.085) 1.93(10.080) 17.6(10.456) 3.93(10.085)
(%) C 3.07(±0.201) 3.02(10.184) 19.8(10.461) 3.74(10.068)
Corrected 60.0 A 2.27(10.546) 2.04(10.597) 17.0(10.382) 2.96(10.303)
Intensity B 1.26(10.085) 1.34(10.080) 17.0(10.456) 3.34(10.085)
(%> C 1.61(10.201) 1.56(10.184) 18.3(10.461) 2.27(10.068)
Cone. 60.0 A 0.05(10.001) 0.04(10.001) 0.329(10.01) 0.058(10.01)
(pg/ml) B 0.02(10.002) 0.023(10.02) 0.350(10.01) 0.066(10.02)




50 50 100 50
Amount 60.0 A 2.26(10.050) 2.03(10.050) 32.9(10.521) 2.92(10.064
Deposited B 1.09(10.100) 1.17(10.100) 34.4(10.690) 3.23(10.032)
fag) C 2.10(10.150) 2.06(10.147) 32.9(10.976) 2.67(10.045)
(%) 60.0 A 5.62(11.12) 5.06(11.24) 82.1(12.62) 7.28(11.66)
Deposited B 2.73(10.825) 2.94(10.762) 86.2(12.58) 8.09(11.72)
C 5.30(11.36) 5.19(11.47) 82.8(12.33) 6.73(11.39)
Table 36: Summary table of TSI deposition data for MLFDS binary blends A, B, and C at 60.0Lmin'1. 




Capsule Device Stage 1 Stage 2
Measured 96.4 A 3.63(±0.397) 3.05(±0.572) 20.7(±0.577) 5.19(±0.119)
Intensity B 1.47(±0.056) 1.52(±0.118) 17.1 (±.065) 5.1 (±0.062)
(%> C 2.87(±0.204) 2.83(±0.081) 19.4(±0.210) 5.34(±0.119)
Corrected 96.4 A 2.81 (±0.397) 2.23(±0.572) 19.9(±0.577) 4.37(±0.119)
Intensity B 0.89(±0.056) 0.94(±0.118) 16.5(±0.065) 4.52(±0.062)
(%) C 1.41 (±0.204) 1.36(±0.081) 17.9(±0.210) 3.87(±0.119)
Cone. 96.4 A 0.05(±0.001) 0.04(±0.001) 0.321 (±0.01) 0.078(±0.02)
(Hg/ml) B 0.02(±0.001) 0.02(±0.002) 0.336(±0.01) 0.092(±0.01)




50 50 100 50
Amount 96.4 A 2.77(±0.053) 2.24(±0.054) 27.4(±1.18) 3.76(±1.27)
Deposited B 0.88(±0.051) 0.93(±0.114) 33.3(±1.28) 4.54(±0.507)
(gg) C 1.94(±0.206) 1.94(±0.053) 32.4(±4.02) 4.07(±0.106)
(%) 96.4 A 6.57(±1.06) 5.47(±1.68) 78.4(±2.53) 9.55(±1.94)
Deposited B 2.23(±0.923) 2.36(±0.983) 83.9(±2.74) 11.5(±2.06)
C 4.82(±1.02) 4.72(±1.16) 80.4(±2.66) 10.1(±2.17)
Table 37: Summary table of TSI deposition data for MLFDS binary blends A, B, and C at 96.4Lmin'1. 
Values in brackets indicate standard deviation, n=10.
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Table 36, page 143 was use to produce the data below in Table 38.
Parameter Blend A Blend B Blend C
Mean Total Recovery (pg) 40.6(±1.43) 40.7(±1.06) 39.8(±1.43)
Mean Total Recovery (%) 101.0(±2.07) 100.9(±1.53) 98.2(±2.12)
Mean Emitted Dose (pg) 35.2(±1.69) 37.6(±1.70) 36.4(±1.73)
Mean Emitted Dose (%) 89.3(±1.39) 94.3(±1.38) 91.5(±1.920)
Mean FPD (pg) 2.87(±0.235) 3.23(±0.309) 2.97(±0.551)
Mean FPF (%) 8.14(±1.13) 8.58(±1.15) 8.16(±1.17)
Mean Fill Weight (mg) 40.7(±1.6) 40.8(±1.47) 80.6(±1.42)
Table 38: Summary table of various parameters calculated from TSI deposition data for MLFDS binary 
blends A, B, and C at 60.0Lmin'1.
Table 37, page 144 was used to produce the data below in Table 39.
Parameter Blend A Blend B Blend C
Mean Total Recovery (pg) 40.8(±1.56) 40.0(±1.10) 40.4(±1.33)
Mean Total Recovery (%) 100.3(±1.06) 100.3(±1.460) 101.3(±1.20)
Mean Emitted Dose (pg) 34.9(±1.90) 37.8(±1.34) 36.5(±1.21)
Mean Emitted Dose (%) 88.0(±1.53) 95.4(±1.48) 90.5(±1.32)
Mean FPD (pg) 3.79(±0.12) 4.54(±0.87) 4.07(+0.86)
Mean FPF (%) 10.9(±1.27) 12.0(±1.16) 11.2(±1.24)
Mean Fill Weight (mg) 41.3(±1.4) 40.4(±1.25) 80.2(±1.35)
Table 39: Summary table of various parameters calculated from TSI deposition data for MLFDS binary 
blends A, B, and C at 96.4Lmin'1.
The distributions of MLFDS binary blends within the TSI, as well as the mean emitted dose 
and fine particle doses are displayed graphically in Figure 49 and Figure 50, page 146 and 
summarised in Figure 51, page 147.
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Results @ 60.0Lmin' Blend A
Results @ 60.0Lmin' Blend B
Results @ 60.0Lmin' Blend C
Capsule Device Stage One Stage Two 
TSI Parameter
Figure 49: Distribution of MLFDS binary blends A, B and C within Apparatus A at 60.0Lmin''. 








Figure 50: Distribution of MLFDS binary blends A, B and C within Apparatus A at 96.4Lmin'1. 
Bars represent the mean + SD of 10 determinations.
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Figure 51: Emitted dose and fine particle dose of MLFDS binary blends A, B and C at 60 and 96.4Lmin1. 
Bars represent the mean + SD of 10 determinations.
Statistics
One-way analysis of variance on the ED of MLFDS binary blends A, B, and C 60.0Lmin_1 
showed significant differences (F=5.88, p=0.008). Significant difference in the ED was also 
observed at 96.4Lmin'1 (F=9.57, p=0.001). Fisher’s pairwise comparisons revealed that the 
ED of blend A was significantly different to that of blends B and C.
No significant differences were observed (F=2.25, p=0.125) for the FPD values for MLFDS 
binary blends A, B, and C bO.OLmin' 1 when one-way analysis o f variance was carried out. 




A ternary blend of MLFDS, coarse lactose (63-90pm), and fine lactose (microtose)(ratio 5: 
90:5 % w/w) was prepared using the rotary bladed blender (Kenwood Mini Chopper, CHI00, 
Kenwood Ltd., Hants., UK) employing the mixing techniques outlined earlier (see section
2.2.6.4 Mixing Techniques, page 118). The content uniformity of the blend was assessed at 
various time intervals and is outlined in Table 40, page 149. The deposition profiles of the 
blend obtained using the TSI (Apparatus A) at 60 and 96.4 L min'1 using the Miat monohaler 
and size three hard gelatine capsules, as described on page 135. The relative intensity of the 
standards (see page 108) and the samples were measured on the Hitachi F2000 fluorimeter, 
Hitachi Ltd., Japan.
MLFDS contains ~1% label by weight. This equates to 40pg of label (total) in blends A / B, 
and 20pg for C for a 40mg load capsule. Thus, to make the analysis easier and to make blend 
C comparable with A and B, a capsule load of 80mg was chosen for blend C. The scale of 
scrutiny of the content uniformity tests was set at 20mg due to sample shortage, but the final 
fill weight of the capsules to be tested were 40mg (blends A and B) and 80mg (blend C).
Content uniformity Experiments
In order to determine the optimum mixing time for each of the above blends, the blender was 
stopped periodically and ten representative samples from the blend were removed. This was 
done by first placing the whole powder bed onto a piece of paper, dividing it into nine sections 
and taking ~40mg from each section and an additional 40mg randomly. Samples were placed 
into 50ml volumetric flasks and made up volume with methanol. The pre-set criteria for a 
blend to be acceptable was that it must have had corrected concentration (pg/ml) RSD of <5%. 
Table 40, below, summarises the results obtained. For more detailed results please refer to 
Appendix 4: Content Uniformity Experiments for Ternary Blends of MLFDS, page 258.
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Mix-Time (min) Average Cone, (gg/ml) Expected Conc.(pg/ml) SD RSD (%)
5 0.397 0.4 0.0247 6 . 2
1 0 0.406 0.4 0.0208 5.1
2 0 0.405 0.4 0.0196 4.9
Table 40: Mixing time versus average concentration (n=10) for a ternary blend of MLFDS, coarse lactose, 
and fine lactose (5:90:5% w/w).
100pm
Figure 52: SEM photomicrograph for a ternary blend of MLFDS, coarse lactose, and fine lactose 
(5:90:5% w/w) at xl500 magnification, mix time: 20min.
Key: FPM / FPL: Fine Particle Multiplet / Lactose.
Figure 53: SEM photomicrograph for a ternary blend of MLFDS, coarse lactose, and fine lactose 
(5:90:5% w/w) at x2500 magnification, mix time: 20min.
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The SEM pictures, on page 149, show examples of the photomicrographs obtained for the 
ternary blends of SAPL. As outlined in the introduction (see section 1.4.2.2.1 Mixing Theory, 
page 45), carrier-based systems contain various combinations of carrier-drug-carrier 
associations. These characteristics are also exhibited. More specifically, the images contain 
FPM and FPL aggregates as well the normal ordered mixing that takes place between the drug 
and the carrier. The associations vary in size from a few aggregated particles to a large mass. 
It should also be noted that particles adhered to coarse lactose are not done so in a uniform 
fashion. Rather, layers of particles adhering both to the carrier and each other are present.
The in-vitro aerosol conditions and method employed were the same as those outlined in 
section 4.1. Flow rates of 60 (ECD50o/o 6.55pm, stage 1 jet 14.2mm, shot time 4.0secs) and
96.4 Lmin'1 (ECD50% 6.51pm, stage 1 jet 16.4mm, shot time 2.5) were used.
Results
Table 41, below, shows the TSI deposition data obtained for a ternary blend of MLFDS, 
coarse lactose, and fine lactose at 60.0 and 96.4 Lmin'1.



































































Table 41: Summary table of TSI deposition data for a ternary blend of MLFDS, coarse lactose, and fine 
lactose (5:90:5% w/w) at 60.0 and OO^ OLmin'1, n=10.
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Parameter Value Obtained or 
calculated (gbO.OLmin' 1
Value Obtained or 
calculated @96.4Lmin'1
Mean Total Recovery (pg) 40.7(±0.602) 40.0(±0.661)
Mean Total Recovery (%) 101.5(±2.15) 99.8(±1.37)
Mean Emitted Dose (pg) 38.9(±1.92) 38.1(±1.70)
Mean Emitted Dose (%) 96.3(±1.89) 95.8(±1.45)
Mean FPD (pg) 3.64(±0.771) 4.84(±0.524)
Mean FPF(%) 9.00(±1.63) 12.7(±1.03)
Mean Fill Weight (mg) 80.7(±0.949) 80.6(±0.478)
Table 42: Summary table of various parameters calculated from TSI deposition data for a ternary blend 
of MLFDS, coarse lactose, and fine lactose (5:90:5% w/w) at 60.0 and 96.4Lmin'1, n=10.
] Results @ 60.0Lmin'1 
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TSI Parameter
Figure 54: Distribution of a ternary blend of MLFDS, coarse lactose, and fine lactose (5:90:5% w/w) at 
60.0 and 96.4Lmin‘1.
Bars represent the mean + SD of 10 determinations.
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Figure 55: Emitted dose and fine particle dose of a ternary blend of MLFDS, coarse lactose, and fine 
lactose (5:90:5% w/w) at 60.0 and 96.4Lmin!.
Bars represent the mean + SD of 10 determinations.
Statistics
One-way analysis of variance on the ED of MLFDS ternary blend at 60.0 and 96.4Lmin'1 
revealed no significant differences (F=1.03, p=0.324). However, there was a significant 
difference (F=37.9, p=<0.001) in the FPD at the two flow rates.
4.1.4 General Discussion
The preparation o f the various blends of MLFDS, their content uniformity, and subsequent 
deposition profiles under two different conditions has been presented. Table 43 and Table 44, 
page 153 summarise the findings.
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Parameter Summary TSI Results at 60.0Lmin'1







ED(pg) 168.5(±4.81) 35.2(±1.69) 37.6(±1.70) 36.4(±1.73) 38.9(±1.92)
FPD(pg) 27.6(±2.58) 2.87(0.235) 3.23(0.309) 2.97(0.551) 3.64(±0.771)
FPF(%) 16.4(±1.27) 8.14(±1.13) 8.58(±1.15) 8.16(±1.17) 9.00(±1.63)
Fill Wt (mg) 20.1 (±0.252) 40.7(±1.60) 40.8(±1.47) 80.6(±1.42) 80.7(±0.949)
Table 43: Summary TSI results obtained for MLFDS and its various blends at 60.0Lmin'1, n=10.
Parameter Summary TSI Results at 96.4Lmin'1







ED(gg) 165.5(±3.94) 34.9(±1.90) 37.8(±1.34) 36.5(±1.21) 38.1(±1.70)
FPD(pg) 33.4(±3.28) 3.79(±0.12) 4.54(±0.87) 4.07(±0.86) 4.84(±0.524)
FPF(%) 20.2(±1.86) 10.9(±1.27) 12.0(±1.16) 11.2(±1.24) 12.7(±1.03)
Fill Wt (mg) 20.5(±0.497) 41.3(±1.4) 40.4(±1.25) 80.2(±1.35) 80.6(±0.478)
Table 44: Summary TSI results obtained for MLFDS and its various blends at 96.4Lmin'1, n=10.
It must be noted that the above results are the distribution of the label within the TSI and not 
the drug itself. Since the label is only present at 1% (w/w) within each capsule, the final 
values need to be multiplied by 100 in order to make the results applicable for the drug itself. 
In addition, the values have been normalised to make all the results directly comparable. 
Therefore, the revised summary tables are as shown below.








ED(mg) 3.34 3.48 3.72 3.60 3.85
FPD(mg) 0.546 0.284 0.320 0.294 0.360
FPF(%) 16.4 8.15 8.59 8.16 9.36
Fill Wt (mg) 20.1 40.7 40.8 80.6 80.7
Table 45: Modified, Summary TSI results obtained for MLFDS and its various blends at 60.0Lmin1.
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ED(mg) 3.28 3.46 3.74 3.61 3.77
FPD(mg) 0.661 0.375 0.449 0.403 0.479
FPF(%) 20.2 10.9 12.0 11.2 12.7
Fill Wt (mg) 20.5 41.3 40.4 80.2 80.6
Table 46: Modified, summary TSI results obtained for MLFDS and its various blends at 96.4Lmin'1.
The results for the modified results show the following:
a) The drug-only formulation performs best, in terms of FPD and FPF, but is the worst at 
actually emptying from the capsule.
b) There seems to be no appreciable differences in the performances of the various binary 
blends and the ternary blend.
Blend
ID










<0.001 169.2 <0.001 209.4
Yes, results at 30 are 
significantly different from 




60.0 0.008 5.88 0.125 2.25





96.4 0.001 9.57 0.073 2.88
ED values of BB-A significantly 




0.324 1.03 <0.001 37.9 FPD values significantly 
different at the two flow rates
Table 47: Summary TSI statistics for LFDS and its various blends at 30,60, and 96.4Lmm'!. 
Key: BB= Binary Blend, TB= Ternary Blend, FR= Flow Rate.
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From the various statistical analyses carried out at the end of each sub-section and summarised 
in Table 47, it can be concluded that for the drug-only formulation, ED is dependent on flow 
rate. At low flow rates pOLmin'1) the capsule does not empty efficiently. In addition, 
because of the cohesive nature of MLFDS, FPD only increases with increasing flow rate and 
turbulence within the capsule. The binary blends of MLFDS showed no significant 
differences in ED at bOLmin'1 (3.48, 3.72, and 3.60% respectively for blends A, B, and C) but 
did so at 96.4Lmin'1 (3.46, 3.74, and 3.61% respectively for blends A, B, and C). This 
difference at 96.4Lmin'1 is unexpected and marginal and one possible explanation is that the 
ED of blend A (10% MLFDS: 90% coarse lactose) is lower than it ought to be. FPD values of 
MLFDS binary blends are concordant and not statistically different. As with the binary 
blends, the ED of the ternary blend was equally good at 60 and 96.4Lmin'1. However, the 
higher flow rate produced a higher FPD, as expected. Although direct comparison of the 
above data is not possible with other powdered surfactant studies (because no published data 
exists), comparisons can be made against standard powder formulations. A study carried out 
by Zeng et al (1999) on ternary mixtures of salbutamol sulphate (5.8pm), coarse lactose 
(90.8pm), intermidiate (15.9pm), and fine lactose (5pm) using the TSI at 60 and 90 Lmin'1 via 
the Rotahaler™ and employing various mixing sequences produced a FPF value in excess of 
the 12.7% obtained in this study. Srichana et al (1998) investigated the effect of the resistance 
of the device and the influence of powder formulation on the deposition of drug and carrier for 
formulations of salbutamol. Results showed FPF values of -20% for several devices tested at 
differing flow rates.
4.2 MSLI Deposition Profiles
Deposition studies of MLFDS and its various blends were performed using the 5-stage liquid 
impinger (as described in section 1.6 Aerosol Testing and Characterisation, page 63). Both 
the instrument and the testing protocols outlined by the EP supplement (1999) are given in 
more detail in the above-mentioned section. A brief description of the method is presented 
below.
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The Miat monohaler (as described on page 135) was used to assess the in-vitro aerosol 
performance of MLFDS and its various blends with lactose. The size 3 hard gelatine capsules 
used to deliver MLFDS were stored in desiccator containing a saturated salt solution of 
ammonium nitrate, for the reasons given on page 135.
4.2.1 Drug Only
The deposition studies were performed at 92.0Lmin'1 (see below for cut-off diameters), which 
corresponded to a 4kPa pressure drop between the atmosphere and stage one of the MSLI 
(PI). Determination of sonic flow revealed values of 815 and 338mBar for P2 and P3 
respectively, ratio P3/P2: 0.41, therefore sonic flow.
Cut-Off Diameters (pm)
Flow Rate Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
92.0Lmin'1 >10.50 5.49 2.50 1.37 0.00
Table 48: The MSLI cut-off diameters at Pl.OLmin*1 flow rate as used in the in-vitro characterisation of 
MLFDS.
Each stage of the MSLI was filled with 20ml of HPLC grade methanol. Five accumulative 
capsules containing ~20mg of MLFDS (-1% label by weight, i.e. lmg total label weight) were 
fired into the system (shot time: 2.61 secs), using the Miat monohaler. The procedure was 
carried out in triplicate. The five capsules and the device were washed with methanol after 
each firing into 50ml volumetric flasks and made up to volume. Once the firing sequence was 
complete, the adaptor and throat were washed into 50ml and 100ml volumetric flasks 
respectively and adjusted volume with methanol. Stage 1 jet was washed with 5ml of 
methanol to ensure that any particulates in the jet were washed down into stage 1. Stage 5 
(after-filter) of the apparatus was removed and the filter paper was sonicated in 20ml of 
methanol for 1 minute, ensuring that drug particles on the filter went into solution. The MSLI 
apparatus was then gently swirled and rotated to recover any drug particles from the walls of 
the apparatus. The apparatus was then turned up side down to carefully wet the ceiling of 
each stage and, thus, recover any drug particles that may have impacted onto the ceiling. The
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swirling motion was carried out for a period of 10 minutes to ensure all drug particles had 
gone into solution. Stages 1 to 5 were all sonicated for 2 minutes and made up to 100ml with 
methanol. The throat and stage 1 were diluted further (1:10) so as their intensity reading from 
the fluorimeter fell within the standard range. The standards were prepared as described 
earlier (see fluorimetric detection of LFDS, page 108). The relative intensity of the standards 



































































































































Table 49: Summary table of MSLI deposition data for MLFDS at 92.0Lmin~1, n=15.
Parameter Value Obtained or calculated
Mean Total Recovery (pg) 191.1(±2.78)
Mean Total Recovery (%) 95.8(±1.42)
Mean Emitted Dose (pg) 183.6(±4.92)
Mean Emitted Dose (%) 96.1(±1.35)
Mean FPD (pg) 26.0(±1.97)
Mean FPF (%) 14.2(±2.59)
Mean Fill Weight (mg) 20.2f±1.2)
Table 50: Summary table of various parameters calculated from MSLI deposition data for MLFDS at 92.0 
Lmin'1.











Figure 56: Distribution of MLFDS within the MSLI at 92.0Lmin'. 
Bars represent the mean + SD of 15 determinations.
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Figure 57: Emitted dose and fine particle dose of MLFDS within the MSLI at 92.0Lmin'1. 
Bars represent the mean + SD of 15 determinations.
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Three different blends of MLFDS and lactose (see below), were prepared as described on page 




Blend Size MLFDS (%w/w) Lactose (%w/w) Lactose Type
A 10g 10 90 Coarse (63-90pm) Fraction
B 10g 10 90 Fine (Microtose) (<10pm)
C 10g 5 95 Coarse (63-90pm) Fraction
Table 51: Table showing the details of the various binary blends of MLFDS with coarse and fine lactose.
The blends were tested for content uniformity and the optimum mixing time for each blend 
was determined, as previously outlined on page 139. The deposition profiles of the blends 
were then obtained using the MSLI method as described on page 156. Five accumulative 
capsules containing ~1% label by weight (i.e. 200pg of label (total) in blends A, B, and C for 
a 40mg and 80mg load capsules respectively) were fired into the system (shot time: 2.61 secs), 
using the Miat monohaler. The procedure was carried out in triplicate. The relative intensity 
of the standards (see page 108 for preparation) and the samples were measured on the Hitachi 
F2000 fluorimeter, Hitachi Ltd., Japan.
Results
Table 52, page 161 is a summary table of MSLI deposition data for MLFDS blend A at 
92.0Lmin'1. Values in brackets indicate standard deviation, n=15.
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Table 52: Summary table of MSLI deposition data for MLFDS blend A at Pl.OLmin*1.
Table 53, page 162 is a summary table of MSLI deposition data for MLFDS blend B at 

































































































































Table 53: Summary table of MSLI deposition data for MLFDS blend B at 92.0Lmin'1.
Table 54, page 163 is a summary table of MSLI deposition data for MLFDS blend C at 

































































































































Table 54: Summary table of MSLI deposition data for MLFDS blend C at 92.0Lmin'1.
Parameter Blend A Blend B Blend C
Mean Total Recovery (pg) 38.5(±3.06) 38.7(±2.72) 39.2(±2.86)
Mean Total Recovery (%) 96.6(±2.88) 97.0(±2.14) 98.3(±2.60)
Mean Emitted Dose (pg) 36.9(±3.11) 37.2(±2.57) 37.7(±2.89)
Mean Emitted Dose (%) 95.9(±2.53) 96.0(±2.40) 96.2(±3.23)
Mean FPD (pg) 5.32(±0.926) 5.41(±1.15) 5.53(±1.31)
Mean FPF (%) 14.4(±1.35) 14.6(±1.48) 14.7(±1.73)
Mean Fill Weight (mg) 40.3(±1.2) 39.9(±1.4) 80.4(±1.9)
Table 55: Summary table of various parameters calculated from MSLI deposition data for blends A, B, 
and C at 92.0Lmin'1.






















20 -  
10 -  
0 -
Cap Dev Adpt Tht Stg 1 Stg 2 Stg 3 Stg 4 Stg 5 
MSLI Parameter
: 58: Distribution of blends A, B, and C within the MSLI at 92.0Lmin'1. 
Bars represent the mean + SD of 15 determinations.
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Figure 59: Emitted dose and fine particle dose of blends A, B, and C at 92.0Lmin‘ 
Bars represent the mean + SD of 15determinations.
Statistics
One-way analysis of variance on the ED of MLFDS binary blends A, B, and C showed no 
significant differences (F=0.23, p=0.799). No significant differences were observed (F=0.09, 
p=0.911) for the FPD values
4.2.3 Ternary Blends
A ternary blend of MLFDS, coarse lactose (63-90pm), and fine lactose (microtose)(ratio 
5:90:5% w/w) as described on page 148 was used in the deposition studies with the MSLI. 
Refer to page 149 for content uniformity and SEM photomicrographs of the blend.
Method
The deposition profiles of five 80mg accumulative capsules containing ~1% label by weight 
(i.e. 200pg of label weight total) were fired into the system at 92.0Lmin'1, corresponding to a 
4kPa pressure drop across the device as described on page 156. A shot time of 2.61 secs was 
employed, using the Miat monohaler as described on page 135. The procedure was carried out 
in triplicate. The relative intensity of the standards (see page 108 for preparation) and the 
samples were measured on the Hitachi F2000 fluorimeter, Hitachi Ltd., Japan.
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Results




























































































































Table 56: Summary table of MSLI deposition data for a ternary blend of MLFDS, coarse lactose, and fine 
lactose (5:90:5% w/w) at 92.0Lmin'1.
Values in brackets indicate standard deviation, n=15.
Parameter Value Obtained or calculated @92.0Lmin'1
Mean Total Recovery (pg) 38.4(±2.14)
Mean Total Recovery (%) 96.2(±1.68)
Mean Emitted Dose (pg) 37.0(±2.66)
Mean Emitted Dose (%) 96.5(±3.09)
Mean FPD (pg) 5.35(±0.427)
Mean FPF(%) 14.4(±1.92)
Mean Fill Weight (mg) 80.2(±1.3)
Table 57: Summary table of various parameters calculated from MSLI deposition data for a ternary blend 
of MLFDS, coarse lactose, and fine lactose (5:90:5% w/w) at 92.0Lmin'1.
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Figure 60: Distribution of a ternary blend of MLFDS, coarse lactose, and fine lactose (5:90:5% w/w) 
within the MSLI at 92.0Lmin'1.
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In-Vitro Aerosol Characterisation of MLFDS Ternary Blend
Figure 61: Emitted dose and fine particle dose of a ternary blend of MLFDS, coarse lactose, and fine 
lactose (5:90:5% w/w) within the MSLI at 92.0Lmin *.
Bars represent the mean + SD of 15 determinations.
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4.2.4 General Discussion
The MSLI deposition profiles of blends of MLFDS, prepared and evaluated for content 
uniformity on page 156, have been presented in this section. Table 58, below summarises the 
findings at92.0Lmin'1.
Parameter Summary MSLI Results at 92.OLmin'1








ED(pg) 183.6(±4.92) 36.9(±3.11) 37.2(±2.57) 37.7(±2.89) 37.0(±2.66)
FPD(pg) 26.0(±1.97) 5.32(±0.926) 5.41(±1.15) 5.53(±1.31) 5.35(±0.427)
FPF(%) 14.2(±2.59) 14.4(±1.35) 14.6(±1.48) 14.7(±1.73) 14.4(±1.92)
Fill Wt (mg) 2 0 .2 (± 1 .2 ) 40.3(±1.2) 39.9(±1.4) 80.4(±1.9) 80.2(±1.3)
Table 58: Summary MSLI results obtained for MLFDS and its various blends at 92.0Lmin'1.
It must be noted that the above results are the distribution of the label within the TSI and not 
the drug itself. Since the label is only present at 1% (w/w) within each capsule, the final 
values need to be multiplied by 1 0 0  in order to make the results applicable for the drug itself. 
In addition, the values have been normalised to make all the results directly comparable. 
Therefore, the revised summary table is shown below.
Parameter Summary MSLI Results at 92.0Lmin'1







ED(mg) 3.64 3.65 3.68 3.73 3.66
FPD(mg) 0.515 0.527 0.536 0.547 0.530
FPF(%) 14.2 14.4 14.5 14.7 14.5
Fill Wt (mg) 2 0 . 2 40.3 39.9 80.4 80.2
Table 59: Modified, summary MSLI results obtained for MLFDS and its various blends at 92.0Lmin'1.
Results show no appreciable differences between the drug-only and the various formulations. 
However, the advantage of the drug-only formulations is its ability to deliver a higher total ED 
and FPD. Statistical analysis on the binary MLFDS systems revealed no significant
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differences in the ED and FPD of the three blends. The FPF values on average are about 2% 
higher than those achieved for the TSI analysis. One possible explanation for this increase 
could be that the airflow through the MSLI is more conducive to deagglomeration of drug 
particles.
The data obtained within this section cannot be compared directly against other aerosolised 
powder surfactant studies using the MSLI because, as yet, there are no such published data 
within the field with implications for asthma. However, comparison of the data can be made 
against in-vitro (MSLI at bOLmin'1) and in-vivo (scintigraphy) data obtained by Pitcairn et al 
(1997) on a novel asthma drug using a device similar to the Miat Monoler (i.e. Cyclohaler®). 
Their studies showed FPF values of -30% for labelled and unlabelled drug, compared with 
-14% which was the best obtained in this section using the MSLI at 92Lmin'1. Pitcairn et al 
(1994) looked at the deposition profiles o f salbutamol and beclomethasone in an MSLI (at 
bOLmin'1) using the Rotahaler® and the Aerohaler®. FPF (particles <b.8 pm) values were: 
Rotahaler®, b. 8  and 5.4%, Aerohaler®, 14.7 and 11.2%, for salbutamol and beclomethasone 
respectively. Pitcairn et al (1994) also reported that significant amount of the powder was 
retained in the capsule, a trend observed in the present study for MLFDS. Pitcairn et al (1997) 
also looked the performance of the Ultrahaler® for the delivery nedocromil sodium for the 
prophylaxis of asthma. The effect of different modes of inhalation (slow and fast) from the 
Ultrahaler® were compared for nedocromil delivery from a pMDI. Results of the study 
showed that the Ultrahaler® used suboptimally or the pMDI used optimally [mean (SD) lung 
deposition values of 13.3 (4.8)%, 9.8 (3.5)%, and 7.5 (2.9)%, respectively], Oropharyngeal 
deposition averaged over 80% of the dose for all three treatment regimens.
In summary, the FPF (-14%) obtained for the various MLFDS formulations in the present 
study compares favourably to some the above-mentioned standard solid dosage forms, 
delivered from various devices.
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Chapter 5 
Deposition Studies of MS
5.0 Deposition Studies of MS
This section outlines the various deposition experiments carried out on MS. The average 
particle size of MS used during the deposition studies was 2.39pm, as determined by LALLS 
(see page 75). The HPLC technique used to quantify the material has been previously 
described (see section 2.2.5.1 HPLC Detection of MS, page 99).
5.1 TSI (Apparatus A) Deposition Profiles
A single dose capsule based device, the Miat monohaler, was used to assess the in-vitro 
aerosol performance of MS. The reasons for choosing the Miat monohaler as the delivery 
device along with size three hard gelatine capsules has been previously outlined on page 135.
5.1.1 Drug Only
The in-vitro aerosol investigations of MS were performed at 30, 60 and 96.4Lmin'1 (see Table 
60, below). Flow rate through the device was adjusted via the needle valve using a mass flow 
meter (Hastings Mass Flow Meter, HFM 201, Teledyne Brown Engineering, Hastings 
Instruments, VA, USA).
Flow Rate Stage 1 Jet Diameter Cut-off Diameter Shot time
30. OLmin' 1 6.9mm 3.2pm 8 .0 secs
60.0Lmin_1 1 1 .6 mm 4.8pm 4.0secs
96.4Lmin'1 16.4mm 6.51pm 2.5secs
Table 60: Table showing the conditions used in the TSI (Apparatus A) deposition study of MS.
A size three hard gelatine capsule was filled to contain approximately 20mg of MS. The 
capsule was placed into the chamber of the Miat monohaler (previously stored in an oven at 
40°C) and pierced evenly using the four sets of pins on either side of the device, care was 
taken not to shatter the capsule. The Miat monohaler was coupled with a TSI, containing 7ml 
and 30ml HPLC grade methanol in stages 1 and 2 respectively, via an adaptor. The shot-time 
on the timing device was adjusted to deliver a total o f four litres of air. Once fired, the
170
capsule and device were washed into separate 50ml volumetric flasks with a minimum amount 
of HPLC grade methanol and adjusted to volume. Stage 1 and throat (plus adaptor) of the TSI 
were washed into 1 0 0 ml volumetric flask with the mixture and diluted so as their 
concentration fell within the standard range. Stage 2 was washed into a 50ml volumetric flask 
and adjusted to volume, and diluted accordingly. The standards and the samples were 
analysed using and chromatographic conditions outlined on page 99. Test sample 
concentrations were determined by solving the quadratic equations presented by the binomial 
relationship between the six standards (see Table 18, page 105 for example). Once solved, the 
values obtained were incorporated into a spreadsheet and a final answer was obtained, 
examples of this process are given in Appendix 13: MS Testing and Stability Study Raw 
HPLC Data, page 270.
Results
Table 61, below is a summary of the results obtained at 3 OLmin'1. For more detailed tables 
please refer to Appendix 5: Detailed tables for the HPLC analysis of MS-TSI Results, page
258.
Parameter FR Capsule Device Stage 1 Stage 2
















PG Cone, (pg/ml) 30.0 2.37
(±0.015)




1 . 6 8
(±0.062)
DPPC Cone, (pg/ml) 30.0 7.95
(±0.483)
7.41
(±0 .2 0 0 )




Dilution Factor 30.0 1 0 0 1 0 0 1 0 0 0 2 0 0









(±0 .0 1 2 )





(±0 .0 2 0 )




% MS Deposited 30.0 5.31
(±1.48)
4.95





Table 61: Summary table of TSI deposition data for MS at SO.OLmin'1, n=10.
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Table 62 and Table 63, below is a summary of the results obtained at bOLmin'1. For more
detailed tables please refer to Appendix 5: Detailed tables for the HPLC analysis of MS-TSI
Results, page 258.
Parameter FR Capsule Device Stage 1 Stage 2





(± 1 0 1 2 )
23977
(±1649)













(±0 .0 2 2 )
2.32
(±0.034)








Dilution Factor 60.0 1 0 0 1 0 0 1 0 0 0 2 0 0





(±0 .0 0 2 )
3.93
(±0 .0 2 2 )
0.464
(±0.007)
Amount of DPPC 
Deposited (mg)
60.0 0.655






(±0 .0 2 2 )








Table 62: Summary table of TSI deposition data for MS at bO.OLmin'1, n=10.
Parameter FR Capsule Device Stage 1 Stage 2






























8 . 1 1
(±0.266)
Dilution Factor 96.4 1 0 0 1 0 0 1 0 0 0 2 0 0




























Table 63: Summary table of TSI deposition data for MS at 96.4Lmin'1, n=10.
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or Calculated @ 
30.0Lmin'1
Value Obtained 
or Calculated @ 
60. OLmin' 1
Value Obtained or 
Calculated @ 
Ob^Lmin' 1
Mean Total Recovery(mg) 19.3(±1.69) 20.1(13.43) 19.3(12.87)
Mean Total Recovery(%) 96.3(14.35) 100.6(11.72) 96.5(12.43)
Mean Emitted Dose(mg) 17.3(11.05) 18.6(11.30) 17.9(12.44)
Mean Emitted Dose(%) 89.6(12.59) 92.4(11.05) 92.7(11.78)
Mean FPD(mg) 1.49(10.210) 1.99(10.381) 2.07(10.366)
Mean FPF(%) 7.76(11.16) 9.87(10.890) 10.7(11.69)
Mean Fill Weight(mg) 19.9(10.4) 20.4(10.3) 20.3(10.2)
Table 64: Summary table of various parameters calculated from TSI deposition data for MS at 30.0, 60.0, 
and 96.4Lmin '.
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Figure 62: Distribution of MS within Apparatus A at different flow rates. 
Bars represent the mean + SD of 10 determinations.
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In-Vitro Aerosol Characterisation of MS
Figure 63: Emitted dose and fine particle dose of MS at different flow rates. 
Bars represent the mean + SD of 10 determinations.
Statistics
One-way analysis of variance on the ED of MS at 30.0, 60.0 and 9 6 A \,m m x showed no 
significant differences (F=1.58, p=0.225). Significant differences were observed on the FPD 
of MS at the three flow rates (F=9.07, p=0.001). Fishers pairwise comparisons showed that 
the FPD of MS at 30Lmin_1 was significantly different to the FPDs obtained at the other two 
flow rates. This is to be expected since at higher flow MS deaggregates better and this in turn 
leads to increased FPD values.
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5.1.2 General Discussion
The TSI deposition profiles of MS at three different flow rates have been presented. The 
findings show that, as expected, deaggregation of the raw drug is more efficient at higher flow 
rates. When comparing the FPD and FPF values of MS with those obtained for MLFDS (see 
Table 65, below and Table 33, page 137 and Table 64, page 173 respectively) it can be seen 
that the FPD of MS is higher whereas its FPF is marginally lower.
MLFDS 
Drug-Only 














ED 149.4pg 168.5pg 165.5pg 17.3mg 18.6mg 17.9mg
FPD 1 0 .6 pg 27.6pg 33.4pg 1.49mg 1.99 mg 2.07 mg
FPF(%) 7.06 16.4 2 0 . 2 7.76 9.87 10.7
Fill Wt (mg) 20.7 2 0 . 1 20.5 19.9 20.4 20.3
Table 65: Comparative summary table of various parameters calculated from TSI deposition data for 
MLFDS and MS at 30.0,60.0, and 96.4Lmin'1
This means that MS empties well from the capsule but does not deaggregate as well as 
MLFDS. The possible reason for this is that MS has a VMD of 2.39pm compared with 
4.12pm for MLFDS. Therefore, a higher FPD is expected but the smaller average size of MS 
also makes the particles more cohesive and less conducive to deaggregation, hence, the 
slightly lower FPF. The data obtained within this section cannot be compared directly against 
other aerosolised powder surfactant studies since there is no such published data within the 
field with implications for asthma. However, some clinical data on humans does exist from 
the studies carried out by Kurashima et al (1991) and Anzueto et al (1997). Kurashima pilot 
study of surfactant inhalation for the treatment of asthmatic attack utilised nebulised 
Surfacten® (lOmg suspended in 1ml of physiological saline) in a double-blind, placebo- 
controlled trial. Results showed an 11.7% increase in FVC and a 27.3% increase in FEVj in 
the treated patients when pre and post lung function tests were compared. In a similar, but 
larger, study Anzueto et al (1997) looked at the effect of nebulised Exosurf® for the treatment
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of chronic bronchitis. Improvements of 11.4% for FEVi and 10.4% for total lung capacity 
were reported.
5.2 MSLI Deposition Profiles
Deposition studies of MS were performed using the 5-stage liquid impinger (as described on 
page 63). Both the instrument and the testing protocols outlined by the EP supplement (1999) 
is given in more detail on page 63. A brief description of the method is presented below.
The Miat monohaler (as described on page 135) was used to assess the in-vitro aerosol 
performance of MS. The size three hard gelatine capsules used to deliver MS were stored in a 
desiccator containing a saturated salt solution of ammonium nitrate, for the reasons given on 
page 135.
5.2.1 Drug Only
The deposition studies were performed at 92.0Lmin'1 (see below for cut-off diameters), which 
corresponded to a 4kPa pressure between the atmosphere and stage one of the MSLI (PI). 
Determination of sonic flow revealed values of 825 and 308mBar for P2 and P3 respectively, 
ratio P3/P2: 0.37, therefore sonic flow.
Cut-Off Diameters (pm)
Flow Rate Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
92. OLmin' 1 >10.50 5.49 2.50 1.37 0 . 0 0
Table 66: The MSLI cut-off diameters at 92.0Lmin‘1 flow rate as used in the in-vitro characterisation of 
MS.
Each stage of the MSLI was filled with 20ml of HPLC grade methanol. Five accumulative 
capsules containing ~20mg of MS were fired into the system (shot time: 2.61 secs), using the 
Miat monohaler. The procedure was carried out in triplicate. The five capsules and the device 
was washed with a minimum amount of methanol after each firing into 50ml volumetric flasks
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and made up to volume. Once the firing sequence was complete, the adaptor and throat were 
washed into a 50ml and 100ml volumetric flask respectively with methanol and adjusted 
volume. Stage 1 jet was washed with 5ml of methanol to ensure that any particulates in the jet 
were washed down into stage 1. Stage 5 (after-filter) of the apparatus was removed and the 
filter paper was sonicated in 2 0 ml of methanol for 1 minute, ensuring that drug particles on the 
filter went into solution. The MSLI apparatus was then gently swirled and rotated to recover 
any drug particles from the walls of the apparatus. The apparatus was then turned up side 
down to carefully wet the ceiling of each stage and, hence, recover any drug particles that may 
have impacted onto the ceiling. The swirling motion was carried out for a period of 10 
minutes to ensure all drug particles had gone into solution. Stages 1 to 5 were all sonicated 
for 2 minutes and made up to 100ml with methanol. The throat and stage 1 were diluted 
further so that they fell within the standard range. The standards and the samples were 
analysed using and chromatographic conditions outlined on page 99. Test sample 
concentrations were determined by solving the quadratic equations presented by the binomial 
relationship (refer to Table 18, page 105 for example) between the six standards. Once 
solved, the values obtained were incorporated into a spreadsheet and a final answer was 
obtained. Examples of this process as well as the raw data are given in Appendix 13: MS 
Testing and Stability Study Raw HPLC Data, page 270.
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Results
The table below is a summary of the results obtained. For more detailed tables please refer to 
the appendix (detailed tables for the HPLC analysis o f MS- MSLI results).
Cap Dev Adp + 
Tht













































1 . 6 6


































































































Table 67: Summary table of MSLI deposition data for MS at Pl.OLmin'1, n=15.
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Parameter Value Obtained or calculated
Mean Total Recovery (mg) 99.K+2.96)
Mean Total Recovery (%) 97.6(±2.45)
Mean Emitted Dose (mg) 93.3(±3.65)
Mean Emitted Dose (%) 94.2(±2.03)
Mean FPD (mg) 11.1(±1.63)
Mean FPF (%) 11.3(±1.79)
Mean Fill Weight (mg) 101.5(±1.8)
Table 68: Summary table of various parameters calculated from MSLI deposition data for MS at 92.0 
Lmin'1.
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Figure 64: Distribution of MS within the MSLI at 92.0Lmin'\ 
Bars represent the mean +SD of 15 determinations.
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Figure 65: Emitted dose and fine particle dose of MS at 92.0Lmin'1.
Bars represent the mean + SD of 15determinations.
5.2.3 General Discussion
MSLI deposition profile of MS has been presented at 92.0Lmin'1 using the Miat monohaler. 
When comparing the FPD and FPF values of MS with those obtained for MLFDS, the results 
show the same trend as was seen in the TSI analysis o f MS and MLFDS.
Parameter Summary MSLI Results at 92.0Lmin'1
MLFDS Drug-Only MS
Emitted Dose 183.6(ng) (±4.92) 93.3(ug) (±3.65)
Fine Particle Dose 26.0(gg) (±1.97) l l . lm g  (±1.63)
Fine Particle Fraction(%) 14.2(±2.59) 11.3(±1.79)
Capsule Fill Wt (mg) 2 0 .2 (± 1 .2 ) 101.5(±1.8)
Table 69: Summary Comparison of Aerosol Parameters for LFDS and MS.
This is to say that the FPD of MS is significantly higher than that of MLFDS, but its FPF is 
lower due to the reasons outlined on page 175.
Results (a> 92.0Lmin'
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TSI and MSLI deposition studies of MS using the Miat monohaler and size three gelatine 
capsules have shown that only modest ED and FPD values are obtained. If SAPL is ever to be 
marketed as an anti-asthma drug, far greater quantities of it actually need to reach the lungs 
(i.e. ~100mg). Thus, an alternative approach to delivering the drug was investigated; 
employing a novel delivery system constructed specifically deliver higher quantities of the 
drug. This is explained further in the next section.
5.3 A Novel Delivery Device for Asthma
A novel delivery device for the administration of MS is described below. Such a system was 
necessary since the FPF obtained by other methods of delivery described earlier either yielded 
poor results, or the change in direction was necessitated because a capsule-based system 
would be impractical when intending to delivery high-doses (~100mg) of SAPL into the 
lungs.
5.3.1 Description of the Device
Figure 6 6 , page 182 is the inhalation delivery system for administration of SAPL. It was 
designed and constructed in colloboration with PA-Consulting (Melbourne, Herts., UK), and 
intended exclusively for clinical investigations. The system is designed to aerosolise a high- 
dose of micronised SAPL into a spacer from which the patient in the clinical study may inhale. 
The early development and component testing was carried out at both Bath University and 
Melbourne. Full characterisation and subsequent testing of the system and its ability to 
aerosolise and deliver SAPL was exclusively carried out Bath University.
The system consists of: -
a) A stainless steel spacer with a volume of approximately 4L, from which the patient is 
intended to breathe.
b) A mesh holder, which aerosolises a sample of MS into the spacer, driven by a regulated 
supply of medical grade air.
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c) A pneumatic assembly that allows the spacer to be connected to and partially evacuated by 
the pump.
d) A control unit that contains vacuum regulating equipment and the electrical systems 
necessary to actuate and time the operation of the system.















Figure 66: Schematic diagram of the MS Inhalation Delivery System.
5.3.2 Operation of the Device
Samples of micronised MS were previously filled by Penn Pharmaceuticals (Tredegar, Gwent, 
UK) into lOOmg vials in a class 10000 laboratory, supplied with filtered air. The humidity 
(<10%) and temperature (18-20°C) of the room was also controlled. These measures were 
taken to minimise moisture absorption from the surrounding atmosphere as outlined on pages 
113 and 191. Samples of micronised MS were then transported to Bath University, under 
controlled conditions (packed using dry-ice), for fine particle assessment.
A photograph of the SAPL delivery device is shown in Figure 67, page 184, part A. 
Operation if the device is initiated by de-crimping of the vial and introducing the sample into
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the mesh holder. Once the sample is loaded (see Figure 67, part B), the mesh holder is placed 
on top of the spacer (Figure 67, part C). The spacer is sealed by depressing the handles until 
fixed in the downward position. The pressure inside the spacer is reduced (-0.5bar) by the 
regulated vacuum system. The powder is then aerosolised and injected into the spacer by 
actuating the compressed air supply (400kPa) using the control unit (see Figure 67, part D). 
The spacer is then vented to atmosphere (see Figure 67, part E), the inlet valve is opened to 
atmosphere (see Figure 67, part F) and the aerosolised cloud is characterised by pulling a pre­
set volume of air (4L) through the spacer into an MSLI. The mesh holder is weighed pre and 
post firing to determine the mass delivered into the spacer. Once the firing is complete, the 
spacer is dismantled as shown in Figure 67, part G.
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Figure 67: Various photographs of the SAPL delivery system, 
a) The Main System b) Connection of the Mesh Holder to the air supply C) Loading of the
Mesh Holder on to the Spacer D) Operation of the Control Unit E) Venting of the Spacer to
Atmosphere F) Opening of the Air Inlet Valve G) Disconnection of the Spacer
5.3.3 Testing Criteria and Deposition Profiles
The delivery system described on page 184 was connected to an MSLI to evaluate the aerosol 
from the lOOmg vials o f MS. The samples were loaded and fired as described on page 181, 
and analysed using HPLC as outlined on page 98. The mass o f MS in each stage was
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glassware and diluting appropriately so that each test solution fell within the concentration 
range of the standard curve.
Pressure drop experiments across the device and sonic flow measurements were carried out 
using the set up procedures described earlier (see section 1.6 Aerosol Testing and 
Characterisation page 63). The pressure drop across the device was measured using a 
differential pressure transducer and was found to be 1.8kPa. Since the EP 1999 supplement 
recommended 4kPa pressure drop could not be achieved, all testing was carried out at 100 L 
min'1. Sonic flow measurements were carried out using an absolute pressure transducer.
In order to evaluate the device and establish operating conditions, the following test criteria 
were employed:
a) Test flow rate: 100 L min-1, shot time: 2.40secs
b) Volume of air drawn through the spacer was chosen to be 3, 4, 8 , and 12L intended to 
mimic equivalent patient inhalations.
c) The settling time of the aerosolised cloud, before sampling into the MSLI, was chosen to be 
20 and / or 30 seconds.
d) The effect of repeated inhalations from the same vial was determined by leaving the MSLI 
in place and allowing a ten second gap between each firing.
e) Dose uniformity experiments from the device were carried out using the set up described in 
section 1.7.1.
Results
Two vials of MS were used for each of the conditions specified on page 184, and the reported 
masses below are the sum totals. Table 70 below, shows the summary results of the tests 
described. Please refer to Appendix 6 : Detailed tables for the HPLC analysis of MS- MSLI 
Results, page 261
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Mass of MS 
delivered 
into spacer
Mass of MS 
delivered (% 
of loaded)
3L One 30 1.80 136.1 119.8mg 8 8 .0 %
4L One 30 2.40 179.1 150.3mg 83.9%
8 L Two 30 2x2.40 169.2 132.5mg 78.3%
12L Three 30 3x2.40 162.0 133. lmg 82.2%
3L One 2 0 1.80 129.7 107.9mg 83.2%
4L One 2 0 2.40 113.5 94.0mg 82.8%
8 L Two 2 0 2x2.40 152.0 124.9mg 82.2%
Table 70: Summary of mass of MS loaded and delivered into the SAPL inhalation system.
Results represent the accumulative masses of two lOOmg vials.
Table 71, page 186 below, shows the summary results for the emitted dose and fine particle 
fraction data obtained by MSLI analysis of the tests described on page 184. Please refer to 
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3L One 30 59.4 49.6 25.0 20.9 42.1
4L One 30 55.3 36.8 46.7 31.0 84.3
8 L Two 30 60.6 45.7 45.5 34.3 75.1
12L Three 30 62.4 46.9 49.9 37.5 80.0
3L One 2 0 42.7 55.4 34.2 23.7 69.4
4L One 2 0 55.4 51.3 46.1 42.7 83.2
8 L Two 2 0 51.1 54.3 41.5 44.2 81.2
Table 71: Summary of emitted dose and fine particle fraction data obtained on the SAPL inhalation 
system by MSLI analysis
Table 72, below, shows the summary results of the tests described above. Please refer to 
Appendix 13: MS Testing and Stability Study Raw HPLC Data, page 270
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Mass of MS 
Loaded 
(mg)
Mass of MS 
Delivered 
(mg)




as a % of 
Delivered
4L 30 89.3 77.7 32.7 42
4L 30 87.1 75.8 33.9 45
4L 30 83.8 73.7 31.7 43
4L 30 83.8 64.7 35.2 54
4L 30 93.8 80.6 31.9 40
4L 30 8 8 . 0 70.5 28.3 40
4L 30 84.2 67.6 27.0 40
4L 30 88.3 74.3 27.8 37
4L 30 86.5 69.5 28.0 40
Mean 87.2 72.7 30.7 42.0
SD 3.21 5.07 3.00 4.98
Table 72: Dose uniformity results of MS delivered at lOOLmin'1 into the SAPL inhalation system from 
individual lOOmg vials.
30sec Settling Time 
20sec Settling Time
ED3 ED4 ED8 ED 12 FPD3 FPD4 FPD8 FPD 12 
(numbes indicate volume o f air drawn through system-Litres)
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Figure 68: Emitted dose and fine particle dose of MS at lOOLmin"1 with varying volume of air drawn 
through the SAPL inhalation system at 20 and 30second aerosol settling time.
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Discussion
Results seem to show that ED is independent of flow rate; this is evident when comparing the 
ED at 8 L with that at 12L. FPD also seems to be independent of the number of inhalations, 
that is to say that 4L of air through the system seems to give comparable FPD results as that at 
12L. FPD values at 20 second settling rate seem to be comparably higher than those at 30 
seconds. This is not unexpected since more powder should settle and deposit on the spacer at 
the longer settling time. However, for clinical trial purposes, the 30second settling rate was 
chosen because of the number of operations that need to be carried out between firing of the 
vial and the patient inhalation is more easily managed. The inhalation system is intended to 
be high-dose unit for pulmonary delivery of SAPL, thus its rather large size and cumbersome 
control levers. The system utilises compressed air and comprises of an elobrate network of 
pipes and valves in order to produce the necessary deaggregating power needed to delivery 
SAPL. With regards to the actual dose delivered (~100mg), it is by far the greatest amount of 
powder administered to date from any DPI. Standard high-dose formulations, such as inhaled 
corticosteroids for chronic obstructive pulmonary disease only utilise about lmg of drug per 
day as shown in the studies carried out by Culpitt et al (1999). The effect of high-dose 
fluticasone propionate and budesonide on lung function and asthma exacerbations in patients 
with severe asthma was investigated by Heinig et al (1999). This study utilised the Diskhaler® 
and Turbuhaler® to deliver 2mg of material to the lungs.
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5.3.4 Stability Studies of MS
Samples of micronised MS previously filled by Penn Pharmaceuticals (Tredegar, Gwent, UK) 
as described on page 182 were stored in incubators at 25°C and 40%RH. Some samples were 
removed at various time intervals (see Table 77, page 190 for details) and deposition studies 
using the MSLI were carried out to ascertain the effects of storage on aerosolisation.
Table 73, Table 74, Table 75, and Table 76 show the summary data obtained by MSLI 
analysis. Please refer to Appendix 13: MS Testing and Stability Study Raw HPLC Data, page 
270 for the full results
Tht Stgl Stg2 Stg3 Stg4 Stg5
PG Cone, (ug/ml) 8.92 7.74 5.09 9.98 15.0 14.6
DPPC Cone, (ug/ml) 21.5 13.7 37.5 34.5 40.8 41.8
Dilution Factor 1 0 0 1 0 0 1 0 0 400 500 1 0 0
PG Deposited (mg) 0.89 0.77 0.51 3.99 7.51 1.46
DPPC Deposited (mg) 2.15 1.37 3.75 13.8 20.4 4.14
MS Deposited (mg) 3.04 2.15 4.26 17.8 27.9 5.60
Table 73: Summary stability study (time point: 1 week) table of MSLI deposition data for MS (2xl00mg 
vials) at lOOLmin'1.
Tht Stgl Stg2 Stg3 Stg4 Stg5
PG Cone, (ug/ml) 11.9 11.5 11.4 16.1 2 0 . 8 2 2 . 2
DPPC Cone, (ug/ml) 24.6 24.3 2 2 . 1 29.9 37.4 40.3
Dilution Factor 1 0 0 1 0 0 1 0 0 400 500 1 0 0
PG Deposited (mg) 1.18 1.14 1.13 6.40 10.4 2 . 2 2
DPPC Deposited (mg) 2.5 2.4 2 . 2 1 2 . 0 18.7 4.03
MS Deposited (mg) 3.65 3.57 3.35 18.4 29.1 6.25
Table 74: Summary stability study (time point: 2 week) table of MSLI deposition data for MS (2xl00mg 
vials) at lOOLmin'1.
Tht Stgl Stg2 Stg3 Stg4 Stg5
PG Cone, (ug/ml) 13.4 9.45 19.1 30.1 18.0 11.5
DPPC Cone, (ug/ml) 31.3 2 2 . 0 44.7 70.2 42.1 26.7
Dilution Factor 50 50 50 1 0 0 2 0 0 50
PG Deposited (mg) 0.7 0.5 1 . 0 3.0 3.6 0 . 6
DPPC Deposited (mg) 1 . 6 1 . 1 2 . 2 7.0 8.4 1.34
MS Deposited (mg) 2 . 2 1 . 6 3.2 1 0 . 0 1 2 . 0 1.9
Table 75: Summary stability study (time point: 1 month) table of MSLI deposition data for MS (lxlOOmg 
vials) at lOOLmin'1.
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Tht Stgl Stg2 Stg3 Stg4 Stg5
PG Cone, (ug/ml) 13.4 9.45 19.1 37.2 24.7 11.5
DPPC Cone, (ug/ml) 32.9 23.9 48.4 91.8 58.9 28.3
Dilution Factor 50 50 50 1 0 0 2 0 0 50
PG Deposited (mg) 0.67 0.47 0.96 3.70 4.92 0.60
DPPC Deposited (mg) 1.64 1 . 2 0 2.42 9.18 1 1 . 8 1.41
MS Deposited (mg) 2.31 1.67 3.37 12.9 16.7 1.99
Table 76: Summary stability study (time point: 3 months) table of MSLI deposition data for MS (lxlOOmg 
vials) at lOOLmin'1.
Table 77, below, shows the summary results for the emitted dose and fine particle fraction 

































lWk 8 L Two Two 1 0 2 0 2 x2 . 60.7 51.3 84.5
2Wks 8 L Two Two 1 0 2 0 2 x2 . 57.2 47.4 82.9
4Wks 4L One One None 30 2.4 39.0 31.6 81.1
12 Wks 4L One One None 30 2.4 24.5 17.4 70.9
Table 77: Summary table of emitted dose, fine particle dose, and fine particle fraction data obtained for 
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Figure 69: Graph showing the change in fine particle fraction of MS stability samples, stored at 25°C and 
40%RH over a period of twelve weeks.
Results were obtained using the MSLI at lOOLmin'1 with varying volume of air drawn through the SAPL 
inhalation system at 20 and 30 seconds aerosol settling time.
5.3.4.1 Moisture Uptake of SAPL
The various SAPL powders were analysed in order to attain their moisture content using Karl- 
Fischer (KF) Analysis. In addition, the relative humidity (RH) conditions, see Table 78, page 
192, were prepared in desiccators and samples of each powder were placed into the 
desiccators and their moisture uptake was monitored over a period of four weeks. The 
saturated salt solutions, shown below in Table 78, were prepared by adding an excess of the 
solute into distilled water.
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Saturated Salt Solution Moisture Range at 25 °C
Potassium Hydroxide 4-10%
Calcium Chloride (CaCl2 .6 H2 0 ) 31-35%
Ammonium Nitrate 62-67%
Table 78: Table showing the saturated salt solutions and corresponding moisture ranges at room 
temperature.
Method










% Moisture Content 3.40 (±0.11) 5.20 (±0.14) 3.25 (±0.04) 1.43 (±0.05)
% Moisture After 
Treatment With P2O5 2.80 (±0.16) 3.90 (±0.09) 2.04 (±0.19) 1.21 (±0.24)
Table 79 : Table showing the moisture content for various SAPL powders stored under various conditions, 
n=5.
Table 79 shows the effect of micronisation on the moisture contents of various SAPL 
powders. It can be seen that after treament phosphorous pentoxide, the moisture content is 
reduced. P2O5 absorbs water to produce phosphoric acid and physically changes from a white 
powder to a waxy material. Table 80 and Table 81, page 194, shows the moisture uptake of 
SAPL over a period of 4 weeks. During the time in which the moisture measurements were 
made, the temperature and relative humidity of the laboratory were measured. The 








% Moisture Content 
Average (n=5)
Zero FDS As Received 3.62 (±0.0680)
24hrs/lDay FDS KOH 4.62 (±0.320)
24hrs/lDay FDS CaCl2 6.55 (±0.182)
24hrs/iDay FDS NH4NO3 7.26 (±0.377)
48hrs/2Days FDS KO H 6.14 (±0.203)
48hrs/2Days FDS CaCl2 6.73 (±0.372)
48hrs/2Days FDS NH4NO3 7.76 (±0.425)
72hrs/3Days FDS KO H 6.18 (±0.430)
72hrs/3Days FDS CaCl2 6.82 (±0.449)
72hrs/3Days FDS NH4NO3 8.45 (±3.29)
1 Week FDS KO H 6.42 (±0.371)
1 Week FDS CaCl2 8.47 (±0.406)
1 Week FDS NH4NO3 11.22 (±0.782)
2 Weeks FDS KOH 7.66 (±0.405)
2 Weeks FDS CaCl2 10.3 (±0.403)
2 Weeks FDS NH4NO3 14.1 (±0.384)
4 Weeks FDS KOH 7.63 (±0.261)
4 Weeks FDS CaCl2 12.4 (±0.401)
4 Weeks FDS NH4NO3 16.1 (±0.651)
Table 80: Table showing the moisture uptake of FDS (n=3).
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Figure 70: Moisture-uptake versus time for FDS under various storage conditions.
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Time Point Sample Storage % Moisture Content
(Hrs /Days) ID Condition Average (n=5)
Zero LFDS As Received 5.87 (±0.392)
24hrs/lDay LFDS KOH 6.05 (±0.416)
24hrs/lDay LFDS CaCl2 9.03 (±0.598)
24hrs/lDay LFDS NH4NO 3 14.2 (±0.745)
48hrs/2Days LFDS KOH 6.79 (±0.526)
48hrs/2Days LFDS CaCl2 10.8 (±0.315)
48hrs/2Days LFDS NH4NO3 18.7 (±0.793)
72hrs/3Days LFDS KOH 7.37 (±0.365)
72hrs/3Days LFDS CaCl2 12.9 (±0.382)
72hrs/3Days LFDS NH4NO3 20.0 (±0.702)
1 Week LFDS KOH 7.81 (±0.483)
1 Week LFDS CaCl2 13.3 (±0.360)
1 Week LFDS NH4NO3 20.5 (±0.853)
2 Weeks LFDS KOH 8.31 (±0.488)
2 Weeks LFDS CaCl2 13.1 (±0.500)
2 Weeks LFDS NH4 NO3 23.1 (±0.815)
4 weeks LFDS KOH 8.40 (±0.266)
4 weeks LFDS CaCl2 16.1 (±0.906)
4 weeks LFDS NH4 NO 1 23.4 (±0.461)
Table 81: Table showing the moisture uptake of LFDS, n=3.
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Figure 71: Moisture-uptake versus time for LFDS under various storage conditions.
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5.3.4.2 Effect of Moisture Uptake on the Ability of SAPL to Reduce the Surface 
Tension of Water
Surface tension (ST) of a liquid is often defined as the force acting at right angles to any line 
of unit length on the liquid surface (Shaw 1996). It can also be defined as the work required 
to increase the area of a surface isothermally and reversibly by unit amount. There is no 
fundamental difference between the terms surface and interface, so far as to say that a 
boundary between two surfaces (one being gaseous) is called a surface, whilst the boundary 
between two non-gaseous phases is an interface. At the interface between two liquids there is 
again an imbalance of intermolecular forces but of a lesser magnitude. Interfacial tensions 
usually lie between the individual surface tensions of the liquids in question.
ST experiments on FDS and LFDS were carried out to ascertain the effect of moisture on the 
ability of the material to reduce the ST of water. These were not direct measurements of ST, 
but rather the change in ST of water when specific amount of surfactant was added to it. Prior 
to the experiments, materials were stored under varying relative humidity conditions for a 
period of four weeks, as described in the previous section. The conditions were: saturated 
potassium hydroxide solution: 4-10% RH, saturated calcium chloride solution 31-35% RH, 
and saturated ammonium nitrate solution 62-67% RH. The moisture content of the samples 
were as follows:
a) FDS: 7.63% (KOH), 12.4% (CaCl2), and 16.1% (NH4NO3).
b) LFDS: 8.40% (KOH), 16.1% (CaCl2), and 23.4% (NH4NO3).
The ability of these materials to reduce the ST of water were compared against:
(a)A fresh sample FDS: Obtained from a sterilised, lOOmg crimped vial, as described in the 
section entitled Artificially Derived Surfactants.
(b) A fresh sample of LFDS: Obtained by the method described in the section entitled 
Fluorescent labelling of FDS.
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Equipment
10L capacity water tank
Heating unit (Grant Instruments, Cambridge, UK) with thermostat control 
Ultra-pure (tripled distilled) water (Millipore Ltd.,)
Tensiometer (constructed in-house) with a MIMA 9000 control unit (Coventry, UK)
An electronic balance, mounted onto the tensiometer in an inverted manner, with a small hook 
protruding from its lowest point to which a small filter paper (1 x 3 cm, Whatman No 1) was 
attached to record the ‘pull’ from the surface of the water.
A small metal basket and 1, 10, 50 and lOOmg aluminium weights.
Wide-bottomed glass flasks, cleaned using chromic acid, rinsed with tap water, distilled water, 
and finally with ultra-pure water.
5.4.3.3 Experiment to Prove the Linear Response of the Tensiometer
The wide-bottomed glass flasks were immersed into the water tank (heated to ~37°C) and 
filled with ultra-pure water and allowed to equilibrate. The small basket was attached to the 
hook protruding from the balance, and the reading (mN/m) was adjusted to zero. The 
aluminium weights (1, 10, 50 and lOOmg) were placed in turn into the basket and the reading 
on the balance was recorded. The results obtained are shown below: -





Table 82: Table showing the aluminium calibration weights and corresponding tensiometer reading.
The readings above were used to construct the graph below.
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Figure 72: Graph showing the relationship between tensiometer reading and the aluminium calibration 
weights.
Slope S.D (Slope) Intercept S.D. (Intercept) Correlation Coefficient
0.519 0.00337 0 0603R o.i m 9 0 99996
Table 83: Table summarising the linear regression data obtained form the calibration plot of tensiometer 
reading versus aluminium calibration weights.
Method
The wide-bottomed glass flasks were immersed into the water tank (heated to ~37°C) and 
filled with ultra-pure water and allowed to equilibrate. The filter paper at the end of the hook 
was lowered so that it just broke the surface of the water in the flask. The filter paper was 
allowed to wet completely and the reading on the balance display was adjusted to zero. About 
5mg of test material was introduced to the surface using a micro-spatula. The change in ST 
was recorded every minute over a period of 25minutes. The drift on the instrument was 
measured for a period of 25minutes, without any addition o f surfactant and the value obtained 
was subtracted from subsequent readings.
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Results
All the materials tested were seen to spread instantly over the surface of the water as soon as it 
was introduced. There was a sudden decrease in ST both with LFDS and FDS and 
equilibrium was reached after approximately 60seconds. The results obtained are shown 
graphically below
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Figure 73: Graph showing the change in surface tension versus time for fresh FDS and FDS stored under 
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A novel inhalation system, intended for use in the clinic, for the delivery of MS has been 
presented. The system has been tested to some extent and the scheduled programme is set to 
continue beyond the scope of this report. Findings have shown that the device performs 
significantly better than the Miat Monohaler and capsule systems outlined on page 170. To be 
more specific, the FPF is increased from 11.3% (for the capsule-based system) to between 70- 
85% for the present system. The FPD for the present system is between 45-50mg for two 
accumulative shots of lOOmg of MS.
From the results, the following conclusions can also be drawn:
a) The total volume of air drawn through the delivery system as a result o f multiple inhalations 
has a small effect on the mass of MS, but no significant effect on the FPD.
b) The volume of initial inhalation does significantly affect the FPD, with higher FPDs 
achieved for 4L inhalations than for 3L inhalations.
c) Settling time (i.e. the time between aerosolisation into the spacer and actual inhalation) does 
not have a significant effect on the FPD.
d) Mass of MS loaded directly affects the FPD, thus, higher masses leads to higher FPD but 
NOT necessarily higher FPF. This point is well illustrated in the stability study results, where 
the difference in FPF between lOOmg and 200mg of delivered drug is marginal.
DUS A results for ten consecutive shots of MS into the inhalation system yielded values 28.0- 
35.2mg being collected in the collection vessel. The target dose for patients in the clinical 
trials is ~100mg (range 85-lOOmg) of SAPL in the peripheral and deep lungs. This 
corresponds to four vials of SAPL being administered to the patient over the course of the 
study. This figure of lOOmg total dose is not an arbitrary one and is based on the dose of 
SAPL currently used for the treatment of nRDS where a lOOmg of the material is nebulised to 
the infant over a period of 48-72hrs. Taking into consideration the relative larger size of the 
adult human lung and the fact that a powder formulation is used as opposed a nebulised liquid, 
then it seems a sensible to go with a lOOmg total dose. The problem in deciding this final
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dose was that there was no previous guideline or reference, either from literature or from the 
any governing body. Kurashima (1991) who carried out the first exogenous surfactant pilot 
study used a dose of lOmg/ml of Exosurf®, but had no idea of the volume to administer. Thus, 
the most sensible policy seemed to be to base our final dose on the existing SAPL product 
currently on the market.
Stability study programme is on-going and further time points at 6 months and 1 year are 
needed, both for use in the clinic and ultimately in deciding a shelf life for the final product. 
Although there appears to be a decrease of ~10% in FPF over the 3 month period, further data 
is required before comments can be made on the effect o f the storage conditions on the fine 
particle properties of the powder.
Moisture determination experiments show that both labelled and raw SAPL are hygroscopic 
and pick up mositure progressively. However, in both cases the moisture content seems to 
reach a peak value after about two to four weeks. Upon closer inspection of the tables and 
graphs, it can be seen that labelled SAPL is slightly more hygroscopic than the raw material. 
The labelled SAPL seems to reach a peak moisture content o f 23% compared with 16% for the 
raw material, the difference may be due to the labelling procedure (see page 121). Although 
SAPL is hygroscopic, the process is rate dependant and the material may be handled without 
too much due concern as long as it is not exposed to the environment for long periods. 
Surface tension experiments show that tension-lowering properties of FDS and LFDS are 
diminished with increasing moisture content of the sample. Furthermore, LFDS appears to be 
less effective in reducing ST than FDS, probably a side effect of the labelling process.
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Chapter 6
Deposition Studies of Radiolabelled SAPL
6.0 Deposition Studies of Radiolabelled SAPL
Chemically radiolabelled PG (labelled with Tritium, 3H) and DPPC (labelled with 14C), two 
constituents of SAPL (3:7% v/v ratio) were provided by Amersham, International, Somerset, 
UK. These were used by Hills and Chen (1998) in ex-vivo experiments using bronchial 
epithelium (derived from porcine lungs) to prove the hypotheses that:
a) Exogenous surfactant can directly bind various tissue surfaces where the adsorption of 
endigenous surfactant had been demonstrated.
b) PG has a physiological role in promoting DPPC adsorption.
Porcine bronchial epithelium was chosen for its relevance to asthma and implication to RDS at 
the alveolar level. Refer to section 1.3 Surfactant Therapy, page 32
Using the materials from the same radiolabelled batch, the following set of experiments were 
intended to demonstrated that:
a) The two constituents could be mixed in solution, at the same ratio as in SAPL, and 
nebulised into an MSLI.
b) An in-vitro deposition of the materials could be quantified.
c) Deposition profiles of the chemically labelled SAPL could be used to validate the 
fluorescent labelling process employed in the detection of FDS, see pagel21.
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6.1 Construction of the Calibration Curve
14C and 3H reference standards (Amersham International, UK) were used to produce two six- 
point calibration curves. To each of the six standards, varying quantities of the quenching 
agent CCI4 and a small amount of scintillant was added. The quantity of the quenching agent 
varied from zero to lOOpl in the six standards, hence a ratio of quenching agent to scintillant 
was established for each standard. The scintillant, Optipha ‘Safe’ (Wallac Scintillation 
Products, Milton Keynes, UK), was a multi-purpose cocktail o f ethyl substituted benzenes, 
and its function was to convert the kinetic energy of nuclear particles into light photons. 
Samples were placed into plastic, screw top vials and placed into a P-Counter (Rack Beta 
Scintillation Counter, LKB Wallac Ltd, Finland) and their activity determined as 
disintergrations per minute (DPM). Since 14C counting window overlapped with the 3H 
window, it was necessary to establish the degree of overlap and the counting efficiency of the 
p-Counter. Therefore, three different types of measurements were made by the p-Counter:
a) 14C alone in the Carbon window.
b) 3H alone in the hydrogen window
c) 14C in the 3H window.
The counting efficiency of the p-counter was determined by measuring each standard set using 
the above combinations to produce six sets of efficiency graphs.
Since 14C is a p-emitter, the 8max= 0.16MeV, but in practice 14C decays in the following way: 
14C * 14N + p® + N (Neutrino). Therefore, the energy is not due to the p-ion alone.
Since p® has an energy of O.lOMeV, the counting window was set to 0.16Mev. A summary 
of the counting experiments are outlined below.
Results
Table 84, page203 shows a summary of the results obtained for the 3H reference standard 
during the counting experiments.
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Std Ratio (Scint / Win Counts Counting Win Counts Counting
No. Quench.) No. per min Efficiency No. Per Min Efficiency
1 0.447 1 2198 5.58% 2 157 0.40%
2 0.611 1 3729 9.51% 2 285 0.73%
3 0.733 1 5573 14.21% 2 402 1.02%
4 0.952 1 8417 21.46% 2 512 1.31%
5 1.207 1 11510 29.34% 2 809 2.06%
6 1.363 1 13566 34.59% 2 1170 2.98%
Table 84: Table showing ratio of scintillant to quenching agent, Counts per minute, and counting 
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Figure 75: Graph Showing Counts per minute Vs Counting Efficiency for the 3H reference standard.
Table 85, page 204, shows a summary of the results obtained for the 14C reference standard 
during the counting experiments.
203
Std Ratio (Scint / Win Counts Counting Win Counts Counting
No. Quench.) No. per min Efficiency No. Per Min Efficiency
1 0.482 1 9596 55.28(%) 2 4295 24.74(%)
2 0.641 1 8803 50.71(%) 2 6333 36.48(%)
3 0.789 1 7566 43.58(%) 2 8670 49.94(%)
4 1.046 1 5628 32.42(%) 2 10907 62.83(%)
5 1.252 1 4553 26.23(%) 2 12138 69.92(%)
6 1.497 1 3616 20.83(%) 2 12985 74.80(%)
Table 85: Table showing ratio of scintillant to quenching, Count per minute, and counting efficiency for 
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Figure 76: Graph Showing Counts per minute Vs Counting Efficiency for 14C reference standard. 
Statistics
The t-test at p=0.005 revealed no significant differences between the slopes of the two 
standard sets (t=0.000608, p=0.500).
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Having obtained the calibration graphs for both isotopes and shown that the count range is 
linear, the p-Counter was reprogrammed with the counting efficiencies and was ready to read 
unknown samples. The sample readings were displayed in DPM since CPM to DPM 
conversion requires count efficiency ratings.
6.2 MSLI Analysis of Radiolabelled SAPL
Practical details of constructing a calibration curve for radio-detection of SAPL and the 
reasons for doing the experiment have been discussed in the previous two sections. This 
section outlines the results of the MSLI analysis of SAPL.
Materials & Equipment
L-3-Phosphatidy-DL-glycerol-2-[9,10(n)-3H]Stearoyl-l-palmitoyl (PG) in Toluene : Ethanol 
(1:1, v/v)- Source (Amersham International, UK).
Total Activity= 5 mCi, Sample volume= 5ml, Specific Activity= 6.14 TBq/ml or 166 
Ci/mmol, Radioactive concentration= 37 MBq/ml or lmCi/ml.
L-3-Phosphatidylcholine, l,2-di[l-14C]Palmitoyl (DPPC) in Toluene : Ethanol (1:1, v/v)- )- 
Source (Amersham International, UK).
Total Activity= lOpCi, Sample Volume= 0.5ml, Specific Activity= 4.22 Gbq/mmol, or 5.72 
MBq/mg.
Absolute ethanol (HPLC grade, Fisons, UK).
Compressor, Nebupump™ (Carri-Med Ltd, Dorking, UK), maximum output: 6.4L min'1. 
Nebuliser: Cirrus™, maximum output: 3.8L min'1.
Pump: Gast 1023, Rotor Vein, Oil-less, (Bucks., UK).
Rack Beta Scintillation Counter (LKB Wallac Ltd, Finland).
5-Stage Liquid Impinger, Stage 5 filter: Type A/E glass fibre, 76mm diameter (Gelman 
Sciences, Mich., USA).
Digital timing unit, Mass flow meter (Hastings Mass Flow Meter, HFM 201, Teledyne Brown 
Engineering, Hastings Instruments, VA, USA).
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50pl and 1ml Gilson pipettes with disposable tips.
Dilutions
PG: 5000pci / 5ml original activity, therefore, lOOOpci in lml. A 1ml of the PG stock was 
taken and pipetted into a 200ml volumetric with absolute ethanol to give a solution with a 
final activity of 5 pci/ml. No further dilutions were necessary.
DPPC:_10pci total activity per 0.5ml. A 50pl aliquot was taken pipetted into 10ml volumetric 
(1:400 dilution) to give a solution with a final activity of 1.25 pci/10ml (0.125pci/ml). No 
further dilutions were necessary.
Method
20ml of absolute ethanol was pipetted into each of the four stages of the MSLI and each stage 
stoppered. 2.1ml of radiolabelled DPPC and 0.9ml of radiolabelled PG were pipetted into the 
nebuliser chamber. Flow rate through the MSLI was set at 60L min'1 using the mass flow 
meter. The nebuliser was connected to the MSLI via an adaptor, as shown below. The 
compressor was connected to the bottom of the nebuliser via vacuum tubing. The timing unit 
was adjusted so that the by-pass switch was activated, which allowed the pump to work 
continuously. The pump was switched on and the compressor was activated and the solution 
was nebulised. It took 8 minutes for the chamber empty to dryness. Stage 5 of the MSLI was 
disconnected from stages 1 to 4 and the MSLI swirled gently to collect droplets that had 
impacted on the sides and then turned up side down to was the ceiling of the apparatus. 
Stoppers from the four stages were removed and each stage was emptied into 50ml 
volumetric. Each stage was further washed with absolute ethanol to recover as much of the 
nebulised material as possible and the solutions were made up to volume using absolute 
ethanol. The metal throat and silicone adaptor were washed into a 50ml volumetric flask and 
made up to volume with absolute ethanol. The glass fibre filter from stage 5 was placed into a 
glass crystallising basin and washed with 20ml of absolute ethanol. The solution was poured 
into a 50ml volumetric and made up to volume with further absolute ethanol. The residual
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liquid left in the nebuliser was washed into a 50ml volumetric flask and made up to volume 
using absolute ethanol. A 1ml aliquot from each of the seven 50ml samples were taken and 
placed into separate, white, plastic, screw-top scintillation tubes. To each 1ml aliquot, 6ml of 
scintillant was added. The tubes were placed into the scintillation counter and counted for five 








Figure 77: Schematic diagram showing the apparatus used in the deposition studies of radiolabelled 
SAPL.
Results
A total of five separate runs (n=5) were carried out with an additional dry-run using only 
absolute ethanol and scintillant as the final solution. The tables below show the distribution of 





























































65.3 1.6 2.7 2.5 3.7 6.2 18.0
Table 86: Distribution of radiolabelled PG within an MSLI at 60L min'1 flow rate, aerosolised from a
Cirrus™ nebuliser using the Nebupump™ compressor operating at 6.4L min'1.
Standard deviation values are also indicated, n=5
14C (DPPC)
Parameter Cut-off Diameter 13.0 6.8 3.1 1.7 0.0
Neb T+A Stgl Stg2 Stg3 Stg4 Stg5
CPM 3886 136 73.5 74.3 61.5 163 769
(±181) (±15.2) (±5.8) (±11.8) (±6.9) (±26.8) (±15.5)
Apparent 11230 394 212 215 178 470 2222
DPM (±241) (±55.1) (±21.0) (±42.5) (±25.1) (±96.8) (±56.1)
Corrected 561488 19711 10621 10730 8887 23483 111091
DPM (±12035) (±2755) (±1048) (±2125) (±1256) (±4841) (±2805)
%
Recovery
75.3 2.6 1.4 1.4 1.2 3.1 14.9
Table 87: Distribution of radiolabelled DPPC within an MSLI at 60L min'1 flow rate, aerosolised from a 
Cirrus™ nebuliser using the Nebupump™ compressor operating at 6.4L min'1.
The results from the previous two tables are summarised in Table 88, page 209.
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Stage 3H (PG) Deposition (%) 14C (DPPC) Deposition (%)
Nebuliser 62.9 52.0
Throat + Adaptor 1.55 4.95
Stage 1 2.60 2.65
Stage 2 2.38 2.70
Stage 3 3.58 2.25
Stage 4 5.95 5.93
Stage 5 17.4 28.0
Total % Recovery 96.4 98.5
FPF(%) 26.9 36.2
Table 88: % Deposition of radiolabelled DPPC and PG within an MSLI at 60L m in1 flow rate, aerosolised 
from a Cirrus™ nebuliser using a Nebupump™ compressor operating at 6.4L min'1.
The data in Table 88 can be represented graphically to produce Figure 78 below.
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Figure 78: Deposition profiles of 3H (PG) and 14C (DPPC) in an MSLI at bOLmin'1 flow rate, aerosolised 








Dry Powder Fluidisation of MLFDS
6.3 General Discussion
The results from the Cirrus™ nebuliser show that over 50% of the 3ml volume of 
radiolabelled material are not aerosolised and remain as residual (dead volume) material 
within the apparatus. For PG (labelled with tritium), only 37.1% of the material actually 
leaves the nebuliser whereas 48% of DPPC (labelled with Carbon-14) is expelled. The 
distribution of the two materials within the MSLI is comparable in stages 1,2, 3, and 4. 
However, distribution differences within the throat and stage 5 may be accountable to the fact 
that 14C counting is only 35% efficient at best whereas 3H counting is over 70% efficient. 
Fine particle fraction (FPF) expressed as a percentage is 26.9 and 36.2 for PG and DPPC 
respectively. Gilliard et al first carried out radiolabelling the phospholipids of lung surfactant 
in 1991. The procedure is now routinely used in the biochemistry field for pathway 
elucidation and adsorption studies (Perochon et al 1997).
7.0 Dry Powder Fluidisation of MLFDS
In this section a novel apparatus for delivering dry powder aerosols is described. The 
construction of the dry powder aerosol generator is and its subsequent coupling to a TSI to 
deliver MLFDS is discussed. No fludisation experiments were carried out on MS, as there 
were insufficient quantities of the drug available. The average particle size of MLFDS used 
during the deposition studies was 4.12pm, as determined by LALLS (see materials and 
general characterisations). The fluorimetric technique used to quantify the material has been 
previously described (see page 108).
7.1 Construction of a Novel Dry Powder Aerosol Generator (DPAG)
The design of the fluidisation chamber (see Figure 79, page 211) was based on that of Lord 
(1993).
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Figure 79: A Photograph of the dry powder aerosol generator (DPAG).
Initially, the chamber was constructed out of perspex (to enable visualisation of the powder 
bed) and later, stainless steel. The main body of the chamber consisted of a single unit (10cm 
x 4.2cm (OD) x 3.9cm (ID) tube, constructed from solid rods of perspex or stainless, bored 
and milled to the dimensions stated. On each side of the tube, a rectangular (10cm x 2.9cm) 
window, made of optically pure and homogenous glass (type: BK7, thickness 4mm, flatness 
X/4, parallelity 15seconds of Arc) was glued on. Sintered glass discs (40mm (diameter) x 
2.95mm (thickness)) with varying porosities of 0 to 5 (Aimer products, Enfield, UK), stainless 
steel discs, and brass were all used as the air distributors. A filter paper (Whatman Nol, 
Maidstone, UK) was placed on top of the sintered glass disc during fluidisation to stop powder 
penetrating and blocking the distributor pores. To make the system more efficient (in terms of 
being less prone to air leakage), rubber o-rings were placed on top and bottom of the sintered 
glass / brass. The flanges on both the top and bottom half of the fluidisation apparatus, were 
fitted with screws to allow the operator to vary the tightness of the fit between the fluidisation 
chamber and the plenum and to ensure that air did not leak though the side walls of the 
distributor. The plenum of the apparatus was constructed of stainless steel and allowed air 
(supplied from a compressor pump, model 5KH10GGR28AS, General Electric, USA) to pass 
into the column. The flow rate was controlled by a needle valve placed on the tubing between 
the pump and the plenum inlet. The flow rate was monitored using a flow meter (type RS3,
2 1 1
‘Meterate’ flow tube GPE Ltd., Herts., UK), placed between the pump and the plenum. The 
whole apparatus was mounted on threaded metal studs (7cm) and supported by bolts and 
washers, allowing the height of the apparatus to be adjusted. To give the apparatus 
robustness, the metal threads were drilled into a metal base support (10cm (diameter) x 2.2 cm 
height x 1kg weight). A small spirit level was used to ensure that chamber was horizontal, 
prior to experiment commencement. The DP AG was connected to a TSI, as shown in Figure 
80, this set-up was used in the deposition studies. Please refer to Appendix 10: Dimensions of 
the DP AG, page 263.
















Figure 80: Diagram showing the DPAG-TSI experimental set-up.
SV: solenoid valve. NV: needle valve, F: pump protection filter, FM: flow meter
7.1.1 Experiments to Ascertain the Best Air-Distributing Material in the DPAG
A number of different materials were used as potential air-distributors within the DPAG. 
These included sintered glass and sintered brass. In order to determine which material 
performed best, pressure drop measurements were carried out using the set-up shown below in 
Figure 81 page 213.
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FM =  NV Compressor
U-Tube
Manometer
Figure 81: Diagram showing the set-up used for the pressure drop experiments to ascertain the best air- 
distributor in the DPAG.
Method
The experimental apparatus were set up as shown in Figure 81. The various different 
distributors were placed in the DPAG. The height of the water u-tube manometer was 
adjusted to zero. The compressor was switched on and the flow rate was adjusted using the 
needle valve. The corresponding pressure drop was measured on the u-tube manometer.
Results
Table 89 page 214, summarises the results obtained. Please refer to Appendix 11: Detailed 































































Table 89: Summary table showing the dimensions and performance of the various air-distributors used in 
the characterisation of the DPAG.
SEM photomicrographs in Figure 82 and Figure 83 show the images obtained for the sintered 
material.
Figure 82: SEM photomicrograph of sintered glass at x200 magnification.
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Figure 83: SEM photomicrograph of sintered brass at x500 magnification.
7.1.2 Discussion
Results for sintered glass show that, as porosity decreases there is greater resistance to the 
flow of air through the distributor resulting in increased pressure drops. However, the sintered 
brass used in the experiments does not exhibit the same resistance to the flow o f air as its glass 
counterpart (i.e. porosity three). This discrepancy may be explained partially by studying the 
SEM images of the two materials. Sintered glass SEM images show dense, irregular pores 
compared with the more ordered pore structure of the sintered brass. It is possible that this 
irregular structure of the sintered glass accounts for the differences in performance, because 
the air has to negotiate a more complex route through the material. For this reason and also 
for its robustness, the brass was chosen as the distributor and used throughout the DPAG/TSI 
experiments. From additional experiments, it was determined that the sintered brass used in 
combination with a flow rate of lOLmin'1 from the compressor fluidised the powder well. 
Thus, this flow rate was kept constant in all DPAG/TSI deposition studies.
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7.2 TSI (Apparatus A) Deposition Profiles of MLFDS using the Dry Powder 
Aerosol Generator
A known amount of powder ~5g for the raw drug, and ~10g for the binary / ternary blends 
were placed into the chamber of the DPAG and the apparatus was coupled to a TSI as shown 
above. The in-vitro aerosol investigations were performed at 60.0 and 96.4 Lmin'1 flow rate 
through the DPAG, whilst a compressor (Nebupump™ , Carri-Med Ltd, Dorking, UK) was 
operating at lOLmin'1.
Flow Rate Stage 1 Jet Diameter Cut-off Diameter Shot time
60.1 Lmin'1 14.2mm 6.55pm 4.0secs
96.4Lmin'1 16.4mm 6.51pm 2.5secs
Table 90: Table showing the conditions used in the TSI (Apparatus A) DPAG deposition study of MLFDS. 
Method
The DPAG was coupled to the TSI (see Figure 80, page212) containing 7ml and 30ml of 
HPLC grade methanol in stages 1 and 2 respectively, via an adaptor. The timing device was 
adjusted to run continuously. The aerosolised cloud from the DPAG was drawn into the air- 
stream created by the vacuum pump and MLFDS was delivered into the TSI. The system was 
turned off after five minutes or when no further sample appeared to be exiting the DPAG. The 
remaining sample in the powder bed and that adhered to the sides of DPAG and its removable 
head-chamber was weighed and the amount entering the TSI was quantified.
Once delivery of the powder was complete, stages 1 and throat (plus adaptor) of the TSI were 
washed into 100ml volumetric with methanol and diluted so as their intensity reading from the 
fluorimeter fell within the standard range. Stage 2 was washed into a 100ml volumetric and 
adjusted to volume with methanol, and diluted accordingly. The inside of the DPAG was 
washed into a 100ml volumetric and adjusted to volume with the methanol, and diluted 
accordingly. The relative intensity of the standards (see 2.2.5.2 Fluorimetric Detection of 
LFDS, page 108 for preparation) and the samples were measured on the Hitachi F2000 




The summary Table 91, page 217 shows the results obtained for MLFDS at 60.0, and 
96.4Lmin'1, compressor flow rate: lOLmin'1.
Parameter FR DPAG Stage 1 Stage 2
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Table 91: Summary table of TSI deposition data for MLFDS using DPAG at 60.1, and 96.4Lmin'1 
(compressor flow rate: lOLmin1).
Values in brackets indicate standard deviation, n=10.
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Table 92, below, was constructed from the results obtained above in Table 91.
Parameter
Value Obtained or 
calculated @ 60. ILm in'1
Value Obtained or 
calculated @ 96.4Lmin'1
Mean Total Recovery 99.5%(±2.04) 99.4%(±1.32)
Mean Emitted Dose 1.46g(±0.168) 1.99g(±0.182)
Mean Emitted Dose 30.1%(±1.44) 41.2%(±1.67)
Mean FPD 0.103g(±0.015) 0.240g(±0.026)
Mean FPF 7.10%(±0.549) 12.1(±0.713)
Table 92: Summary table of various parameters calculated from TSI deposition data for MLFDS using 
the DPAG (compressor flow rate: lOLmin'1) at 60.0, and 96.4 Lmin'1.
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Figure 84: Distribution of MLFDS within Apparatus A at different flow rates in experiments using the 
DPAG.
Bars represent the mean + SD of 10 determinations.
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In- Vitro Aerosol Characterisation of MLFDS 
Using the DPAG/TSI
Figure 85: Emitted dose and fine particle dose of MLFDS at different flow rates in experiments using the 
DPAG.
Bars represent the mean + SD of 10 determinations.
Statistics
One way analysis of variance on the ED of MLFDS at 60.1, 96.4 with lOLm in1 compressor 
flow rate revealed significant differences (F=44.2, p= <0.001). Significant differences 
(F=210, p= <0.001) were also observed for the FPD values.
7.2.2 Binary Blends
Three different blends of MLFDS and lactose (see below), were prepared as described in 
chapter four using the rotary bladed blender (Kenwood Mini Chopper, C H I00, Kenwood Ltd., 
Hants., UK) employing the mixing techniques outlined earlier (see page 118). The blends 
were tested for content uniformity and the optimum mixing time for each blend was 
determined, as previously outlined on page 139.
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A 10g 10 90 Coarse (63-90pm) Fraction
B 10g 10 90 Fine (Microtose) (<10pm)
C 10g 5 95 Coarse (63-90pm) Fraction
Table 93: Table showing the details of the various binary blends of MLFDS with coarse and fine lactose 
used in DPAG deposition studies.
Content uniformity Experiments and SEM Images
Please refer to page 139, Figure 46, Figure 47, and Figure 48, page 142for the details and 
results of the content uniformity experiments and SEM photomicrographs of MLFDS binary 
blends.
Deposition Study Method
The in-vitro aerosol conditions and method employed were the same as those outlined om 
page 216. Flow rates of 60.1 (ECDso% 6.55pm, stage 1 jet 14.2mm) and 96.4Lmin'1 (ECDso% 
6.51pm, stage 1 jet 16.4mm) were used, compressor flow rate: lOLmin1. Amount of powder 
placed into the DPAG chamber was ~10g. In a lOg load into the DPAG, blend A and B 
contain lg  of drug by weight, whereas blend C contains a total of 0.5g of MLFDS. Excess 





DPAG Stage 1 Stage 2
Amount of 60.1 A 7.39(±0.538) 2.57(±0.152)
powder by weight B 6.92(±0.424) 3.18(±0.166)
(g) C 7.37(±0.496) 2.29(±0.104)
Measured 60.1 A 31.2(±0.176) 30.7(±0.183) 19.4(±0.126)
Intensity (%) B 22.8(±0.153) 28.5(±0.179) 21.1 (±0.148)
C 29.8(±0.147) 25.7(±0.135) 14.1(±0.105)
Corr. 60.1 A 25.5(±0.176) 25.0(±0.183) 15.6(±0.126)
Intensity B 22.2(±0.153) 27.9(±0.179) 20.5(±0.148)
(%) C 28.4(±0.147) 24.3(±0.135) 12.7(±0.105)
Cone. 60.1 A 0.493(±0.074) 0.484(±0.086) 0.302(±0.025)
(pg/ml) B 0.461 (±0.051) 0.580(±0.062) 0.424(±0.018)
C 0.566(±0.055) 0.435(±0.055) 0.234(±0.011)




Amount 60.1 A 0.739(±0.062) 0.242(±0.011) 0.0151(±0.003)
Deposited (g) B 0.672(±0.068) 0.282(±0.013) 0.0206(±0.005)
C 0.737(±0.053) 0.211 (±0.009) 0.011(±0.001)
(%) Deposited 60.1 A 74.2(±3.02) 24.3(±1.81) 1.52(±0.096)
B 69.0(±3.15) 28.9(±1.96) 2.11 (±0.105)
C 76.8(±3.47) 22.1 (±2.06) 1.18(±0.073)
Table 94: Summary table of TSI/DPAG deposition data for MLFDS binary blends A, B, and C at 




DPAG Stage 1 Stage 2
Amount of 96.4 A 7.02(±0.427) 2.96(±0.148)
powder by weight B 6.63(±0.343) 3.23(±0.157)
(g) C 6.97(±0.416) 2.72(±0.155)
Measured 96.4 A 30.0(±0.142) 34.9(±0.136) 29.0(±0.174)
Intensity (%) B 22.5(±0.141) 29.9(±0.147) 27.7(±0.163)
C 28.2(±0.128) 30.8(±0.120) 22.0(±0.179)
Corr. 96.4 A 24.4(±0.142) 28.6(±0.136) 23.6(±0.174)
Intensity B 21.9(±0.141) 29.3(±0.147) 27.3(±0.163)
(%) C 26.8(±0.128) 29.4(±0.120) 20.5(±0.179)
Cone. 96.4 A 0.473(±0.032) 0.552(±0.038) 0.457(±0.018)
(gg/ml) B 0.455(±0.030) 0.609(±0.024) 0.563(±0.023)
C 0.478(±0.022) 0.523(±0.024) 0.369(±0.014)




Amount 96.4 A 0.709(±0.0456) 0.276(±0.143) 0.0228(±0.003)
Deposited (g) B 0.663(±0.0394) 0.296(±0.129) 0.0274(±0.003)
C 0.697(±0.310) 0.254(±0.120) 0.0180(±0.001)
(%) Deposited 96.4 A 70.3(±4.16) 27.4(±1.86) 2.27(±0.134)
B 67.2(±3.77) 30.0(±1.71) 2.78(±0.148)
C 71.9(±3.96) 26.2(±2.01) 1.85(±0.100)
Table 95: Summary table of TSI/DPAG deposition data for MLFDS binary blends A, B, and C at 
96.4Lmin~1 (compressor flow rate: lOLmin'1), n=10.
Parameter Blend A 
At 60.1 At 96.4
Blend B 
At 60.1 At 96.4
Blend C 



































































Table 96: Summary table of various parameters calculated from TSI/DPAG deposition data for MLFDS 
binary blends A, B, and C at 60.1 and 96.4 Lmin*1 (compressor flow rate: lOLmin'1).








1 1 Blend A @ 60.1 Lmin'1
(Compressor @ lOLmin'1) 
W&y/A Blend B @ 60.1 Lmin'1
(Compressor @ lOLmin'1) 
Blend C @ 60. ILmin'1 
(Compressor @ lOLmin'1)
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DPAG/TSI Parameter
Figure 86: Distribution of MLFDS binary blends A, B and C within Apparatus A 
(compressor flow rate: lOLmin1) in experiments using the DPAG.
Bars represent the mean + SD of 10 determinations.
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Figure 87: Distribution of MLFDS binary blends A, B and C within Apparatus A 
(compressor flow rate: lOLmin !) in experiments using the DPAG.





1 Blend A @ 60.1 Lmin 
Blend A (a). 96.4Lmin
Blend B @  60.1 Lmin 
e ™  Blend B @ 96.4Lmin 
Blend Cc  200 o 60.1 Lmin
t n ™  Blend C @ 96.4Lmino 150
(Compressor @ lOLmin )
Emitted Dose FPD
In-Vitro Aerosol Characterisation o f MLFDS 
Using the DPAG/TSI
Figure 88: Emitted dose and fine particle dose of MLFDS binary blends A, B and C at 60 and 96.4Lmin'' 
(compressor flow rate: lOLmin'1) in experiments using the DPAG.
Bars represent the mean + SD of 10 determinations.
Statistics
One way analysis of variance on the ED of MLFDS binary blends A, B, and C at 60.1Lmin'‘ 
(with lOLmin'1 compressor flow rate) showed significant differences (F=299, p=<0.001). 
Fisher’s pairwise comparisons revealed that the ED of all three blends were all statistically 
significantly different and did not overlap in anyway. Similar findings were obtained for the 
ED values of the three blends at 96.4Lmin'1 (F=254, p=<0.001). Statistics on the FPD of the 
three blends at 60 and 96.4Lmin'1 also produced widely disagreeing results (F=91.7, 
p=<0.001), (F=58.3, p=<0.001) respectively.
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7.3 General Discussion
Table 97 and Table 98, below, show the summary results obtained in the DPAG/TSI 
experiments.
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Table 97: Summary DPAG/TSI results obtained for MLFDS and its various blends at 60.1 and 96.4Lmin"1 
(compressor flow rate: lOLmin’1), n=10.
From the above table and the data presented within this chapter, it can be seen that the drug 
only formulation appears to be performing the best. But, if  the final FPD values were divided 
by ten, so as to make them directly comparable with blends A and B, and by twenty in the case 
of blend C, then a different pattern emerges (see below). Similarly, values for blend C have 
been multiplied by two to make them comparable with the other formulations.









FPD(mg) 10.3 24.0 
±1.50 ±2.60
14.7 22.2 





Table 98: Modified, summary DPAG/TSI results obtained for MLFDS and its various blends at 60.1 and 
96.4Lmin'1 (compressor flow rate: lOLmin’1).
The modified results show that blend C actually performs best. If the results are analysed 
closely, then they are not so suprising. Blend C, contains the largest amount of lactose (w/w)
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and the least amount of drug. Since lactose fluidises well in comparison to the raw drug, the 
implications are:
a) The DPAG does not effectively cause the separation of the drug particles from each other 
or the carrier particles. This is probably because the fluidising action is not turbulent 
enough and does not cause sufficient shear forces for physical separation.
b) The drug particles or aggregates of drug-drug and drug-carrier cannot negotiate the bend at 
the top of the fluidisation chamber (leading into the TSI) and impact on the ceiling of the 
DPAG, instead of following the airstream.
c) If the aggregates mentioned above do negotiate the bend, then they are not deaggregating 
sufficiently and deposit in stage 1, thus, low FPD values.
The DPAG is a concept device and a similar set-up to the DPAG/TSI system could not be 
found in cited literature. However, since the DPAG is essentially a fluidised bed, comparisons 
can be made to other such systems. Theory of fluidisation (Geldart 1973,1984, and Geldart et 
al 1986), factors affecting it (Baems 1966, Vissier 1989), entrainment of particles from 
fluidised beds (Akiyama et al 1989) can be found elsewhere. Geldart (1973) proposed a 
system of classification of powders as A, B, C, and D-powders, on the basis of their varying 
modes of expansion when fluidised. Although the classification was based purely on 
empirical observations, it is still used today to describe powder behaviour. Geldart (1973) 
concluded that pharmaceutical powders (<2 0 pm in diameter) are difficult to fluidised due to 
their cohesive nature and fall into group C in the classification system. This will explain why 
low FPD values were obtained for the studies carried out in this section.
The DPAG/TSI system is not sufficiently well developed or engineered to deliver MLFDS 
effectively. The reason for this is that on the outset of the project, the goals were to develop a 
dry powder fluidisation system, but as the objectives of the project changed, effort was 
directed to other areas. Further work is necessary to fully evaluate and develop the DPAG.
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Chapter 8 
A Novel Delivery Device for Glue Ear
8.0 A Novel Delivery Device for Glue Ear
A prototype glue ear delivery device (GEDD) for aerosolising a fixed amount of FDS from a 
vial is shown below (Figure 89, page 227). The device was designed and constructed at Bath 
University. The device consists of perspex housing which holds a vial of FDS (mounted onto 
a metal bracket), a plastic actuation chamber used to house a standard MDI canister, and a 
standard 20ml canister (lOOpl valve) filled with approximately 12-14ml of HFA134a. HFA 
134a was preferred over HFA 227 because its vapour pressure is higher at 20°C (i.e. 5.70bar 
c.f. 3.90Bar, see appendix 1, page 250). The outlet from the chamber is connected to the vial 
of FDS via a small plastic (OD 2.23mm, ID <0.5mm) tube, plastic tubing (OD 2.58mm, ID 
2.08mm) and by a 17-gauge needle was used to pierce the rubber septum on the vial. The 
inlet 17-gauge needle is used to channel the HFA aerosol into the vial once the canister is 
depressed, and is located approximately 20mm from the powder bed. A similar 17-gauge 
outlet needle provides an escape route for the aerosolised powder, which is directed into the 
ear insertion tube by more plastic tubing (OD 1.30mm, ID 0.68mm). A fine cloud of FDS is 
expelled from the metal ear insertion tube.
Curved metal tube 
for ear insertion
Plastic tubing Fistic tubing




Generated cloud of FDS
Vial of FDS
Hard plastic tube 
OD= 2.23mm, 
ID= <0.5mm




to hold vial and 





onto which the 
HFA canister sits
Figure 89: Glue ear delivery device (GEDD) for FDS
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8.1 Testing and Evaluation of the Device
In order to evaluate the efficiency of delivery of FDS powder from the device the following
experiments were devised:
a) Variation in delivery of HFA 134a from a pressurised canister fitted with lOOpl valve.
b) The number of actuations needed to empty a vial containing lOOmg of FDS powder, 
amount of powder aerosolised per actuation, and the particle size of the aerosol cloud 
produced.
c) Amount of residual FDS powder left in the vial, unaerosolised.
d) The calculation of the equivalent amount of air dispensed per actuation of HFA 134a from 
the canister.
Method & Results
Each of the above test criteria were carried out in turn, the method and subsequent result(s) 
obtained are given below.
a) 50 consecutive shots of HFA 134a were fired to waste from a pressurised canister
containing 12-14ml of solution. Table 99 shows a summary of the variation in delivery.
Shot No Wt of Canister Before Wt of Canister After Amount of HFA 134a
Actuation (g) Actuation (g) Aerosolised (mg)
1 18.8038 18.6788 125.0
5 18.3025 18.1751 127.4
1 0 17.6643 17.5374 126.9
15 17.0343 16.9106 123.7
2 0 16 4090 16.2824 126.6
25 15.7819 15.6540 127.9
30 15.1464 15.0204 126.0
35 14.5208 14.396 124.8
40 1.3.8921 13.7678 124.3
45 13.2666 1.3.1389 127.7




Table 99: Table showing the variation in the amount of HFA 134a delivered from a standard 20ml 
pressurised canister fitted with a lOOpl valve.
The results in Table 99 show an average of 125mg of HFA 134a delivered per shot. A relative 
standard deviation of <2 % is acceptable.
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b) A vial of freeze-dried SAPL containing lOOmg of powder was loaded into the test apparatus 
as shown above. The weight of the vial was recorded before and after firing to determine the 
amount aerosolised. Particle size of the aerosol cloud produced, per shot, was assessed using 
the Malvern Master Sizer X. The insertion tube, shown above in the test apparatus was held at 
a fixed distance (~10mm) from the laser beam. The aerosol cloud produced caused -20% 
obscuration of the beam, and the instrument was configured to analyse the cloud for a fixed 
period (i.e. 3 seconds). The 300mm lens (size range 0.2-180pm) was used during the 
measurements. The experiment was carried out in triplicate, and a summary of the results 
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Table 100: Table showing the variation in the amount of FDS delivered from a vial and the corresponding 
particle size of the aerosolised cloud.
c) After twelve consecutive shots, each vial was emptied and its contents weighed to 
determine the residual amount of FDS left. The results are shown below.
Number of Actuations 
Needed to Empty a vial
Total Amount of 
FDS Delivered (mg)
Residual Material 
Left in the Vial (mg)
1 2 39.5 31.0
1 2 45.2 24.7
1 2 48.0 23.4
Table 101: Summary table evaluating the GEDD for delivery of FDS.
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d) Calculation of the equivalent amount of air dispensed per actuation of HFA 134a from the 
canister:-
Density of HFA 134a @ 20°C= 1226 kgm*3= 1.226 gem*3
Valve size: lOOpl^O.lcm*3 0.1226g or 122.6g of HFA 134a delivered per shot
0.1226 ,
Molecular Wt.: 102.03 g/mol .\ ■■;■ = Moles per shot = 1.202 x 10 mol
& 102.03 F
Under Standard Conditions, 1 mol of gas occupies 0.02241383m3 volume.
.-. Per shot: (1.202 x 10*3)*0.02241383 = -2.7 x 10*5m3=27cm3
To confirm the above calculation experimentally, ten consecutive shots of HFA were fired 
into a water bath into an inverted measuring cylinder to record the volume of water displaced. 
The average volume of water displaced was found to be - 3 1cm3.
8.3 General Discussion
GEDD was tested as stated above and the following information was attained:
a) The mass of HFA 134a delivered from a lOOpl valve, pressurised canister was found to 
125.7mg, with a variation of 1.27%. This equated to -27cm3 of equivalent air used to 
aerosolise the powder each time the canister was depressed.
b) On average, it took 12 shots to effectively empty a vial of FDS. It took two shots per vial 
before the system was primed, and although powder was aerosolised in the first two shots, 
there was a net weight gain in the system as a result of HFA introduction. Total, 
measurable amount of FDS delivered per vial was ~45mg with a -25mg of powder left as 
residual material.
c) The average particle size of the aerosolised FDS is -18pm, which is comparable to the 
findings revealed by TOFABS analysis (see materials and general characterisations).
The prototype GEDD needs to be developed further and refined before it is suitable for any 
type of clinical trial experiments on humans. However, the experiments in this section have
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Chapter 9 
A Novel Delivery Device for 
Post-Surgical Adhesion
shown that HFA is not a suitable propellant for this application as it appears to be absorbed by 
the SAPL. In addition, propellant-based systems may not be the best option for use in the 
middle ear, for obvious reasons. Published literature searches did not yield any applications of 
HFA propellants as a means of aerosolising powder.
9.0 A Novel Delivery Device for Post-Surgical Adhesions
The basic system described in chapter nine was used. The only modifications made were:
a) The size of the inlet and outlet needles was increased from 17 to 16-gauge.
b) The size of the tubing from the outlet need was increased.
c) The propellant used to aerosolise the powder was changed from HFA 134a to compressed 
medical grade carbon dioxide in order to aerosolise more powder per actuation.
d) The valves on the canister were changed from lOOpl to a continuous type (Bespak 
BK0018005, King’s Lynn, UK). This valve comprised o f a standard core valve assembly with 
black nitrile elastomers and a standard force spring.
e) The canisters were also changed (see section 10.2).
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Figure 90: Schematic of the adhesion delivery system (ADS).
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9.1 Clinical Requirements of the device
The primary concern was sterility of the product upon delivery, since it will be applied 
directly onto the site of action (i.e. abdominal cavity), thus, the use of medical grade CO2 . 
The final device may also need to be sterilised (perhaps with ethlyene oxide) but for animal 
studies this may not be applicable. The outlet tube needs to have an external, diameter of 
5mm and needs to be between 30-33cm long. The amount of powder displaced per actuation 
was determined gravimetrically. The internal diameter of the tubing that enters the abdomen 
of patients undergoing laparascopic surgery will accommodate a 5mm (external diameter) 
catheter, but a 1 0 mm (external diameter) catheter will be too big for the majority of ports.
9.2 Determination of the Leakage Rate from the Canisters
Presspart Manufacturing Ltd., Blackburn, UK, supplied the C l28 canisters used in the study. 
These were standard 19ml pMDI canisters but possessed a strengthened inner wall to 
accommodate high-pressure gasses. The cans were first crimped with the BK0018005 valves 
and filled with compressed CO2 at pressures of 10, 1 2 , and 14 Bar, using the laboratory filling 
plant, Pamasol 2016 apparatus (DH Industries, UK). The crimping specifications for the 
canisters were the same as those employed for the standard Bespak BK357 valves (i.e. Height 
6.7mm, Diameter 17.6mm). The canisters were stored in an oven at 25°C and 40%RH. At 
each time point (see below) five canisters were removed from the storage condition and its 
pressure recorded using the Pamosol pressure gauge (Haenni, Switzerland). The leakage rate 
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Table 102: Table showing the leakage rate of C 02 from the strengthened C128 canisters..
Over a period of three moths there is a loss of approximately 3Bar pressure form the canisters. 
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Figure 91: Graph showing the leakage rate of C02 from the C128 canisters over a period three months.
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9.3 Determination of the amount of FDS Aerosolised using the ADS
The canister was placed into the empty plastic actuation chamber, ensuring the valve of the 
canister fitted into the nozzle embedded at the bottom of the actuation chamber. The canister 
was twisted during insertion to ensure a secure fit. The FDS vial was shaken and tapped 
vigorously before use to ensure the powder plug was fully dispersed. The vial was inserted 
upright into the metal bracket which was mounted onto the perspex housing. The circular 
covering from the top of the vial was removed, the rubber septum remained intact along with 
the rest of the crimp. The rubber septum was pierced with the 16-gauge needle (connected to 
the actuator chamber). The septum was pierced again with the needle connected to the outlet 
tubing. The outlet tubing was held and directed whilst the thumb was placed on top of the 
metal canister. The canister was depressed and held for about two seconds to accurately 
deliver the content of carbon dioxide. Before removing the empty vial o f FDS, the needles 
were disconnected from the septum. When removing the empty canister, care was taken not to 
damage the embedded nozzle at the bottom of the actuator.
The FDS vials were weighed between successive shots to determine the amount aerosolised. 
Table 103, page 236 shows the summary results obtained.
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Canister Vial Amount Amount Expelled Amount Expelled Total Amount
Pressure No Expelled after After 2nd Shot After 3rd Shot Aerosolised
(Bar) 1st Shot (mg) (mg) (mg) (mg)
10 1 49.6 11.3 5.9 66.8
10 2 44.2 22.5 8.9 75.6
10 3 12.3 11.6 35.9 59.8
10 4 21.5 31.6 14.7 67.8
10 5 51.9 22.7 6.2 80.8
Average 70.2(±8.17)
12 1 36.0 21.7 20.4 78.1
12 2 52.4 18.1 4.9 75.4
12 3 53.5 18.2 7.3 79.0
12 4 39.8 24.8 9.7 74.3
12 5 50.0 19.9 7.7 77.6
Average 76.9(±1.96)
14 1 36.7 31.9 9.3 77.9
14 2 49.7 18.5 7.1 75.3
14 3 40.0 27.3 8.5 75.8
14 4 46.4 17.4 7.7 71.5
14 5 38.0 27.9 6.4 72.3
Average 74.6(±2.63)
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Figure 92: Graph showing the amount of drug aerosolised in three consecutive shots from a vial of FDS 
using the Cl 28 canisters at 10,12, and 14 Bars of compressed C 0 2.
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Figure 92, page 236 shows that 12 and 14Bar canisters aerosolise more powder from the FDS 
vials than the lOBar canisters. There seems to be little or no difference between the 12 and 
14Bar canister, with an average of ~75% (75mg) of the vial being emptied after three 
consecutive shots.
9.4 Further Development of the ADS
In order to improve the leakage rate from the canisters and to optimise the amount aerosolised 
from the vial, the crimping diameters (i.e. Height 6.98mm, Diameter 17.8mm) were fine-tuned 
and the C l28 (19ml Volume) canister were changed to the C326 (28ml volume) canisters. In 
addition, four different types of valves were tested to ascertain which had lowest leakage rate.
Valve Number Valve Details
BK0024956 This valve variant has standard black nitrile elastomers. It also 
possesses a modified core assembly with a larger sealing flange, to 
give a greater contact sealing area with the canister. It also has a high 
force spring to effect greater compression of core sealing flange on 
the outer seat.
BK0024958 This variant has a clean nitrile elastomers RB 190NT (carbon-black 
free), a modified core assembly with alarger sealing flange and a high 
force spring to effect greater compression of core sealing flange on 
the outer seat.
BK0024960 This variant has a clean nitrile elastomer RB 190NT (carbon-black 
free), a modified core assembly with a larger core sealing flange and 
a standard force spring.
BK0024971 This variant has a Trefsin thermoplastic elastomer moulded outer 
seat and gasket with a clean nitrile elastomer RB 190NT inner seat. 
Like the others, above it also has a modified core assembly with a 
larger sealing flange and a high force spring.
Table 104: Table decribing the various valves used in the further development of the ADS.
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Using the valves above, 50 canisters for each batch (total 200 canisters) were crimped and 
filled with medical grade CO2 up to a pressure of 14Bar, as described previously, above. The 
filled canisters were split into equal groups and one half was placed into an oven at 25°C and 
40%RH. At each time point (see below) five canisters were removed from the storage 
condition and its pressure recorded using the Pamosol pressure gauge (Haenni, Switzerland). 
The leakage rate of the cans is displayed below. The other half was irradiated (gamma 
radiation) by Isotron PLC, Swindon UK. The irradiation was carried out to prove two things. 
Firstly, the final product had to be sterile for clinical trial purposes, if  the product were ever to 
go that far. Secondly, the effect of irradiation on the valve and the subsequent effect on 
leakage had to be ascertained. The samples were packed into steel boxes (in case of 
explosion) and exposed to a Cobalt (Co60) source for 3-4 hours, receiving a dose of between 
2.5-3.0MRad (25-30kGy) of radiation. This dose was sufficient to render the canister and its 
contents sterile, the samples were then placed in an oven at 25°C and 40%RH. The leakage 
test was carried out specific time points after the exposure by removing five canisters and
testing them as before, the average results are shown below.








BK0024956 1 Week 13.7-14.5 No 14.H+0.0831)
1 Week Yes 13.6±0.152
4 Weeks No 13.5±0.200
4 Weeks Yes 13.2±0.148
BK0024958 1 Week 14.1-14.8 No 13.8(±0.141)
1 Week Yes 13.2±0.228
4 Weeks No 13.4±0.122
4 Weeks Yes 12.9±0.167
BK0024960 1 Week 14.5-15.0 No 14.5(±0.265)
1 Week Yes 13.8+0.311
4 Weeks No 14.0±0.332
4 Weeks Yes 13.4+0.207
BK0024971 1 Week 14.0-14.5 No 13.5(±0.0894)
1 Week Yes 12.4+0.270
4 Weeks No 12.7+0.0550
4 Weeks Yes 11.9+0.179
Table 105: Table showing the leakage rate of C 02 from the C326 (28ml volume) canister using four 
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Figure 94: Graph showing the leakage rate of C 02 from irradiated C326 canisters over four weeks.
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C326 canisters coupled with surplus BKOO18005 valves were filled and used immediately to 
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13.6-13.8 1 57.7 25.5 Zero 80.2
2 63.3 2 0 . 8 5.7 89.8
3 57.8 23.0 6 . 8 87.6
4 34.6 38.5 1 0 . 0 83.1
5 79.9 10.3 2.5 92.8
6 69.3 18.1 3.8 91.1
7 38.1 31.1 18.5 87.7
8 60.2 25.7 8 . 0 94.0
9 50.8 27.7 1 2 . 0 90.5







Table 106: Table showing the aerosolisation data on vials of FDS using the ADS with C326 canisters and 
BK0018005 valves.
The results in Table 106 show that>85% of FDS vials are emptied after three consecutive 
shots using the C326 canisters.
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Figure 95: A schematic representation of the modified ADS.
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9.5 General Discussion
From the results generated, the following conclusions were drawn:
The leakage rate of the CO2 from the C l28 (19ml volume) canisters has been determined. 
Approximately 2.5 Bar of pressure is lost over a period of three months. This leakage rate is 
unacceptable, and thus the need to develop the new prototype ADS coupled with C326 (28ml 
volume) canister. The leakage rate of non-irradiated C326 canisters, coupled with the four 
different valve variants, was between 0.5 and 1.5Bar over a period of four weeks. Of the four 
different valve variants, BK0024960 seems to perform the best, only losing 0.5Bar of pressure 
over four weeks. Next best is BK0024956, followed by BK0024958 and finally BK0024971, 
losing 1.5Bar of pressure over the same period. Irradiated canisters showed only marginally 
higher leakage rates and the effect of irradiation on the integrity of the canister seems to be 
minimal. The order of performance was unaffected by irradiation process 
It takes three consecutive shots to effectively empty a lOOmg vial of FDS. For the original 
C128 canisters, approximately 75% (75mg) of the vial is emptied, with about 25mg of powder 
remaining in the vial as residual material. The results for the C326 show that>85% of FDS 
vials are emptied after three consecutive shots. The increase in the amount aerosolised is 
probably due to the higher CO2 volume throughput through the vial.
Implications of the findings to any future commercially or clinically viable system is that, 
multiple pressurised canisters (at the very least two canisters) will be necessary to deliver the 
FDS effectively. With this in mind, the new prototype shown earlier was designed with the 
ease of canister and vial replacement at the forefront of its development.
The ADS is not an inhaler and cannot be compared directly against devices on the market for 
inhalation. However, there are at least three devices currently in development that utilise 
compressed air as a means of dispersing the powder that they deliver. These include 
Airboost™, Biohaler™, and the Prohaler™ (Nichols 1997), see Table 2, page 58 for 
additional detail. Jet nebulisers also use a source of compressed air to deliver drug material, 
be it in a solution form, see page 61 for additional information. Nichols (1997) stated that 




Overall General Discussion and Conclusions
10.0 Overall General Discussion and Conclusions
This research programme was initially undertaken to improve the method of delivery of SAPL 
in neonatal RDS. Design, construction and testing of a DP AG for use in neonates was 
initiated, with the aim of producing a powder system which could nebulise a certain dose of 
SAPL over a period time. However, the course of the study was altered when literature 
published by a number of authors (Enhoming et al 1996, Hills et al 1996a, 1996b, Liu et al 
1995, 1996) implied that SAPL had possible applications in respiratory diseases such as 
asthma, and ARDS. Other citations (Hills et al 1982, Grahame et al 1985, Rozga et al 1990, 
Kappas et al 1992, Anderson 1996, and Heu et al 1997) linking the possible, additional uses 
of SAPL in non-respiratory conditions such as intraperitoneal post-surgical adhesions and 
otitis media (Nemechek et al 1997) with effusion (glue ear) also served to change the goals of 
the programme. Thus, research was aimed at developing the SAPL product (ALEC™ also 
called pumactant) produced by Britannia Pharmaceuticals Ltd., and licensed in the UK for 
neonatal RDS. Specifically, the main effort was diverted to produce a delivery system for 
principal use in asthma and to test the hypotheses that SAPL had a therapeutic effect against 
the disease, by getting the drug to phase I clinical trials. Smaller, but no less important, effort 
was directed towards investigating SAPL use in postsurgical adhesions and glue ear.
Various forms of SAPL, ranging from unmicronised freeze-dried labelled material to 
micronised non freeze-dried material have been studied and characterised. The way in which 
the material is manufactured seems to dictate its morphological properties. Freeze-drying 
produces amorphous particles, existing as aggregates of no definitive size. The amorphous 
nature of the particles is an artefact of the lyophilisation process in which the water is 
extracted from the system in a non-discriminative way (Craig et al 1999). Lyophilisation also 
tends to produce particles with smoother surfaces than counter-parts, which are produced via 
other routes. When subjected to labelling and micronisation, particles are no longer 
amorphous as shown by various photomicrographs. The route of manufacture that does not 
utilise freeze-drying produces large, irregularly shaped particles, which are reduced in size 
upon micronisation.
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The route of manufacture does not affect true density and melting point properties of the 
various forms of SAPL. However, bulk densities of the materials do differ, FDS (Hausner 
ratio (HR) 1.48, Carr’s index (Cl) 32.6%) has been classified as having poor flow which 
improves if the material undergoes the labelling procedure to become LFDS (HR 1.18, Cl 
15.2%). UMS and MS both show good flow (HR 1.17, 1.18 and Cl 14.6, 15.3 respectively). 
XRPD analysis of SAPL produced difffactograms with a characteristic main, broad peak at 
~21.0 two theta degrees. The broadness of this peak may arise from very small crystallite 
size, or lattice distortion, or both. The broad peak coupled with the noisy baseline observed in 
the results is indicative of the amorphous nature of most organic material, which tends to be 
semi-crystalline in nature as first described by Alexander and Klug (1974).
Moisture content analysis of SAPL was carried out using a Karl-Fischer coulometer. Results 
revealed that the various forms had an indigenous water content o f between three to five 
percent. Moisture uptake experiments over a period of four weeks showed SAPL to be fairly 
hygroscopic. The level of hygroscopicity seemed to reach a maximum between two to four 
weeks for the various forms. Closer inspection of the results revealed that LFDS (23%) is 
slightly more hygroscopic than FDS (16%). Although SAPL picks up surrounding water 
readily, the process is rate dependant and careful handling and shielding from the environment 
severely limits the water content of the material. The hygroscopic nature of phospholipids is 
well documented and can be found in a recent review by Nakaya and Li (1999).
The analytical techniques used to separate and quantify SAPL involved the use of HPLC 
instrumentation coupled to an evaporative light scattering (mass) detector as well as 
fluorimetry. HPLC analysis of phospholipids coupled to a mass detector is routinely carried 
in industry for screening puroposes (Mancini et al 1997) and has been shown to be a reliable 
method of detection. The mass detection technique in this study showed that there was a 
binomial relationship between standard concentration and peak area. Statistical analysis of the 
linearity and repeatability experiments showed that the precision of the assay was acceptable. 
Fluorimetric analysis revealed that standard concentration versus sample intensity was linear. 
Statistical analysis showed the method to be robust and reproducible. Fluorimetric detection 
of LFDS was necessary because on the outset of the research programme a light scattering 
detector was not available; therefore, an alternative route of detection was necessary. Before 
deciding on fluorimetry, other routes of detection were investigated namely, UV, atomic
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absorption (AA), and refractive index (RI) analysis. However, these proved unsuccessful 
since FDS does not have a chromophore for UV detection. Indirect AA quantification of FDS 
by measuring the calcium and sodium content levels also proved unsuccessful. The reasons 
for this were two-fold. Firstly, there were batch-to-batch variations in the levels of the salts. 
Secondly, and more importantly, FDS was poorly soluble in aqueous solutions. RI analysis of 
standards revealed that the technique was not significantly sensitive to detect small quantities 
of the drug. A full range scan of a relatively concentrated solution of FDS, using a 
fluorescence spectrophotometer, showed the drug to be very slightly fluorescent, too small to 
be quantifiable in any deposition studies. Thus, in order to quantify FDS and its various 
blends, a fluorescent probe (n-octadecyl dansylamide-l%w/w) was introduced to produce 
LFDS; similar experiments were carried out by (UbarretxenaBelandia et al 1999). The new, 
labelled material was identified by NMR analysis and characterised by the same physical tests 
used on FDS. In order to prove that the fluorescent probe was distributed uniformly 
throughout the drug, content uniformity experiments were undertaken and cross referenced 
with deposition experiments involving chemically labelled SAPL. Results showed that the 
probe was evenly distributed throughout a given sample of LFDS.
Micronisation of the various SAPL forms were initially carried out on a laboratory scale fluid 
energy mill, and later on industrial mills which were used to prepare the bath of MS used in 
the clinical trials for asthma. The reason for the change of strategy was three fold. Firstly, the 
efficiency of the milling in the lab-scale model was typically around 65%, with most of the 
sample being lost during transfer. Secondly, the industrial mills and their surroundings were 
better controlled and monitored. The milling was carried out under a stream of nitrogen and 
all air was eliminated from the system, so as not to expose the drug to moisture. Thirdly, 
standard bacterial swab tests were carried post micronisation to assess the level of hygiene, 
necessary for inhalation grade material.
In-vitro deposition studies of the various forms of SAPL were performed using traditional 
pharmaceutical testing apparatus and procedures. Blends of SAPL with coarse and fine 
lactose to produce binary and ternary mixtures were prepared using a high-shear blender. 
Geometric and ad-hoc blending techniques using a pestle and mortar were also employed but 
yielded poor content uniformity results. Also, the mechanical stress and grinding action 
produced by the hand blending raised questions about the stability o f SAPL. Therefore, hand
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blending was discontinued. Turbulent tumbling mixing also produced blends with poor 
content uniformity, probably due to low-shear. Thus, only the blends produced by the high- 
shear techniques were tested.
TSI analysis of MLFDS (drug only), binary, and ternary blends at 30, 60, and 96.4Lmin'1 
using the Miat Monohaler and size three gelatine capsules produced varying results. The 
basic conclusions were that the drug-only formulation is the best in terms FPD and FPF, but 
its ED is flow rate dependant. At SOLmin"1 the drug only formulation is not expelled well 
from the capsule and subsequent deaggregation is also poor, leading to lower FPF (7.1%). ED 
and FPF (16.4 and 20.2% at 60 and 96.4Lmin'1 respectively) improve with increasing flow 
rate. These blends compare favourably with ternary mixtures of standard salbutamol sulphate 
with coarse, intermidiate and fine lactose formulations, using the TSI at 60 and 90Lmin"1 via 
the Rotahaler™ and employing various mixing sequences, as carried out by Zeng et al (1999). 
MSLI analysis of MLFDS and its various blends at 92Lmin'1 using the Miat Monohaler and 
size three gelatine capsules showed no appreciable differences in the FPF results obtained. 
However, the advantage of the drug-only formulation over the other blends was its ability to 
deliver a higher total ED and FPD. The FPF values obtained were on average about 2% 
higher than those achieved for the TSI analysis. One possible explanation for this increase 
could be that the airflow path through the MSLI is more conducive to deagglomeration of drug 
particles. Comparison of the data against in-vitro (MSLI at bOLmin'1) and in-vivo 
(scintigraphy) data obtained by Pitcairn et al (1997) on a novel asthma drug using a device 
similar to the Miat Monoler (i.e. Cyclohaler®), showed MLFDS deposition to be lower (~30% 
c.f. -14%).
TSI analysis of MS (drug-only) at 30, 60, and 96.4Lmin'1 using the Miat Monohaler and size 
three gelatine capsules show that, as expected, ED, FPD and FPF are higher with increasing 
flow rate. No blends of MS were made or studied because it was decided that any SAPL 
formulation, which ultimately made it to clinical trials, using a size three capsule and Miat 
Monohaler, had to be delivered in greater quantities than had been possible in binary or 
ternary blends with lactose, previously studied for MLFDS. FPD and FPF values obtained for 
MS were compared with those for MLFDS. Results showed that FPD for MS was higher 
whereas its FPF was marginally lower. This means that MS is expelled from the capsule more 
efficiently but does not deaggregate as well as MLFDS. One possible reason for this is that
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MS has a VMD of 2.39pm compared with 4.12pm for MLFDS. Therefore, smaller average 
size of MS would make the particles more cohesive and less susceptible to deaggregation. 
MSLI analysis of MS at 92Lmin'1 using the Miat Monohaler and size three gelatine capsules 
produced the same trend in results as seen in TSI deposition profiles. Comparison of MS and 
MLFDS results also showed a higher FPD but a slightly lower FPF, due to the reasons 
outlined in the previous paragraph.
TSI and MSLI results for MS although good, only produced modest ED and FPD values in 
terms of weight. Thus, an alternative approach to delivering greater quantities of MS more 
efficiently was investigated. This led to the design, construction and testing of a novel asthma 
inhalation system. Before construction of the equipment, an asthma study protocol was 
designed and a dosing range of 85-100mg was chosen to be administered to the patient. Since 
there were no previous studies of SAPL, as a powder, being delivered to the lungs to use as a 
reference, the dosing range was based on the FDS currently on the market to treat RDS in 
neonates. Although in RDS the product is delivered as an intratracheal suspension, the total 
amount of material delivered was lOOmg. Based on this information the inhalation system 
was constructed to effectively deliver 85-lOOmg of drug from single or multiple vials of MS 
filled under near sterile conditions. Deposition results on a lOOmg vial of MS show ED 
values of >80%, FPF of ~25%. Although these are not great improvements over the Miat 
Monohaler and gelatine capsule delivery method, the mere fact that the initial load is five 
times as much make this route more attractive. The disadvantage of the inhalation system is 
that it is big, bulky, and tedious to use. However, since the initial objective was delivering a 
certain quantity of SAPL to the patient to test its therapeutic effect in asthma, the 
disadvantages of the system are of no immediate concern. Depending upon the results of the 
clinical trial, future work may be aimed at miniaturisation of the system or finding an 
alternative, equivalent system. Direct comparison of the results obtained for MS with other 
powder surfactant studies could not be made as such data does not exist. The only clinical 
data available are those from the studies carried out by Kurashima et al (1991) and Anzueto et 
al (1997). In both these studies, the surfactant was nebulised and improvements in the region 
of 11% for FVC and 25% for FEVi were reported.
The DP AG system, designed to carry out the initial objectives of the present study (to offer an 
alternative way of delivering SAPL in neonatal RDS) was designed and built over a period of
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time. Modifications to the device were made with in-vitro testing in mind, such that it could 
be coupled to a TSI. Results of the testing on SAPL (drug-only) and binary blends showed 
low FPD and FPF values. This implied that the fluidisation method used was not turbulent 
enough to separate drug-drug or drug-carrier aggregates. In addition, the design of the top- 
half of the fluidisation chamber was not sufficiently optimised or engineered, causing 
aerosolised particles to impact on the ceiling of the apparatus. Further development work 
needs to be done on the system before it can efficiently deliver SAPL.
A novel delivery device for glue ear (GEDD) was constructed, utilising the current FDS vials 
on the market as well as HFA 134a as a propellant. The propellant filled into 19ml volume 
canisters and dispensed in shots of lOOpl. This system was only partially tested and then 
discontinued. The reasons for this were two-fold, firstly firing of pressurised systems into the 
inner ear raised safety issues. Secondly, the use of HFA 134a as a propellant to aerosolise a 
powder system was novel and would require regulatory approval. The basic design of the 
GEDD was taken and modified to produce the ADS to be used in post-surgical adhesions. 
This system utilised pressurised large-volume (28ml) canisters of carbon dioxide at 10, 12, 
and 14Bar to aerosolise the FDS via a continuous valve. Various valve and gasket 
combinations on canisters were evaluated and tested for leakage rates before and after 
irradiation using a Cobalt-60 source. The canisters were irradiated because the system 
intended for phase I clinical trials had to be sterile, it therefore seemed more rational to fill the 
canister then irradiate, rather than fill in a sterile environment. The systems was refined with 
the final version expelling >85% of FDS from the lOOmg vials. The ADS is not an inhaler
IJ1W rp» # rrni *
and only a few inhalers utilising compressed air (Airboost , Biohaler , and the Prohaler ) 
as a means of dispersing the powder they deliver actually exist.
No definitive conclusions as to the success of the drug in asthma trials, or the efficiency of the 
inhalation system to deliver the required dose to the patient can be made, since the trial date is 
late 1999. However, one can conclude that the drug has a good chance of being delivered at 
the correct dose to the desired site of action. This statement can be partly justified by the in- 
vitro results obtained during this study, i.e. 25-30% FPF equating to 28-35mg of powder 
capable of being delivered to the lungs of asthmatics.
It may also be said that, trends seen in both the published literature and in patent applications 
point to the conclusion that surfactant therapy in respiratory disease treatment is on an upward
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spiral. Whether or not SAPL has a sufficient therapeutic effect against asthma remains to be 
seen, but even if the improvements are minimal several interpretations can be obtained: -
a) The drug would be the first powdered surfactant to undergo trials for asthma.
b) A benchmark dosage of surfactant for asthma will be set.
c) The drug may have applications as a co-drug with another class o f asthma drug; either in a 
solution based HFA form or incorporated into an existing formulation.
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Appendices
Appendix 1: Summary of the Physical Properties of Hydro Fluoro Alkane (HFA) 
134a and 227
HFA 134a= 1,1,1,2- Tetrafluoroethane (CF3 CH2F)
Trade Name= Dymel®
Boiling point= -26.22°C at 1 bar, purity= 99.98%
Vapour pressure @ 20°C= 5.70 bar Vapour pressure @ 25°C= 6.63 bar
Molecular mass= 102.03 g/mol Density @ 20°C= 1226 kg/m3
Physical form= Colourless gas
source o f data= 1) Technical information booklet, DuPont Inc. (2) Physical property data 
sheet, ICI Klea, Cheshire, UK
2) HFA 227= 1,1,1,2,3,3,3- Heptafluoropropane (CF3CHFCF3)
Trade Name= Solkane® 227 Phams,
Produced by, Solvay Fluor und Derivative (SFD) GmbH, Hannover, Germany 
International Name= Apaflurane
Molecular mass= 170.03 g/mol Physical Form= Coulourless gas
Boiling Point= -16.5°C at lbar Vapour Pressure @ 20°C= 3.902bar
Density= 1.415 kg/1 @ 20°C
Source of data= (1) Physical properties data booklet, Hoechst Chemicals, Frankfurt, Germany 
(2)SFD, Hannover, Germany.
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Appendix 2: Detailed Particle Size Analysis Tables of SAPL Powders by Laser 



















FDS Cvclohexane 0.1%Lecithin 25-30 0 14.8 54.8 120.8
FDS Cvclohexane 0.1%Lecithin 25-30 15secs 4.85 36.9 92.8
FDS Cvclohexane 0.1%Lecithin 25-30 30secs 3.95 22.1 57.6
FDS Cvclohexane 0.1%Lecithin 25-30 1 minute 3.72 19.6 42.9
FDS Cvclohexane 0.1%Lecithin 25-30 2minutes 3.09 18.6 39.9
FDS Acetone None 25-30 0 34.4 135.8 172.9
FDS Acetone None 25-30 15secs 24.6 53.9 124.8
FDS Acetone None 25-30 30secs 10.3 38.3 101.0
FDS Acetone None 25-30 1 minute 8.51 36.9 72.0
FDS Acetone None 25-30 2minutes 7.27 33.7 66.9
FDS Air None n/a n/a 25.9 83.3 164.7
Table 107: Particle size analysis results for FDS. For measurements using the small volume stirred cell 



















UMLF Cvclohexane 0.1%Lecithin 25-30 0 6.58 49.4 151.1
UMLF Cvclohexane 0.1%Lecithin 25-30 1 minute 1.66 12.9 69.2
UMLF Cvclohexane 0.1%Lecithin 25-30 2minutes 1.51 12.4 64.9
UMLF Acetone None 25-30 0 14.2 125.2 172.4
UMLF Acetone None 25-30 1 minute 7.88 111.4 170.2
UMLF Acetone None 25-30 2minutes 4.28 53.1 164.6
UMLF Air None n/a n/a 21.2 64.9 140.2
Table 108: Particle size analysis results for UMLFDS. For measurements using the small volume stirred 




















MLFD Cvclohexane 0.1%Lecithin 25-30 0 4.71 32.9 151.3
MLFD Cvclohexane 0.1%Lecithin 25-30 15secs 3.48 22.0 87.8
MLFD Cvclohexane 0.1%Lecithin 25-30 30secs 1.81 5.30 14.9
MLFD Cvclohexane 0.1%Lecithin 25-30 1 minute 1.69 4.19 8.90
MLFD Cvclohexane 0.1%Lecithin 25-30 2minutes 1.61 4.12 8.51
MLFD Acetone None 25-30 0 29.2 135.3 174.0
MLFD Acetone None 25-30 15secs 21.8 98.6 166.0
MLFD Acetone None 25-30 30secs 13.2 56.9 154.3
MLFD Acetone None 25-30 1 minute 3.43 21.5 134.2
MLFD Acetone None 25-30 2minutes 2.26 19.3 62.4
MLFD Air None n/a n/a 17.8 99.2 168.4
Table 109: Particle size analysis results for MLFDS. For measurements using the small volume stirred cell 



















UMS Cvclohexane 0.1%Lecithin 25-30 0 12.7 83.1 165.3
UMS Cvclohexane 0.1%Lecithin 25-30 15secs 9.85 51.4 92.0
UMS Cvclohexane 0.1%Lecithin 25-30 30secs 7.27 36.9 61.3
UMS Cvclohexane 0.1%Lecithin 25-30 1 minute 3.25 14.1 31.3
UMS Cvclohexane 0.1%Lecithin 25-30 2minutes 2.61 13.4 28.2
UMS Acetone None 25-30 0 11.2 58.8 86.2
UMS Acetone None 25-30 15secs 9.48 47.6 82.3
UMS Acetone None 25-30 30secs 9.06 42.8 79.9
UMS Acetone None 25-30 1 minute 8.78 38.2 76.5
UMS Acetone None 25-30 2minutes 8.64 31.6 68.9
UMS Air None n/a n/a 14.3 78.7 160.9
Table 110: Particle size analysis results for UMS. For measurements using the small volume stirred cell 




















MS Cvclohexane 0.1%Lecithin 25-30 0 1.70 4.68 27.8
MS Cvclohexane 0.1%Lecithin 25-30 15secs 1.44 3.60 8.54
MS Cvclohexane 0.1%Lecithin 25-30 30secs 1.41 3.05 8.38
MS Cvclohexane 0.1%Lecithin 25-30 1 minute 1.32 2.51 7.97
MS Cvclohexane 0.1%Lecithin 25-30 2minutes 1.28 2.39 7.62
MS Acetone None 25-30 2minutes 4.83 12.7 24.6
MS Air None n/a n/a 10.4 61.9 147.8
Table 111: Particle size analysis results for MS. For measurements using the small volume stirred cell 
n=5, for measurements using the dry powder feeder n=10.
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Appendix 3: Content Uniformity Experiments for Binary Blends of MLFDS
Blend Time Sample Intensity Corrected Cone. Corrected Expected






A 5 19.5 25.87 25.45 0.392 0.403 0.4
A 5 19.8 22.61 22.19 0.342 0.346 0.4
A 5 20.1 21.65 21.23 0.327 0.326 0.4
A 5 20.4 22.09 21.67 0.3.34 0.328 0.4
A 5 20.4 28.66 28.24 0.436 0.427 0.4
A 5 20.8 22.61 22.19 0.342 0.329 0.4
A 5 21.2 22.84 22.42 0.346 0.326 0.4
A 5 19.7 29.15 28.73 0.443 0.450 0.4
A 5 19.9 26.30 25.88 0.399 0.401 0.4
A 5 20.2 24.12 23.70 0.365 0.362 0.4
Average 0.370  
SD 0.0468 
RSD(%) 12.7
A 10 20.4 25.74 25.32 0.390 0 383 0 4
A 10 20.9 25.60 25.18 0.388 0.372 0.4
A 10 21.4 29.94 29.52 0.455 0.426 0.4
A 10 19.6 25.90 25.48 0.393 0.401 0.4
A 10 20.9 26.25 25.83 0.398 0 381 0.4
A 10 19.2 23.88 23.46 0.362 0.377 0.4
A 10 21.7 29.65 29.23 0.451 0.416 0.4
A 10 19.9 29.61 29.19 0.450 0.453 0.4
A 10 20.5 26.84 26.42 0.407 0.398 0.4
A 10 20.1 23.98 23.56 0.363 0361 0.4
Average 0.397  
SD 0.0279 
RSD(%) 7.0
A 15 22.4 29.69 29.27 0.451 0.403 0.4
A 15 20.7 28.21 27.79 0.429 0.414 0.4
A 15 20.6 25.99 25.57 0.394 0.383 0.4
A 15 21.0 27.84 27.42 0.423 0.403 0.4
A 15 21.1 27.68 27.26 0.420 0.399 0.4
A 15 21.7 29.32 28.90 0.446 0 411 0.4
A 15 22.6 26.12 25.70 0.396 0.351 0.4
A 15 20.7 26.94 26.52 0.409 0.395 0.4
A 15 20.2 25.77 25.35 0.391 0.387 0.4
A 15 20.4 26.45 26.03 0.401 0.394 0.4
Average 0.394  
SD 0.0180  
RSD(%) 4.6
Table 112: Content uniformity table for MLFDS binary blend A (10% MLFDS:90% coarse lactose).
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Blend Time Sample Intensity Corrected Cone. Corrected Expected






B 5 19.7 25.79 24.32 0.436 0.442 0.4
R 5 20.1 24.62 23.15 0.415 0.413 0.4
R 5 21.9 24.38 22.91 0.411 0.375 0.4
R 5 19.5 24.34 22.87 0.410 0.421 0.4
R 5 20.6 25.81 24.34 0.436 0.423 0.4
R 5 21.2 24.57 23.10 0.414 0.391 0.4
R 5 20.7 24.65 23.18 0.416 0.402 0.4
R 5 19.9 23.42 21.95 0.395 0.397 0.4
R 5 20.0 21.95 20.48 0.369 0.369 0.4
R 5 22.3 24.84 23.37 0.419 0.376 0.4
Average 0.401 
SD 0.0239  
RSD(%) 6.0
R 10 20.9 25.46 23.99 0.430 0.411 0.4
R 10 20.4 26.28 24.81 0.444 0.435 0.4
R 10 19.8 23.87 22.40 0.402 0.406 0.4
R 10 19.6 21.80 20.33 0.366 0.374 0.4
R 10 20.3 21.81 20.34 0.367 0.361 0.4
R 10 21.5 25.65 24.18 0.433 0.403 0.4
R 10 20.3 23.82 22.35 0.401 0.396 0.4
R 10 22.5 27.79 26.32 0.470 0.418 0.4
R 10 20.6 23.84 22.37 0.402 0.390 0.4
R 10 20.9 25.01 23.54 0.422 0 4 0 4 0.4
Average 0.400 
SD 0.0212  
RSD(%) 5.3
R 15 22.2 25.57 24.10 0.432 0.389 0.4
R 15 20.4 24.07 22.60 0.406 0.398 0.4
R 15 19 8 25.42 23.95 0.429 0.433 0.4
R 15 21 3 25.55 24.08 0.431 0.405 0.4
R 15 21.5 24.58 23 11 0.415 0.386 0.4
R 15 20.3 23.83 22.36 0.402 0.396 0.4
R 15 21.4 26.97 25.50 0.456 0.426 0.4
R 15 20.6 25.41 23.94 0.429 0.416 0.4
R 15 19.9 24.87 23.40 0.420 0.422 0.4
R 15 20.4 24.09 22.62 0.406 0.398 0.4
Average 0.407 
SD 0.0165  
RSD(%) 4.1
Table 113: Content uniformity table for MLFDS binary blend B (10% MLFDS:90% fine lactose).
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Blend Time Sample Intensity Corrected Cone. Corrected Expected






C 5 20.4 17.91 17.49 0.269 0.264 0.2
C 5 20.6 15.84 15.42 0.237 0.231 0.2
C 5 19.9 16.43 16.01 0.247 0.248 0.2
C 5 19.6 12.85 12.43 0.191 0.195 0.2
C 5 20.8 16.0.3 15.61 0.240 0.231 0.2
C 5 20.5 11.05 10.63 0.163 0.159 0.2
C 5 19.7 11.98 11.56 0.178 0.181 0.2
C 5 19.7 12.09 11.67 0.180 0.182 0.2
C 5 20.6 14.7.3 1.3.81 0.213 0.206 0.2
C 5 20.3 15.00 14.58 0.224 0.221 0.2
Average 0.212  
SD 0.0329  
RSD(%) 15.5
C 10 19.2 14.87 14.45 0.222 0.232 0.2
C 10 19.8 12.51 12.09 0.186 0.188 0.2
c 10 19.5 12.84 12.42 0.191 0.196 0.2
c 10 20.1 15.23 14.81 0.228 0.227 0.2
c 10 20.4 15.04 14.62 0.225 0.221 0.2
c 10 19.8 13.85 13.43 0.207 0.209 0.2
c 10 20.6 14.69 14.27 0.220 0.213 0.2
c 10 21.1 15.07 14.65 0.226 0.214 0.2
c 10 20.3 14.16 1.3.74 0.212 0.208 0.2
c 10 19.5 15.47 15.05 0.232 0.238 0.2
Average 0.215 
SD 0.0155  
RSD(%) 7.2
C 15 22.5 16.51 16.09 0.248 0.220 0.2
C 15 20.6 1.3.90 13.48 0.208 02.01 0.2
c 15 22.8 15.98 15.56 0.240 0.210 0.2
c 15 21.2 14.94 14.52 0.224 0.211 0.2
c 15 19.8 13.04 12.62 0.194 0.196 0.2
c 15 20.6 13.55 13.13 0.202 0.196 0.2
c 15 21.1 15.89 15.47 0.238 0.226 0.2
c 15 20.8 14.40 13.98 0.215 0.207 0.2
c 15 20.4 14.00 13.58 0 2 0 9 0.205 0.2




Table 114: Content uniformity table for MLFDS binary blend C (5% MLFDS:95% coarse lactose).
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Appendix 4: Content Uniformity Experiments for Ternary Blends of MLFDS
Time Sample Intensity Corrected Cone. Corrected Expected




5 39.6 23.21 22.382 0.430 0.434 0.4
5 40.4 2.3.29 22.462 0.431 0.427 0.4
5 40.5 22.74 21.912 0.421 0.416 0.4
5 40.5 20.96 20.1.32 0.387 0.382 0.4
5 40.2 20.52 19.692 0.378 0.376 0.4
5 39.8 21.03 20.202 0.388 0.390 0.4
5 39.6 20.45 19.622 0.377 0.381 0.4
5 40.2 22.89 22.062 0.424 0.422 0.4
5 40.8 20.77 19.942 0.383 0.376 0.4




10 .39.8 21.15 20.322 0.390 0.392 0.4
10 39.6 21.39 20.562 0.395 0.399 0.4
10 40.6 21.84 21.012 0.404 0.398 0.4
10 40.8 20.79 19.962 0.383 0.376 0.4
10 40.4 22.76 21.932 0.421 0 4 1 7 0.4
10 40.5 22.77 21.942 0.421 0.416 0.4
10 41 3 2.465 7.3 822 0.457 0.443 0.4
10 41.0 23.56 22.732 0.437 0.426 0.4
10 41.1 22.85 22.022 0.423 0.412 0.4




20 40.5 21.54 20.712 0.398 0.393 0.4
20 41.0 20.96 20.132 0.387 0.377 0.4
20 41.5 23.47 22.642 0.435 0.419 0.4
20 41.0 21.73 20.902 0.401 0.392 0.4
20 40.6 22.70 21.872 0.420 0.414 0.4
20 40.2 24.26 23.432 0.450 0.448 0.4
20 40.5 22.55 21.722 0.417 0.412 0.4
20 40.9 22.16 21.332 0.410 0.401 0.4
20 40.7 21.94 21.112 0.406 0.399 0.4




Table 115: Content uniformity table for a ternary blend of MLFDS, coarse lactose, and fine lactose 
(5:90:5% w/w).
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Appendix 5; Detailed tables for the HPLC analysis of MS-TSI Results
Parameter FR Capsule Device Stage 1 Stage 2
















































































Dilution Factor 30.0 100 100 1000 200




































Table 116: Summary table of TSI deposition data for MS at 30.0L.inin'1.
Values in brackets indicate standard deviation, n=10.
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Parameter FR Capsule Device Stage 1 Stage 2
















































































Dilution Factor 60.0 100 100 1000 200






































Table 117: Summary table of TSI deposition data for MS at 60.0Lmin'1.
Values in brackets indicate standard deviation, n=10.
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Parameter FR Capsule Device Stage 1 Stage 2


























































































Dilution Factor 96.4 100 100 1000 200






































Table 118: Summary table of TSI deposition data for MS at 96.4Lmin'1.
Values in brackets indicate standard deviation, n=10.
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Appendix 6; Detailed tables for the HPLC analysis of MS- MSLI Results
Cap Dev Adp + 
Tht








































































DPPC as a 
























































































































































































Table 119: Summary table of MSLI deposition data for MS at 92.0Lmin'1.
Values in brackets indicate standard deviation, n=15.
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Appendix 7: Structure and Physicochemical Properties of Dansyl Chloride
N (C H 3)2
Figure 96: Dansyl Chloride (5-[DimethylaminojNapthalene-l-Sulfonyl Chloride).
Formulae = Ci2H i2C1N02S, RMM= 269.7, Purity«  95%
Appendix 8: Structure and Physicochemical Properties of Octadecylamine
Figure 97 Octadecylamine (Stearylamine)
Formulae = Ci8H37NH2, RMM= 269.5, Purity « 98%
Appendix 9: Structure and Physicochemical Properties of n-Octadecyl 
Dansylamide
N(CH3)2
Figure 98 n-Octadecyl Dansylamide l-(Dimethylamino)-5-Napthalene Sulfonyl Octadecylamine.
Formulae = C28H48N 2S 0 2, RMM= 476, M.P= 69-72°C, A.ex=345nm, =
482nm
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Appendix 10: Dimensions of the DPAG
All the figures stated below are in mm.
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Figure 99: Detailed Dimensions of the DPAG
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Appendix 11: Detailed Pressure Drop Tables Using the DPAG
DPAG Distributor Type: Sintered Glass ('3orosity: 0)










Table 120: Flow rate versus pressure drop for sintered glass (porosity zero).
DPAG Distributor Type: Sintered Glass ( 3orosity: 1)










Table 121: Flow rate versus pressure drop for sintered glass (porosity one).
DPAG Distributor Type: Sintered Glass (1Porosity: 2)










Table 122: Flow rate versus pressure drop for sintered glass (porosity two).
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DPAG Distributor Type: Sintered Glass ( 3orosity: 3)










Table 123: Flow rate versus pressure drop for sintered glass (porosity three).
DPAG Distributor Type: Sintered Glass ( 3orosity: 4)










Table 124: Flow rate versus pressure drop for sintered glass (porosity four).
DPAG Distributor Type: Sintered Brass (Porosity: N/A)










Table 125: Flow rate versus pressure drop for sintered brass (porosity N/A).
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Appendix 12: Particle Size Distribution Curves for SAPL and Lactose.
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Figure 100: Particle Size Distribution of FDS.
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Figure 101: Particle Size Distribution of UMLFDS.
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Appendix 13: MS Testing and Stability Study Raw HPLC Data
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Deposition studies of ALEC, using the PA device-HPLC results
2x lOOmg vials were fired into the MSLI at 1001/min (2.0KPa pressure drop), 2 inhalations per vial.
30 seconds settling time
Sample dilutions: Adp to stg5 were washed intolOOml volumetries, then diluted as follows: adp+tht, stgl, stg2, stg3= 1:4, stg4= 1:5 diln, stg5= No diln
Chromatographic conditions: Duplicate injections at 8min per injection, PG Retention= 2.7min, DPPC+ 3.7min Concentration A + B*sqrt(C+D*area)
Column= LiCN (10pm) 250x 4.6mm (Hichrom Ltd, UK), Column Temp= Ambient, Mobile Phase= HPLC grade Methanol PG factors DPPC factors
Flow rate= l.Oml/min, Detector= PL-ELS 1000 (Polymer Labs, UK), N2 inlet pressure= 53psi, Evaporator temp= 80°C A -24.28 A -9.1
Nebuliser Temp=80°C, Gas Flow= 0.7 SLM, Exhaust temp= 50°C B 0.0025 B 0.0013
HPLC software: Borwin Chromatography Software V I.22 (JMBS developments, Grenoble, France) C 96554501 C 61621500
















Area as a 
% of total
CF Corrected 
PG as a 
%  o f total
DPPC 





1 Stdl 11600 33348 11594 32620 25.8 1.16 30.0 70.0 13264
2 11588 31891 26.7 1.13 31.0 69.0 13698
3 Std 2 25608 95800 27152 95800 21.1 1.42 30.0 70.0 36885
4 28696 95799 23.0 1.30 32.8 67.2 40308
5 Std 3 46325 185251 47144 192887 20.0 1.50 30.0 70.0 72009
6 47962 200523 19.3 1.55 28.9 71.1 69480
7 Std 4 55991 245990 55793 251526 18.5 1.62 30.0 70.0 92195
8 55594 257061 17.8 1.69 28.8 71.2 88416
9 Std 5 67914 317787 66693 310413 17.6 1.70 30.0 70.0 113132
10 65472 303039 17.8 1.69 30.3 69.7 114151
11 Std 6 90141 469174 91945 469988 16.1 1.86 30.0 70.0 168580
12 93749 470801 16.6 1.81 30.9 69.1 173702
13 Tht+Adp 17868 67061 20253 64420 21.0 1.43 30.0 70.0 25402
14 22638 61778 26.8 1.12 38.2 61.8 32379
15 Stage 1 11638 30101 10514 32353 27.9 1.08 30.0 70.0 12860
16 9390 34604 21.3 1.41 23.0 77.0 9844
17 Stage 2 36911 161270 38198 160350 18.6 1.61 30.0 70.0 59564
18 39484 159429 19.8 1.51 32.0 68.0 63482
19 Stage 3 34292 137306 34758 139396 20.0 1.50 30.0 70.0 52246
20 35224 141486 19.9 1.51 29.9 70.1 52114
21 Stage 4 44054 184689 43982 185440 19.3 1.56 30.0 70.0 68826
22 43909 186190 19.1 1.57 29.7 70.3 68195
23 Stage 5 45851 189307 45967 189778 19.5 1.54 30.0 70.0 70723




















Amount o f 
ALEC (mg)
Throat 8.92 100 0.89 21.5 100 2.15 3.04
Stage 1 7.74 100 0.77 13.7 100 1.37 2.15
Stage 2 5.09 100 0.51 37.5 100 3.75 4.26
Stage 3 9.98 400 3.99 34.5 400 13.8 17.8
Stage 4 15.02 500 7.51 40.8 500 20.4 27.9
Stage 5 14.61 100 1.46 41.4 100 4.14 5.60
Total 60.7
Fine particle fraction (mg) 51.3
As a % o f total amount fired 26.7
As a % o f  total amount delivered= 84.5
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Deposition studies of ALEC, using the PA device-HPLC results
2x lOOmg vials were fired into the MSLI at 1001/min (2.0KPa pressure drop)
20 seconds settling time
Sample dilutions: Adp to stg4 were washed into 100ml volumetries, stg 5 to 50ml, then diluted as follows: adp+tht, stgl, stg2, all undiluted 3+4+5= 1:2 diln
Chromatographic conditions: Duplicate injections at 8min per injection, PG Retention= 2.7min, DPPC+ 3.7min Concentration = A + B*sqrt(C+D*area)
Column= LiCN (10pm) 250x 4.6mm (Hichrom Ltd, UK), Column Temp= Ambient, Mobile Phase= HPLC grade Methanol PG factors DPPC factors
Flow rate= l.Oml/min, Detector= PL-ELS 1000 (Polymer Labs, UK), N2 inlet pressure= 53psi, Evaporator temp= 80°C A -20.07797271 A -15.88912134
Nebuliser Temp=80°C, Gas Flow= 0.7 SLM, Exhaust temp= 50°C B 0.00278474 B 0.00041841
HPLC software: Borwin Chromatography Software V1.22 (JMBS developments, Grenoble, France) C 46267228 C 1443756895
















Area as a 
% of total
CF Corrected 








1 Stdl 13983 28119 11897 28579 33.2 0.90 30.0 70.0 12143
2 9810 29039 25.3 1.19 22.8 77.2 9232
3 Std 2 23632 81890 22956 83180 22.4 1.34 30.0 70.0 31841
4 22279 84469 20.9 1.44 28.0 72.0 29673
5 Std 3 40648 149337 40674 150297 21.4 1.40 30.0 70.0 57291
6 40700 151256 21.2 1.41 29.7 70.3 56775
7 Std 4 47695 185399 46923 190569 20.5 1.47 30.0 70.0 71247
8 46150 195738 19.1 1.57 28.0 72.0 66433
9 Std 5 56072 235131 57012 227124 19.3 1.56 30.0 70.0 85241
10 57951 219117 20.9 1.43 32.6 67.4 92591
11 Std 6 74747 354604 77118 343658 17.4 1.72 30.0 70.0 126233
12 79488 332711 19.3 1.56 33.2 66.8 139825
13 Tht+Adp 15901 65180 15500 66416 19.6 1.53 30.0 70.0 24575
14 15099 67652 18.2 1.64 27.9 72.1 22864
15 Stage 1 20822 62538 18811 57002 25.0 1.20 30.0 70.0 22744
16 16799 51465 24.6 1.22 29.6 70.4 22407
17 Stage 2 27827 125156 28573 123431 18.2 1.65 30.0 70.0 45601
18 29318 121706 19.4 1.55 32.0 68.0 48668
19 Stage 3 24519 155469 29077 150849 13.6 2.20 30.0 70.0 53978
20 33634 146228 18.7 1.60 41.2 58.8 74096
21 Stage 4 19983 81635 20797 80955 19.7 1.53 30.0 70.0 30525
22 21610 80274 21.2 1.41 32.4 67.6 32924
23 Stage 5 23948 114720 25823 112109 17.3 1.74 30.0 70.0 41379


























Throat 11.85 100 1.18 24.6 100 2.46 67.5 3.65
Stage 1 11.45 100 1.14 24.3 100 2.43 68.0 3.57
Stage 2 11.35 100 1.13 22.1 100 2.21 66.1 3.35
Stage 3 16.06 400 6.4 29.9 400 12.0 65.1 18.4
Stage 4 20.80 500 10.4 37.4 500 18.7 64.2 29.1
Stage 5 22.21 100 2.22 40.3 100 4.03 64.4 6.25
Total 643
Fine particle fraction (mg) 53.7
As a % o f total amount fired 28.0
As a % of total amount delivered= 83.6
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S tability : 1 m o n th  t im e p o in t
Deposition studies of ALEC, using the PA device, Penn filled vials-HPLC results
lx lOOmg vials fired into the MSLI at 100 1/min (2.0KPa pressure drop). Single 4 litre inhalation.
30 seconds settle
Sample dilutions: Adp and stages 1, 2 and 5 were washed into 50ml volumetries. Stgs 3 and 4 into 100ml volumetries 
Chromatographic conditions: Duplicate injections at 8min per injection, PG Retention= 2.7min, DPPC+ 3.7min 
Column= LiCN (10pm) 250x 4.6mm (Hichrom Ltd, UK), Column Temp= Ambient, Mobile Phase= HPLC grade Methanol 
Flow rate= l.Oml/min, Detector= PL-ELS 1000 (Polymer Labs, UK), N2 inlet pressure= 53psi, Evaporator temp= 80°C 
Nebuliser Temp=50°C, Gas Flow= 1.0 SLM, Exhaust temp= 50°C
HPLC software: Borwin Chromatography Software VI.22 (JMBS developments, Grenoble, France)
HPLC Hardware: Jasco Systems Ltd, Detector soflware= PL-ELS 1000 V l.l 
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6995 23445 23.0 1.31 77.0 0.9 30 70 9132
C oncentration  = A + B *sqrt(C +D *area)
PG factors D PPC factors
A 1.6537545 A 3.8581856
B 0.0029797 B 0.0034758
C -4506157 c -18026538
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A l.F .C  (m g )
Throat n/a n/a 13.4 50 0.67 32.9 50 1.64 71.0 2.31
Stage 1 n/a 10.07 9.45 50 0.47 23.9 50 1.20 71.7 1.67
Stage 2 10.07 5.27 19.1 50 0.96 48.4 50 2.42 71.6 3.37
Stage 3 5.27 2.40 37.2 100 3.7 91.8 100 9.18 71.1 12.9
Stage 4 2.40 1.32 24.7 200 4.9 58.9 200 11.8 70.4 16.7
Stage 5 1.32 0.00 11.5 50 0.6 28.3 50 1.41 71.2 1.99
Mass fired into device (mg) 77.0
Emitted dose (mg) 39.0
Emitted dose (% of fired) 50.6
Fine particle dose (mg) 31.6
FPD as a % of total amount fired 41.1











Throat Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
MSLI Stage
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3  m onth  tim epoin t; 2 n d  re p e a t
Deposition studies of ALEC, using the PA device, Penn filled vials-HPLC results
lx lOOmg viais fired into the MSLI at 100 1/min (2.0KPa pressure drop). Single 4 litre inhalation.
30 seconds settle
Sample dilutions: Adp and stages 1, 2 and S were washed into SOml volumetries. Stgs 3 and 4 into 100ml volumetries 
Chromatographic conditions: Duplicate injections at 8min per injection, PG Retention= 2.7min, DPPC+ 3.7min 
Column= LiCN (10pm) 250x 4.6mm (Hichrom Ltd, UK), Column Temp= Ambient, Mobile Phase= HPLC grade Methanol 
Flow rate= l.Oml/min, Detector= PL-ELS 1000 (Polymer Labs, UK), N2 inlet pressure= 53psi, Evaporator temp= 80°C 
Nebuliser Temp=50°C, Gas Flow= 1.0 SLM, Exhaust temp= 50°C
HPLC software: Borwin Chromatography Software VI.22 (JMBS developments, Grenoble, France)
HPLC Hardware: Jasco Systems Ltd, Detector software= PL-ELS 1000 VI.1 
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5291 10613 33.3 0.90 66.7 1.0 30 70 4771 11133
Concentration = A + B*'sqrt(C+D*area)
PG factors DPPC factors
A 1.6537545 A 3.85818561
B 0.0029797 B 0.003475843
C -4506157 C -18026538





























Throat n/a n/a 14.71 50 0.7 35.8 50 1.8 70.9 2.5
Stage 1 n/a 10.07 9.85 50 0.5 22.9 50 1.1 70.0 1.6
Stage 2 10.07 5.27 22.37 50 1.1 56.0 50 2.8 71.4 3.9
Stage 3 5.27 2.40 29.51 100 3.0 74.1 100 7.4 71.5 10.4
Stage 4 2.40 1.32 20.00 100 2.0 50.2 100 5.0 71.5 7.0
Stage 5 1.32 0.00 7.23 50 0.4 16.2 50 0.81 69.1 1.2
Mass fired into device (mg) 71.8
Emitted dose (mg) 26.6
Emitted dose (% of fired) 37.1
Fine particle dose (mg) 18.6
FPD as a % of total amount fired 25.8
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Appendix 14: Additional Information on SAPL
General Info about SAPL
(a) Transition temperature of SAPL is 34°C and higher. This is the temperature at which the 
surfactant spreads instantaneously over given surface to form the monolayer. More 
specifically, the transition temperature of DPPC is 40°C, and of PG is 31°C. When these 
components are mixed in the ratio of 7:3, the transition temperature becomes 34°C.
(b) Molecular formula and molecular weight of PG are dependent on the composition of its 
acyl substituents, which in turn is dependent on the source of purified lecithin used as raw 
material in the synthesis of PG. Ri and R2 are 5 fatty acids, C16:0, C18:0, C18:1, C18:2 
and C20:4, in the approximate proportions 40, 10, 30, 20 and 3% respectively.
(c) DPPC has a single chiral centre at the 2-position in the glycerol backbone. PG has two 
chiral centres, one at the 2-position of the glycerol head group and the other at C2 in the 
glycerol backbone.
(d) Since there are several different acyl chain groups as well as two chiral centres, PG is 
theoretically a mixture of a considerable number of optical isomers.
(e) Nycomed-Amersham, UK manufactures SAPL. Synthesis o f DPPC involves five steps, 
whereas PG is manufactured via two steps. The two components are mixed in a 7:3 ratio, 
dissolved in chloroform, filtered and freeze-dried.
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Figure 107: The General Structure of Phospholipids and the Various Head Groups.
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Figure 108: The Structure of Sphingomyelin.
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